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1 Abstract 
Recombinant human Acid Alpha Glucosidase (GAA) is the therapeutic enzyme used for the 
treatment of Pompe disease, a rare genetic disorder characterised by GAA deficiency in the cell 
lysosomes. The manufacturing process for GAA can be challenging, in part due to protease 
degradation. The overall goal of this project was to understand the effects of GAA 
overexpression on cell lysosomal phenotype and host cell protein (HCP) release, and any 
resultant consequences for protease levels and ease of manufacture. To do this we first generated 
a human recombinant GAA producing stable CHO clonal cell line and then developed a two-step 
bioprocess based on capture chromatographic step anion exchange (IEX) and intermediate 
hydrophobic interaction (HIC).  The purity of GAA after HIC was determined via LC/MSMS to 
be above 80%. We then collected images of cell lysosomes via transmission electron microscopy 
(TEM) and compared the resulting data with that from a Null CHO cell line. TEM imaging 
revealed 72% of all lysosomes in the GAA cell line were engorged indicating extensive cell 
stress; by comparison, only 8% of lysosomes in the Null CHO had a similar phenotype. 
Furthermore, comparison of the HCP profile among cell lines [GAA, mAb and Null] capture 
eluates, showed that while most HCPs released were common across them, some were unique to 
the GAA producer, implying that cell stress caused by overexpression of GAA has a molecule 
specific effect on HCP release. Protease analysis via zymograms showed an overall reduction in 
proteolytic activity after the capture step but also revealed the presence of co-eluting proteases at 
approximately 80 KDa, which MS analysis putatively identified as dipeptidyl peptidase 3 and 
prolyl endopeptidase.  
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2 Introduction 
2.1 Impact statement 
The work contained within this thesis has addressed the manufacture of therapeutic protein 
representative of the challenges faced in manufacturing such medicines. 
These medicines are complex and labile so that bioprocess development times and costs tend 
to be high due to unforeseen issues that occur during scale-up of the manufacturing processes. 
Currently there is little scope to alter a manufacturing processes because we cannot readily 
predict the effects that such changes will have. This research will allow researchers in the area 
to gain a better prediction of the likely routes for manufacture of medicines. The tools here 
described, will enable the biotechnology industry to design more efficient bioprocesses that 
fit to available as well as emerging manufacturing platforms. 
Bioprocess engineering offers a remarkably high return on investment to improve the state of 
manufacturing, with worldwide revenues of ~£110 billion in 2009. In comparison to other 
areas of manufacturing, bioprocess engineering is unusual in several respects. Typical product 
quantities are small (~250 kg/year), but are manufactured to extremely high purity and quality 
specifications (impurities < 0.001%). If the product does not meet specifications, no rework 
or reprocessing is allowed. Continuous improvement efforts (such as the popular 6s initiative) 
cannot be applied directly due to the high variability intrinsic to bioprocesses; it is estimated 
that the best that could be achieved is 3-4s. These sources of variability have led to highly 
regulated manufacturing, whose dictum is that “the process is the product”. No significant 
change can be made to a licensed manufacturing process without detailed and time-
consuming review by the regulatory authorities. Developing and validating a bioprocess for 
manufacture takes ~10 years at a cost of £800M.  
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2.2 Literature review 
2.2.1 Biopharmaceutical industry 
Pharmaceutical industry has its roots in the chemists and rudimental pharmacies dating as far 
back as the Middle Ages, however the pharmaceutical industry as we know today generated in 
the middle of 19th century. Merck and GlaxoSmithKline were possibly the first trademarked 
names in this industry and started their business selling alkaloids (firstly isolated by Emanuel 
Merck in early 19th century) and other chemicals such as laxatives.  
Living microorganisms had been employed for thousands of years in the food industry but it was 
not until the early twentieth century that one single product derived from fungi had such a big 
impact in global health that its founder was awarded with the Nobel Prize in 1945 for it. The 
product was penicillin and its discoverer, Alexander Fleming.   
Eight years later in 1953, Watson and Crick arguably made the discovery of the century, the 
DNA structure, and the first steps in proteomics started to be made. At this point, the scientific 
world started realising the potential of utilising human DNA sequences or genes and host living 
organisms to produce recombinant therapeutic proteins. A new branch of pharmaceutical 
industry was born: biopharmaceuticals. However, it was not for another two decades that the first 
recombinant protein made it to the market. In 1976 Eli Lilly, launched recombinant human 
insulin using Escherichia coli. 
In the following decades more and more products followed using genomic engineering 
techniques, including recombinant Human Growth Hormone, (also known as Protropin®) in 1981 
by Genentech (Genentech, 1985), recombinant hepatitis B vaccine by Valenzuela in 1986 (Fisher, 
1986), recombinant blood clotting factor in 1992 (RECOMBINATE® Factor VIII) by (Baxter, 
2011), and more. 
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Beginning in 1986 a new class of therapeutic molecules started being produced: monoclonal 
antibodies (mAbs). These proteins have the great advantage of being highly specific to an 
antigen, therefore they can be used to target specific cells in the human body, such as cancer 
cells, and take advantage of the patient’s immune system to neutralise them, minimizing side 
effects deriving from other therapies such as chemotherapy or radiotherapy. The first mAb to be 
approved by the FDA was Muronomab-CD3 in 1986 for treatment of transplant rejection (Hooks 
et al., 1991). In the next two decades, mAbs sales have grown exponentially, due to multiple 
companies entering the market. Some of the blockbusters mAbs of the last two decades include 
Rituximab for treatment of non-Hodgkin lymphoma in 1997 (BiogenIdec/Genentech, 2012), 
Natalizumab® in 2004 for treatment of Multiple Sclerosis and Crohn’s disease (BiogenIdec/Elan, 
2012) and more. 
Biopharmaceuticals also include other proteins construct such as enzymes, nucleic acids and 
living microorganisms such as viruses and vaccines.  
2.2.2 Biopharmaceutical global market  
The pharmaceutical industry has seen an exponential growth in the last two decades; especially 
in the last 8-10 years, the growth rate has been in the double digits. This can be attributed mainly 
to two factors: research and development investment increase and market expansion.  
Recent developments in recombinant protein products using mammalian cell cultures and new 
fermentation techniques have pushed titer levels up to 10g/l and over as described by Huang et al 
(Huang et al., 2010), which has had a dramatic impact on amount of product per batch produced. 
This figure is of particular impact when compared with early 2000s industry averages of barely 
1.5 g/l for CHO cell lines. 
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Although the number of new molecular entities (NMEs) approved by the FDA has been steady 
especially in the last fifteen years, R&D investments have grown steadily (Figure 2-1) which has 
meant that more and more block buster drugs have reached the masses. 
 
Figure 2-1 NME vs R&D expenditure. R&D expenditures are adjusted for inflation; curve is a 3-
year moving average for NME/NBEs. Sources: Tuffs CSDD; PhRMA, 2014 Industry Profile, with 
permission. 
Market penetration into booming economies has also played an important role in market growth. 
Reports from last year show that China alone has accounted for over $16bn in biopharmaceutical 
sales in 2009, number destined to increase by 4 fold by 2020 (China national Bureau of Statistics, 
2012). India, Russia and Brazil also are also headed the same way. 
2.2.3 Rare diseases: lysosomal glycogen storage disease type II. 
2.2.3.1 Rare diseases 
There is not a commonly accepted definition of rare diseases in the western world. According to 
the FDA, a disease is to be considered rare when “it affects less than 200 thousand people in the 
US” (FDA, 2013), or 1 in every 1500 people. The European Commission on Public Health 
19 
 
defines rare diseases as “diseases, including those of genetic origin, that are life-threatening or 
chronically debilitating, which are of such low prevalence that special combined efforts are 
needed to address them” (EuropeanCommission, 2004). 
There are over 6000 rare diseases recognised by the WHO, and although each one of them might 
be considered rare, the effect as a whole on the world population is definitely non-negligible. 
International collaboration has proven necessary in treating such diseases, as sometimes the 
number of people with a particular disease in a particular country is so low that it is impossible 
to gather enough of them to run clinical trials, “There are just three cases of progeria in France,” 
says Paloma Tejada, communications director at the European Organization for Rare Diseases 
(EURORDIS). “You cannot organize clinical trials on that basis. You have to achieve critical 
mass and that means international collaboration”(WHO, 2012). 
2.2.3.2 Pompe disease 
Pompe is a rare hereditary progressive disease caused by a mutation on the GAA gene and its 
symptoms include muscular weakness especially to lower limbs, heart and skeletal muscles, 
which get worse with time and can provoke respiratory problems. The genetic transmission is 
autosomal recessive, meaning that the gene is not localised on sex chromosomes, therefore it is 
only transmitted when both parents carry the defective gene. In this case, at each pregnancy, only 
25% of the times the new-born manifests Pompe’s symptoms (affected individual); in 50% of the 
cases only one defective gene is transmitted (unaffected carrier), and the remaining 25% of the 
cases, both good copies are transmitted (unaffected non-carrier). 
People that suffer from this disease lack a specific enzyme, called lysosomal acid alpha 
glucosidase (GAA), which function is to convert glycogen stored in the muscle cells lysosomes 
into glucose, used by the organism for multiple functions. When glycogen cannot be converted, 
it accumulates and it damages the cells, affecting muscular functionality. Since glycogen in cells 
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is always stored in lysosomes, this disease is also called ‘lysosomal glycogen storage disease’ 
(LSD). 
2.2.3.3 Available treatments 
Current commercial treatments are based on an enzyme replacement therapeutic approach. 
Recombinant human GAA enzyme produced via CHO culture is administered intravenously to 
the patient. At the time of writing, only two molecules are licensed by the FDA for the treatment 
of Pompe disease. Both drugs are manufactured by Genzyme: Lumizyme® for adults and 
Myozyme® for paediatric patients. According to one recent FDA news release article, 
Lumizyme®, reserved for late on-set of the disease, “is believed to work by replacing the 
deficient GAA, thereby reducing the accumulated glycogen in heart and skeletal muscle cells”.  
“This drug is approved with a risk evaluation and mitigation strategy (REMS). It will only be 
available through a restricted distribution system called the Lumizyme® ACE (Alglucosidase 
Alfa Control and Education) program to ensure that it is used by the correct patient group”(FDA, 
2010). The safety and effectiveness of Lumizyme® are based on clinical study in 90 patients, 
aged 10-70 years, with late on-set Pompe disease. 
The only other approved treatment for Pompe in the United States is Myozyme®. This drug has 
been in short supply due to limited manufacturing capacity and is currently reserved for infantile 
Pompe form (8 years and younger) (FDA, 2010).  
Bio Marin, a global pharmaceutical company based in Novato CA, specialises in enzyme 
replacement therapies for a number of rare diseases (BioMarin pipeline summarised in Table 
2-1). In 2010 they purchased Zesters Therapeutics Inc. for $22 million, and acquired rights to 
ZC-701, an IGF2-GAA complex at the time in early development for Pompe disease (Leuty, 
2010). This molecule is formed by a complex of insulin-like growth factor 2 (IGF2) linked to 
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GAA enzyme. IGF2 is believed to aid in the process of attachment and assimilation of the 
therapeutic enzyme into muscle cells.  
Compound ZC-701, renamed to BMN-701 completed a phase 1/2 open label, multicentre, 
multiple dose escalation clinical trial, and was expected to publish results in December 2015 
(ClinicalTrials.gov, 2013b). A parallel study of long-term effects of BMN-701 was also being 
conducted, with results expected to be published towards the end of 2016 (ClinicalTrials.gov, 
2013a). 
UPDATE: In June 2016, BioMarin decided to discontinue the clinical development of the BMN 
701 (reveglucosidase alfa) Pompe program (BioMarin, 2016) even though safety and 
effectiveness had been established. This was due to economic unprofitability of the program. 
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Name Disease Causes Symptoms Incidence/ status 
Naglazyme® MPS VI lack of the lysosomal enzyme N-
acetylgalactosamine 4-sulfatase 
- Severe skeletal dysplasia 
- Short stature 
- Motor dysfunction 
1 in 75k 
Approved in EU US AU 
Aldurazyme® MPS I lack of the lysosomal enzyme alpha-L-
iduronidase 
- Mental retardation 
- Retinal degeneration 
- Corneal clouding 
- Cardiomyopathy 
1 in 100k. Approved in EU 
US AU 
Kuvan® PKU (Cofactor to 
PAH enzyme) 
The lack of PKU causes accumulation of Phe 
(Phenylketonuria) 
- Mental retardation 
- Seizures 
1 in 10k Approved in EU,US, 
JP 
Firdapse® LEMS (Lambert-
Eaton myasthenic 
syndrome) 
Delays the repolarisation of nerve terminals 
after a discharge, allowing more calcium to 
accumulate in the nerve terminal 
- Muscular weakness in 
lower limbs 
Approved in EU, Phase III 
CT in US 
BMN-111 Achondroplasia growth factor receptor, which causes a change 
in the way cartilage mutates into bone tissue 
- Dwarfism Early Phase II CT 
poly ADP-ribose 
polymerase 
Repair damaged 
DNA 
detection and initiation of repair of damaged 
DNA in cancer patients diagnosed with 
mutations on gene BRCA1 and BRCA2 
- Breasts and ovarian 
cancer 
Phase I CT 
BMN 701 Pompe disease lack of acid alpha-glucosidase (GAA) causes 
accumulation of glycogen with consequent 
muscle cell death 
- Heart 
- Liver 
- Neurons 
- Myocytes 
1 in 140k 
Phase II CT 
Table 2-1. BioMarin Pharmaceuticals Inc. pipeline as of 12/2013 (BioMarin_Pharmaceutical_Inc., 2013)
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2.2.4 The Product 
2.2.4.1 Structure 
“Human acid α-glucosidase (glycan 1,4 α glucosidase) is a typical lysosomal enzyme with 
substrate specificity to glycogen, maltose and isomaltose” (Rosenfeld, 1975).  The enzyme is 
“most active at low pH (4.0 to 5.0) and hydrolyses both the α-1,4 and α-1,6 glycosidic linkages” 
(Jeffrey et al., 1970).  
As shown in Figure 2-2, the gene in the human genome is located on chromosome 17, q21-23 
(Martiniuk et al., 1985), and it counts 3636 nucleotide pairs.  
 
Figure 2-2 Diagram of human chromosome 17 showing GAA gene location (Martiniuk et al., 
1985) 
There are three common alleles of GAA in the human genome: GAA1, GAA2 and GAA4. GAA 
1 is the most common, alleles GAA 2 and  GAA 4 are much rarer (UniProt, 2012). The isoform 
of interest is the 110kDa isoform (952 aminoacids). 
Despite the absence of crystallographic data of human GAA, a group of researchers from the 
Chinese Culture University of Taiwan (Ho, 2011), was able to “construct a structural model of 
human maltase-glucoamylase (MGAM) through homology modelling using the structural 
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information as a template”. Due to the fact that there is a high similarity between the two 
molecules (GAA and template), they were able to overlay the active site region for both GAA 
and MGAM and the key catalytic residues. With the aid of molecular modelling software MIFit 
(MIFit, 2010) and Molecular Operating Environment (MOE, 2012) it was possible to draw the 
3D structure of GAA and characterise it.  
Results show that GAA is composed by five domains (Figure 2-3):  
“a trefoil type-II domain (res. 89-135), an N-terminal b-sandwich domain (res. 136-346), the 
catalytic (β/α) barrel domain (res. 347-723), a proximal C-terminal domain (res. 724-818) and a 
distal C-terminal domain (res. 819-952)” (UniProt, 2012).  
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Figure 2-3. GAA 3D Structure. (Top) Different domains are identified by different colors. 
(Bottom) Asp-518 active site highlighted. Source (UniProt, 2012)  
The GAA catalytic site was further studied in the work of (Hermans et al., 1991). The behaviour 
of the enzyme in presence of active site-directed inhibitor conduritol B epoxide (CBE) was 
observed and measured in the presence of natural (glycogen) and artificial (4-
methylumbelliferyl-α-D-glucopyranoside) substrates. This is based on the fact that “the 
inactivation of the enzyme is time and concentration dependent and results in the covalent 
binding of CBE”. “Since catalytic activity is required for binding to occur, CBE-labelled 
peptides containing the catalytic residue of the lysosomal GAA were isolated and identified by 
micro sequencing and amino acid analysis”. It was found that “based on sequence similarity and 
CBE binding, Asp-518 is an essential carboxylate in the active site of lysosomal GAA”, which is 
“situated between residue Phe-512 and Glu-521” (Hermans et al., 1991).  
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2.2.4.2 Synthesis 
In eukaryotic cells, the genetic information of a gene present on the DNA is transcribed to a 
messenger RNA (mRNA), which is then transferred to the cytoplasm and translated into 
polypeptides via ribosomes.  
RNA polymerase II pairs complementary bases to the gene of interest on the DNA and catalyses 
the formation of pre-mRNA, a single stranded copy of the gene that can be transferred to the 
cytoplasm.  Before the pre-mRNA is transported to the cytoplasm, it undergoes a series of 
modifications that transform it to mature mRNA. Firstly, a 5` cap is added to the front (5` end) of 
the mRNA shortly after the start of transcription. This is critical to creating the mature version of 
the RNA and it ensures stability of the molecule during translation. Secondly, the mRNA 
molecule is spliced, which is the process by which non-coding sequences, such as introns, are 
removed. Lastly, mRNA undergoes polyadenylation, which is the addition at the 3` end, of a 
sequence of multiple adenines that prevent degradation by exonucleases. The mature 3.6kb 
mRNA is therefore transported outside of the nucleus through nuclear pore, where translation 
occurs with the help of ribosomes and tRNA.  
The polypeptide precursor chain of the GAA enzyme has a size of 100kDa. This molecule 
undergoes a series of post translational modifications that transform it into the mature active 
110kDa and other isoforms. The synthesis of GAA was thoroughly studied by (Hoefsloot et al., 
1988). In his work it was describes how this precursor “enters the lumen of the RER (rough 
endoplasmic reticulum), where glycosylation occurs, and this results in the 110kDa molecular 
specie” (Vanderhorst et al., 1987). “The 110kDa specie enters the Golgi complex where high-
mannose type oligosaccharide side-chains are phosphorylated” (Reuser, 1985). Additional 
binding of the precursor to the “mannose-6-phosphate receptor ensures further transport to the 
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lysosomes, where mature GAA isoforms of 70 and 76 kDa are most abundant”. GAA species of 
“105, 100, 95 and 91kDa have also been identified as processing intermediates” (Reuser, 1985). 
The trafficking of lysosomal enzymes within cellular cytoplasm was also looked into by 
(Kornfeld, 1987). In his work, it was described how specific receptors are responsible for the 
movement of the enzymes through different organelles. The overall pathway is summarised in 
Figure 2-4 Table 2-2 below. 
 
Figure 2-4 GAA Pathway with permission from The FASEB journal (Kornfeld, 1987). 
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Just outside the nucleus 
- The hydrophobic amino-terminal region at the end of the neo-formed polypeptide interacts with a signal recognition 
particle, an 11S ribonucleoprotein. 
- Polypeptide is transported into the ER (endoplasmic reticulum). 
RER 
- Cotraslational glycosylation of selected asparagine residues. 
- A large preformed oligosaccharide [Dol*] is transferred from an intermediate to the nascent polypeptide. 
- The signal recognition particle is excised [ ] 
- Three glucoses and one mannose are excised from the oligosaccharide 
- The protein moves to Golgi apparatus by vesicular transport [  ] 
[Dol*]:  three glucose [  ], nine mannose [  ] and 2 N-acetylglucosamine [  ] residues. 
Golgi 
- Two enzymes, a phosphotransferase and an acetylglucosaminidase, add phosphomannosyl [  ] residues to the 
polypeptide. 
- The resultant phosphomonoester serves as an essential component of a recognition marker that leads to high affinity 
binding to mannose-6-phosphate receptors (MPRs) in Golgi. [ ] 
- In this way, lysosomal enzymes are segregated from other proteins destined to secretion. 
- A small percentage of produced enzyme (10 to 20%) is secreted out of the cell through secretory granules [   ]. 
- This complex exits the Golgi via coated vesicle [  ] and is directed to a pre-lysosomal compartment. 
Prelysosomal Acidified 
Compartment 
- The complex enzyme-MPR enters a prelysosomal acidified compartment where the low PH facilitates dissociation of 
the enzyme from the receptor. 
- The receptor returns to Golgi to pick up a new enzyme. 
- Some secreted enzyme renters the cell via coated pits [  ], and ends up in the prelysosomal compartment. 
Lysosome - The finished enzyme moves from the prelysosomal acidified compartment to the lysosome. 
Table 2-2 Transport mechanism of lysosomal enzymes in human fibroblasts. Adapted from(Kornfeld, 1987) (Hoefsloot et al., 1988, Vanderhorst et 
al., 1987, Reuser, 1985) 
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2.2.4.3 Mechanism of action 
The GAA molecular mechanism in human cells was studied by (Chiba, 1997). In this work the 
activity of α-glucosidases and glucoamylases was compared and it was observed that essentially 
the two are distinguished by releasing α or β glucose respectively. “These enzymes are exo-type 
α-glucosidic O-linkage-hydrolases releasing D-glucose from the non-reducing end of the 
substrate” (Chiba, 1997). 
According to Chiba’s work, reaction of GAA occurs by splitting of the bond between the 
anomeric carbon of the glucosyl residue and glucosidic oxygen (C1-O). The glucosyl residue is 
replaced by a proton from water or an acceptor, namely an exchange reaction between the 
glucosyl residue and the proton in both hydrolysis and transglucosylation. The reaction and 
mechanism of action are shown in Figure 2-5, Figure 2-6 below. 
 
Figure 2-5 Hydrolytic and Transfer Reaction Scheme for α-glucosidase. R. reducing side sugar; 
H-OA. Acceptor; ----. Cleavage point. (Chiba, 1997) 
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Figure 2-6. GAA mechanism of action. Source: The Swedish Information Centre for Rare 
Diseases 
The molecule under BioMarin development (BMN-701) is a fusion protein of GAA and 
glycosylation-independent lysosomal targeting (GILT) tag, which contains a portion of insulin-
like growth factor II, to create an active, chimeric enzyme with high affinity for the cation-
independent mannose 6-phosphate receptor. This compound showed to be taken up by L6 
myoblasts more efficiently that recombinant human GAA (Maga et al., 2013). 
2.2.5 Production of material 
2.2.5.1 Cell cloning and selection 
Generation of stable recombinant protein expressing mammalian cell lines was traditionally a 
long and tedious task, mainly due to the bottleneck operation of clone selection, however with 
the advent of high throughput and cell sorting technologies this has become a much more stream 
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lined procedure such that stably expressing clones can typically be established in 3-4 months 
(Browne and Al-Rubeai, 2007). (Yoshimoto et al., 2013) 
One of the first steps in recombinant GAA production is to establish a stable CHO cell line. This 
is a very important step as it allows the generation of product in a reproducible and consistent 
fashion. The choice of bioreactor size and fermentation time and conditions, and size and type of 
instruments required for downstream processing will largely depend on the amount of protein 
that the cultured cell line is able to produce. “Expression systems can be bacterial, yeast plant 
insect and mammalian. Mammalian cells, mainly CHO, despite lower yields is the system of 
choice mainly because they are more similar to human cells in regards to post translational 
modifications and glycosylation patterns” (Browne and Al-Rubeai, 2007) 
Generally, the process consists of cloning the gene carrying the sequence to the protein of 
interest into a plasmid vector. The vector carries resistance to some antibiotic in order to allow 
for selection of clones that have not acquired the gene. Plasmid is then incorporated into the cell 
via the use of lipid transfection agent such as PEI (Polyethylenimine) or physical aids such as 
electroporation. Once the genetic material is inside the cell’s nucleus, it is replicated like the rest 
of genetic material. In a few occasions, the vector will actually be incorporated within the host 
DNA in which case a much more stable product production is obtained. All cells will have 
different expression levels because the way the vector is incorporated into the host DNA is 
random. Sometimes it will be placed into non coded regions of the host genome, some others in 
more active regions.  
At this point cell line selection can start. In order to select the best clone among all, usually a 
specific antibiotic firstly is added to the mix. All cells that have incorporated the vector carrying 
the gene codifying for the resistance to that specific antibiotic will survive, all others will die. To 
now select among the surviving cells the best clone, the limiting dilution cloning (LDC) 
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technique is executed. This technique consists of preparing in a 96 well microtiter plate, 200µl 
dilutions of the cell broth in a way that in each aliquot there is chance of having one or less cells. 
Wells that show growth are those in which one cell carrying the resistance and the target protein 
was able to divide. Usually this process is done twice to ensure that the colony truly derives from 
one single cell. “A clone of cells derives from one single cell. This is necessary to ensure that all 
organisms in the culture have the exact identical genetic pool and will behave identically” 
(Browne and Al-Rubeai, 2007). At this point all wells are screened to find out the highest 
producing clone, usually using an immunoassay. The content of the well is expanded. Lastly, 
aliquots of this ‘parent’ cell line are banked for future use. 
In Table 2-3 below we summarize some of the more common cloning and selection techniques. 
The process of CHO cell line development involved the use of human GAA ready transfer 
construct from (Origene, 2013),  pcDNA/3.1 and pcDNA5/FRT vectors from Thermo Fisher 
Figure 2-7 and took place at University of Kent.  
There are many challenges associated with the production of a recombinant product in CHO host, 
one being that the transfection of a plasmid into the CHO genome is a rare random event and 
therefore a very low number of clones will present the desirable features of high titre and good 
quality product. Data shows that this procedure is very inefficient, as low as 1 in 10000 clones 
will have favourable features (Gorman and Bullock, 2000).  The reason for this is known as the 
‘position effect’ (Huang et al., 2007): as a rare random event, the odds that a plasmid integrates 
in a highly transcribed section of the host genome (away from chromatin or other less-
transcribed areas) are very slim. Current practice for the selection of high producing clones 
involves a time-consuming and laborious screening strategy due to the fact that the random 
integration of the transgene of interest gives rise to very different expression levels due to 
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variation in the chromosomal surroundings or unpredictable cross-interactions of multiple gene 
copies (Wolffe, 1998) 
Several strategies have been proposed to overcome the positional dependency of random 
integration. One of the most promising methods is the use of homologous recombination system 
for site-directed recombination such as the Flp-in/FRT system from S. cerevisiae (Li et al., 2010). 
Notable work in this field has been done by Laboratory of Protein Engineering of Institute of 
Biotechnology in Beijing, China (Zhou et al., 2010). In their paper, it was described how they 
used the pcDNA5/FRT vector in conjunction with pMCEscan selection system to rapidly 
generate recombinant proteins without cloning.  
In this work we used the Invitrogen developed Flp-In FRT system (Cat# K601001, Thermo 
Fisher) to shorten the clonal screening process due to its ‘site-directed recombination’, which 
facilitates integration of the gene of interest into a specific highly transcribed FRT site in the host 
genome, and allows all clones generated to produce considerable and comparable levels of 
recombinant product. 
 
Figure 2-7. plasmid vectors pcDNA 3.1 and pcDNA5/FRT (Invitrogen, 2013a, Invitrogen, 
2013b)
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Cloning 
Limiting Dilution 
Cloning (LCD) 
Simple, low cost. 
Slow (6-8 weeks to reach viable clone). 
Done on 96well microplate, suspension diluted so that less than 1 cell in a 200µl aliquot. Aliquots are placed in plate wells. 
Based on assumption that colonies in each well come from 1 single cell (not always valid). 
Colonies that proliferate successfully are isolated and tested for productivity using enzyme linked immunoassay (ELISA). 
Surface Protein 
expression 
Based on correlation between surface expression of recombinant proteins and levels of secreted product. 
Recombinant protein linked to a non-fluorescent reporter molecule (such as CD20). Proteins are lined by an internal ribosome entry 
site. (IRES), meaning that both are expressed by same mRNA, therefore relative expression levels but separate translation. 
Cells are analysed via flow cytometry for high level expression of reporter molecule with fluorescent anti reporter Ab.  
Green Fluorescent 
protein (GFP) 
Based on use of reporter molecule such as GFP. Several mammalian cell lines show correlation between GFP expression and 
recombinant production. Fluorescent based selection using flow cytometer. 
Methotrexate Fluorescently labelled MTX permeates cells and bind to dihydrofolate reductase (dhfr).  
The higher fluorescence, the higher are levels of dhfr 
Cells are transfected with a gene carrying dhfr, which confers resistance to MTX, and the gene for recombinant product. 
High producing cell lines are selected based on MTX resistance. 
Gel Microdrop 
technology 
(Bohm et al, 2004) 
Useful for cells that are not permeable to fluorescent molecules, or when this can affect product quality. 
Based on creation of viscous layer around the cell that traps expressed product. 
Cells are grown in biotinylated agarose medium, cell surface is covered in biotin (red dots), then with avidin 
(yellow crosses), and with an Ab against the product conjugated to biotin.                                                   
Cells are incubated to allow them to secrete product, which is trapped on surface. 
Product is stained with secondary Ab conjugated with fluorescent label. 
Selection 
Laser-enabled 
analysis and 
processing (LEAP) 
Cells are grown on capture matrix immobilises secreted protein, which is labelled with fluorescent Ab. 
Image is captured and software analyses image. 
Low producing colonies are eliminated using a pulsed laser beam. 
Automated colony 
picker 
ClonePix system from Genetix or CellCelector from Aviso 
Cells are immobilised in semi-solid medium and incubated to form colonies. Product is secreted and retained in cell vicinity. Halo of 
product is visualised by addition of fluorescent labelled capture Ab.  
Cello system High throughput selection of high producing clones,  
Automated advanced robotic system that handles medium handling, incubation and measurement of cell growth 
Transfected cells are fed into the machine, which seeds them automatically into plates 
Clonality is measured via integrated microscope 
Throughput 600-800 plates, thousands of cell lines can be screened. 
Table 2-3 Common cloning and selection methods. Adapted from (Browne and Al-Rubeai, 2007) 
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2.2.5.2 Available GAA bio processes comparison 
2.2.5.2.1 Generation of recombinant GAA in bacteria. 
Due to the considerably faster and simpler fermentation of bacteria compared to mammalian 
cells, attempts have been made to produce human GAA using prokaryotic systems. A group of 
researchers from New York Medical Centre came to the conclusion that: The “resulting molecule 
had an antigenic reaction to polyclonal rabbit antibody to human GAA using ELISA and western 
techniques, however it was enzymatically inactive. This suggests that glycosylation may play a 
role in enzymatic function” (Martiniuk et al., 1992). The bioprocess is summarised in Table 2-4 
below. 
Table 2-4. GAA bioprocess using prokaryotic systems. Adapted from (Martiniuk et al., 1992) 
Vector 
preparation 
- cDNA containing full human GAA gene,  was subcloned at the HindIII site 
of expression fusion plasmid pMalp-RI and pMalc-RI. 
- The gene-plasmid constructs were sequenced with maltose binding protein 
(MBP) to generate a fusion protein. 
- TB1 and DH5 alpha bacterial strains were transformed with the constructs. 
Fermentation 
- MBP-GAA fusion protein was generated in both strains that containing the 
vector. 
- Non-transfected colonies were eliminated by addition of NZCYM-ampicillin. 
- Induction by IPTG (0.3mM) and growth for additional 2 hr. 
Primary 
Purification 
- Harvest by centrifugation. 
- Localisation of MBP-GAA protein performed according to manufacturer’s 
instructions (New England Biolabs). Protein found in insoluble fraction. 
- Protein was solubilised in 8M urea, followed by dialysis. 
- Fusion protein was digested with Xa protease to separate MBP from GAA. 
Analysis 
- Digested protein created a 106kDa and 40kDa bands on SDS PAGE, as expected 
from the 150kDa fusion protein. 
- GAA reacted with rabbit polyclonal antibody to human GAA by western blotting 
- GAA was not enzymatically active as shown by incubation with artificial 
substrate 4-methylumbelliferyl-α-D glucoside at pH 4.0. 
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2.2.5.2.2 Generation of recombinant GAA in insect cells. 
A few years after Martiniuk tried to produce human recombinant GAA in bacteria, another group 
of researchers tried a similar experiment using insect cells instead. Insect cells expression system 
was chosen because it “apparently gives post-translational modifications and folding similar to 
mammalian cells and relatively large quantities of enzyme can be produced in a relatively short 
period of time” (Wu et al., 1996). The study resulted in production of catalytically active GAA, 
but that was not efficiently taken up by Pompe patients’ fibroblasts. This again proved that 
choice of host expression system has a crucial impact to correct enzyme activity. Although 
similar, differences exist between mammalian and insect cell post translational modifications.  
The bioprocess is summarised in Table 2-5 below. 
Plasmid construction 
- GAA cDNA was excised with Eco RI from specific vector from Reuser 
(Erasmus University) and ligated into pBacPAK8 plasmid, to create vector 
pJW22. 
Transfection 
- Sodoptera Frugiperda cells (IPLB-SD21) were cotransfected with pJW22 by 
lipofectin mediated transfection. 
- Cells carrying GAA gene propagate.  
Purification - Not specified. 
Analysis - Activity was assessed by measuring glucose released from maltose. 
Uptake 
- Fibroblasts from Pompe patients were incubated in medium with enzyme. 
- Poor uptake observed. This is due to differences in posttranslational 
glycosylation, phosphorylation and or proteolytic processing.   
Table 2-5 GAA bioprocess using insect cells. Adapted from (Wu et al., 1996) 
2.2.5.2.3 Generation of recombinant GAA in CHO cells 
Van Hove et al (Van Hove, 1996) worked on the production of recombinant human lysosomal 
GAA in CHO cells and tested the enzyme activity in vitro on human fibroblasts and in vivo on 
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guinea pigs. It was demonstrated that the GAA produced using mammalian cells is active and 
up-taken by target tissue. This was due to the fact that post translational modifications to GAA 
from mammalian cells are crucial for correct enzyme activity. The bioprocess is summarised in 
Table 2-5 below. 
Plasmid prep 
- GAA sequence excised from cDNA of vector (pSHAF2) using Eco R1 
and ligated to mammalian expression vector (pcDNA3). 
- Final plasmid contains GAA, DHFR (resistance and selection by 
MTX) and gene for resistance to Geneticin. 
Cell culture selection 
and transfection 
- Cells + plasmid incubated 2 days with electroporation. 
- Cells cultured in Geneticin and MTX. 
- Cloning (limiting dilution method). 
- Cells lysed. Enzyme activity in supernatant tested. 
- Best 10 clones further grown in MTX. 
- Stability monitored for 3 weeks. 
Primary clarification 
- Harvest centrifuged  
- Supernatant concentrated and dialysed in Buffer A (50mM sodium 
phosphate, 500mM NaCl, PH6.5). 
- Precipitate discarded. 
Chrom. 1 
- Loaded on Concavalin A Sepharose 4B.  
- Washed with buffer A and eluted in buffer A  + 1M methyl α-D 
glucopyranoside 
Concentration  and 
buffer exchange 
- Eluate was concentrated  (PM30)  and dialysed with buffer B 
(20mMsodium acetate buffer, 25mM NaCl, 1mM EDTA, pH 5.2) 
Chrom. 2 and 
concentration 
- Clarified lysate loaded on Sephadex G-200 column. 
- Fractions containing different GAA isoforms collected. 
- Eluate concentrated using 10KDa cartridges. 
Analysis 
- Purity assessed by SDS-PAGE. 
- Activity assessed by measuring conversion rate from glycogen to glucose 
- Patient fibroblasts incubated with enzyme for 24 hours. 
- Guinea pigs were injected with GAA to observe enzyme localisation. 
Tissue analysed after 24 hours. 
Table 2-6 GAA bioprocess using CHO. Adapted from (Van Hove, 1996). NOTE: Primary 
clarification, chromatography 1 and concentration/buffer exchange steps are from (Elferink et 
al., 1984) as described in Van Hove’s article. 
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Enzyme activity was measured by assessing the conversion rate of glycogen and mannose to 
glucose. The precursor 110KDa form was found to have lower Vmax and Km than mixtures 
containing the more mature forms.  
2.2.5.2.4 Isolation of GAA from human placenta. 
The enzyme isolation and purification from human placenta was described in a 1985 article from 
(Reuser, 1985). The process is schematically summarised below in Table 2-7 below. 
Homogenisation 
- 10Kg of Human placenta was thawed from -70, blended in a 1:1 
(w/v) solution with 25mM NaCl, and pH adjusted to 5.2 using 2M 
HCl. 
Centrifugation - Cellular debris was removed by centrifugation at 25000 g for 30min. 
Filtration 
- After filtering the supernatant through cotton wool, the PH was again 
adjusted to 6.6. 
Concentration 
adjustment 
- The solution concentration was adjusted to 10mM using 1M sodium 
phosphate and further clarified by centrifugation at 55000 g for 30 min. 
Binding 
- The supernatant was added to a 200ml Sepharose 4B in 10mM sodium 
phosphate and allowed to bind under continuous stirring overnight. 
Wash and Elute 
- The beads were collected and washed with 10mM sodium phosphate 
pH 6.6 and subsequently the proteins were eluted from the beads at RT 
with 1.5 litres of wash buffer + 1 M methylglucoside. 
Concentration and 
buffer exchange 
- The eluate was concentrated using Amicon hollow fibre and dialysed. 
Chromatography 
- The material was further concentrated and loaded on a Sephadex G200, 
in which the GAA affinity bound to the substrate. 
Table 2-7 Human Placenta GAA purification 
The final eluate had a 10000 fold purification factor and was active. The yield using this method 
however was of only 4mg of enzyme per Kg of human placenta. 
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2.2.5.2.5 Isolation of GAA from human urine. 
The process of isolation of GAA from human urine was described in (Elferink et al., 1984) work. 
This is summarised in Table 2-8 below 
Collection 
- Adult male urine is collected and concentrated to less than 1% volume 
using hollow fibre. 
Centrifugation 
- Concentrate was dialysed in Buffer A (50mM sodium phosphate, 500mM 
NaCl, PH6.5) and centrifuged at 15000 g for 15 minutes.  
- Precipitate discarded. 
Chromatography 1 
- Multiple batches (50) pooled and loaded on Concavalin A Sepharose 4B.  
- Washed with buffer A and eluted in buffer A  + 1M methyl α-D 
glucopyranoside 
Concentration  and 
buffer exchange 
- Eluate was concentrated  (PM30)  and dialysed with buffer B (20mM 
sodium acetate buffer, 25mM NaCl, 1mM EDTA, pH 5.2) 
Chromatography 2 
- Eluate loaded into Sephadex G-100 column. Eluted with buffer B (Q 12 
ml/h). 
Table 2-8 Human Urine GAA purification 
Sephadex G100 allowed separation of the precursor form (110KDa) from the mature isoforms 
(70 and 76KDa). According to the authors, “separation is due to a combination of affinity 
chromatography and gel filtration”, and also they affirm that “the molecular masses of the two 
forms differ sufficiently to allow separation by gel filtration”(Elferink et al., 1984). 
The ability to separate the isoforms allowed the authors to further study and compare the 
properties of the two polypeptides. From this resulted that there is a “striking difference in the 
mannose 6-phosphate (M6P) content of the two forms. The high molecular mass form (110KDa) 
contains about 3.5 M6P residues/polypeptide chains. The two mature forms contain next to none 
M6P” (Elferink et al., 1984). This result was also confirmed by the results of (Gabel et al., 1982) 
work, and the more recent (Van Hove, 1996). 
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2.2.5.2.6 Summary table 
Table 2-9 below summarises the production methods discussed in this section. 
Recombinant human GAA produced in bacteria and insects cells was either inactive or not able 
to be taken up by human fibroblasts. This is due to substantial differences in post translational 
glycosylation.  
Human GAA isolated from human placenta or urine was, as expected, active and functional, 
however this method would not be feasible for production in large scale. These two methods 
were reviewed as they gave important information about purification methods available.  
The only really viable method involved the use of mammalian cells as hosts. 
 
Immunogeni
c 
Enzymaticall
y active 
Cell 
Up-
take 
Feasible 
for 
market 
productio
n 
Purification summary 
Bacteria 
cells 
YES NO NO YES Not specified 
Insect cells YES YES NO YES Not specified 
Human 
urine 
YES YES YES NO 
Concavalin A Sepharose 4B 
Sephadex G100 column 
Human 
placenta 
YES YES YES NO 
Binding onto Sepharose 4B 
Eluate loaded on Sephadex 
G200 
CHO cells YES YES YES YES 
Clarified broth loaded on 
Concavalin A Sepharose 4B 
Eluate concentrated and 
dialysed. 
Eluate loaded on Sephadex  
G-200 column 
Isoforms divided in fractions 
and concentrated 
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Table 2-9 GAA production methods. Summary table. 
2.2.6 Proteases 
Proteases are enzymes that cleave specific peptide bonds. They are present in all living 
organisms and are involved in many processes, from food digestion to regulation of protein 
metabolism to neuropeptide processing and processing of precursors of proteins and 
polypeptides such as hormones and proenzymes. Proteases can be generally classified based on 
the specificity or catalytic mechanisms: endopeptidases hydrolyse internal peptide bonds within 
the protein and exopeptidases remove aminoacids sequentially from the ends of protein 
fragments (Agarwal, 1990). 
The presence of proteases during a bioprocess for pharmaceutical production must be understood 
and tightly controlled, as it might affect target molecule purity and activity. 
The production of complex therapeutic proteins often uses mammalian cell cultures. Cell lines 
such as Chinese hamster ovary (CHO), murine myeloma cell line (NS0) or human retina derived 
cell (PER.C6) are commonly employed for high level expression of recombinant proteins (Birch 
and Racher, 2006). Target protein productivity has risen vertiginously in the last decade with 
titer levels surpassing 10g/l, to support increasing demands, high drug dosage, and control 
production costs of therapeutic proteins such as antibodies, fusion proteins (Robert et al., 2009) 
and enzymes.  
Because of the high value per batch of current large scale fermentation runs, more now than ever 
it is of categorical importance to be able to minimize product degradation early on in the process, 
by optimizing fermentation and downstream processing conditions. One important factor that 
affects product quality is protease levels in the broth during fermentation. As CHO cells secrete 
target protein together with many other proteases, it is important to have a clear understanding of 
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which  proteases are secreted, how they interact with the product and how and if they need to be 
inhibited to prevent product degradation. 
This area has been extensively studied in the last two decades, and overall four major families of 
proteases have been identified to be secreted by CHO cells: metalloproteases or gelatinases, 
serine proteases, cathepsins (part of cysteil or aspartyl proteases) and cysteine proteases. 
2.2.6.1 Metalloproteases 
In a 2003 work (Elliott et al., 2003), the authors monitored the protease activity secreted by 
CHO-K1 cell line grown in serum free media and found that the most common extracellular 
protease was a pro form of matrix metalloproteases-9 (pro-MMP-9), also known as gelatinase B. 
The protease was identified by western immunoblotting by running on an electrophoretic gel a 
solution of clarified media and MMP antiserum and a secondary antibody conjugated to HRP 
(Horseradish Peroxidase). After staining the gel, the bands were identified as pro and active form 
of MMP-9.  
Metalloproteases are cation-dependent proteases that require Zn2+ or Ca2+ to maintain activity. 
These proteases are typically not expressed in normal, healthy, resting tissues, while in contrast 
they are expressed in any repair or remodeling process, in any diseased or inflamed tissue and in 
essentially any cell type grown in culture (Parks, 1999). This enzyme can be inhibited by specific 
Tissue Inhibitor MetalloProteases (TIMPs), which are substrate-based inhibitors containing a 
hydroxamic acid moiety that chelates the active Zn2+ site and renders MMPs catalytically 
inactive (Moore and Spilburg, 1986). As later determined, iron citrate inhibits metalloproteases 
by blocking the Zinc atom in the enzymatic catalytic domain (Clincke et al., 2011).  
The authors concluded that MMPs are highly active proteases against their substrates. This 
protease cleaves collagens, gelatins, proteoglycans and elastins (Nagase and Woessner, 1999). 
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Heterologous protein sensitivity to MMP should therefore be assessed as a first step (Elliott et al., 
2003). 
2.2.6.2 Serine Proteases 
Serine proteases are widely present in nature and take part in several biological activities 
including digestion process, immunoresponse, blood coagulation and reproduction. They are 
called serine proteases because they catalyse the hydrolysis of peptide bonds in polypeptides, 
and they all have a serine residue that plays a critical role in the catalytic process. The catalytic 
site is common for all serine proteases and is composed by an aspartate residue (Asp102), 
histidine residue (His57) and a serine residue (Ser195) (Mathews et al., 2003). 
They can be divided in two major groups based on principal structural folding: trypsin and 
subtilisin-like as shown in Figure 2-8. “Trypsin-like structure (a) consists of two β barrels with 
the catalytic triad coming together at the interface of two domains. Members of this family in 
eukaryotic cells include cathepsin G, chymase, chymotrypsin, elastase, factor D, factor VIIa, 
thrombin and trypsin. Subtilisin-like structure (b) consists of a three layer αβα sandwich fold 
with catalytic serine and histidine the ends of adjacent helices” (Madala et al., 2010). 
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Figure 2-8 a) trypsin-line serine proteases b) subtilisin-like serine proteases. Source 
pubs.acs.org 
This class of proteases has been identified in CHO matrix in the 2011 work of Clinke et al. By 
using specific protease inhibitors several proteases were discovered in the CHO culture clarified 
medium, among which serine proteases by using phenylmethylsulfonyl fluoride (PMSF) and 
Complete Inhibitor Cocktail (Roche). The presence of metalloproteases was also reconfirmed by 
using EDTA inhibitor. Similarly to Elliott’s experiments, clarified medium was analyzed via 
western immunoblotting. 
In one review paper, (Madala et al., 2010) summarised some of the most common serine 
proteases found, and identified inhibitors to most of them. Of these, only a small portion is 
secreted extracellularly. The data can be seen in Table 2-10 below. 
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Serine Protease EC code Inhibitor PDB Code 
brachyurin C 3.4.21.32 1azz 
cathepsin G 3.4.21.20 1kyn, 1au8, 1cgh 
chymase 3.4.21.39 1klt, 1pjp 
α-chymotrypsin 3.4.21.1 1acb, 1cgi, 1cgj, 1cho, 1gl0, 1gl1, 1hja, 1mtn, 2cha, 6cha 
γ-chymotrypsin 3.4.21.1 1ab9, 1afq, 1ca0, 1cbw, 1gcd, 1gct, 1gg6, 1ggd, 1gha, 1ghb, 1gmc,1gmd, 1gmh, 1k2i, 1n8o, 1vgc, 2gct, 
2gmt, 2vgc, 3gch, 3gct,3vgc, 4gch, 4vgc, 6cha, 6gch, 7gch 
δ-chymotrypsin  1dlk 
complement factor D 3.4.21.46 1bio, 1dfp, 1dic 
cytomegalovirus 
assemblin 
3.4.21.97 1jq7, 2wpo, 1njt, 1nju, 1nkk, 1nkm 
human neutrophil 
elastase 
3.4.21.37 1b0f, 1h1b, 1hne, 1ppf, 1ppg 
pancreatic elastase I 3.4.21.36 1b0e, 1bma, 1btu, 1e34, 1e35, 1e36, 1e37, 1e38, 1eai, 1eas, 1eat,1eau, 1ela, 1elb, 1elc, 1eld, 1ele, 1elf 
pancreatic elastase II 3.4.21.71 1bru 
enteropeptidase 3.4.21.9 1ekb 
coagulation factor VIIa 3.4.21.21 1cvw, 1dan, 1fak, 1qfk 
coagulation factor IXa 3.4.21.22 1pfx, 1rfn 
coagulation factor Xa 3.4.21.6 1ezq, 1f0r, 1f0s, 1fax, 1fjs, 1fxp, 1g2l, 1g2m, 1ioe, 1iqe, 1iqf, 1iqg,1iqh, 1iqi, 1iqj, 1iqk, 1iql, 1iqm, 1iqn, 
1j17, 1kig, 1ksn, 1kye,1lqd, 1lpg, 1lpk, 1lpz, 1mq5, 1mq6, 1nfu, 1nfw, 1nfx, 1nfy, 1p0s,1xka, 1xkb 
granzyme B (natural 
killer cell protease) 
3.4.21.79 1fi8, 1iau 
hepatitis C NS3 4a 
protease(hepacivirin) 
3.4.21.98 1dxw, 1dy8, 1dy9 
kallikrein 3.4.21.35 1hia, 1l2e, 1lo6, 2kai, 2pka 
kexin 3.4.21.61 1ot5, 1r64 
kumamolisin 3.4.21.- 1gtj, 1gtl 
lysyl endopeptidase 3.4.21.50 1arc 
R-lytic protease 3.4.21.12 1gbb, 1gbc, 1gbd, 1gbf, 1gbh, 1gbi, 1gbk, 1gbl, 1gbm, 1p01, 1p02,1p03, 1p04, 1p05, 1p06, 1p10, 1p11. 
matripase 3.4.21.- 1eaw 
Mesentericopeptidase 3.4.21.62 1mee 
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plasmin 3.4.21.7 1bui 
t-plasminogen activator 3.4.21.68 1bda, 1rtf, 1a5i, 1a5h 
prolyl oligopeptide 3.4.21.26 1e5t, 1e8m, 1e8n, 1h2y, 1h2z, 1o6f, 1o6g, 1qfm, 1qfs 
proteinase K 3.4.21.64 1bjr, 1pek, 1pfg, 1pj8, 1oyo, 3prk 
protein C (activated) 3.4.21.69 1aut 
sedolisin (pseudomona-
pepsin) 
3.4.21.100 1ga1, 1ga4, 1ga6, 1kdv, 1kdy, 1kdz, 1ke1, 1ke2 
signal peptidase I 3.4.21.89 1b12 
streptogrisin A 
(proteinase A) 
3.4.21.80 1sgc, 3sga, 4sga, 5sga 
streptogrisin B 
(proteinase B) 
3.4.21.81 1cso, 1ct0, 1ct2, 1ct4, 1ds2, 1sgd, 1sge, 1sgn, 1sgp, 1sgq, 1sgr,1sgy, 2sgd, 2sge, 2sgf, 2sgp, 2sgq, 3sgb, 
3sgq, 4sgb 
streptogrisin E (glutamyl 
endopeptidase II) 
3.4.21.82 1hpg 
subtilisin BPN 3.4.21.62 1a2q, 1gns, 1gnv, 1lw6, 1sbn, 1sib, 1sua, 1sue, 1sup, 1ubn, 2sic,2sni, 3sic, 5sic 
subtilisin Carlsberg 3.4.21.62 1a10, 1av7, 1avt, 1be6, 1be8, 1cse, 1oyv, 1r0r, 1scn, 1vsb, 3vsb 
subtilisin DY 3.4.21.62 1bh6 
thermitase 3.4.21.14 1tec, 2tec, 3tec 
thrombin 3.4.21.5 1a46, 1abj, 1ay6, 1bth, 1de7, 1fph, 1k22, 1nrn, 1nro, 1nrp, 1nrq,1nrs, 1tbq 
tricorn 3.4.21.- 1n6d, 1n6e, 1n6f 
trypsin 3.4.21.4 1aut, 1ezx, 1sbw, 1tyn, 3btg 
urokinase plasminogen 3.4.21.73 1c5w, 1c5x, 1c5y, 1ejn, 1f5k, 1f5l, 1f92, 1fv9, 1gi7, 1gi8, 1gi9,1gj7, 1gj8, 1gj9, 1gja, 1gjb, 1gjc, 1gjd 
venom plasminogen 3.4.21.- 1bqy 
Table 2-10 Crystal structure Listing for 220 Inhibitors Complexed with 44 Serine Endoproteases. EC code: Enzyme Commission number; PDB 
code: Protein Data bank Code. Adapted from (Madala et al., 2010) 
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2.2.6.3 Cysteine Endopeptidase 
Among proteases found to be secreted by cultured CHO cells, cysteine proteases are also found. 
From one review paper written by Satoh et al in 1990, the activity of proteases present in serum 
free conditioned medium of DHFR-deficient CHO cells was analysed using Methyl Cumaryl 
Amide (MCA) substrates at pH 7.0. They found that some substrates were degraded by the 
serum consistently with increment of non-viable cells, indicating the presence of intracellular 
proteases released by the dying cells. There was also observed to be peptidase activity towards 
peptidyl substrate, Boc-Leu-Arg-Arg and Z-Phe-Arg in particular. This activity was found to be 
inversely proportional to the number of viable cells, indicating the secretion by intact CHO 
(Satoh et al., 1990). In the paper, the effects of various inhibitors were also assessed. It was 
found that known “cysteine protease inhibitors had measurable effects on the activity of the 
medium, indicating the presence of cysteine proteases”. In particular the inhibitors used were 
leupeptin, E-64 and chymostatin. The pH optima for the endopeptidases was found to be 
between 6.0 and 9.5. 
Overall this study showed how exopeptidases were mainly secreted intracellularly, and released 
outside during cell lysis, whereas endopeptidases were actively secreted by viable CHO cells. 
2.2.6.4 Cathepsins  
Most cathepsins are cysteine proteolytic enzymes mainly localised in the lysosome. With a few 
exceptions, the majority of cathepsins belong to the endopeptidases family (Agarwal, 1990). 
They catalyse the hydrolysis of a variety of protein substrates with different specificities and are 
involved in a wide range of processes. In particular they have been identified responsible of 
intracellular protein turnover and post-translational processing of some precursors such as 
endorphin and insulin and are involved in several pathological processes such as tumour 
metastasis, muscular dystrophy and arthritis (Agarwal, 1990). 
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 In one review paper, Agarwal et al describes how just like GAA, cathepsins are synthetised on 
membrane bound ribosomes, then transferred through the RER and finally into the Golgi 
apparatus. After modifications to the tertiary structure, they are transported into the lysosomes 
via MPRs, and also that just like GAA, they are active at acidic pH (4 to 5).  
It has been pointed out that although rarely secreted, in some cases, the precursors of these 
lysosomal enzymes escape the normal pathway and continue along the secretory route, entering 
the storage granules and finally getting released into the extracellular space. This occurs in 
activated macrophages, osteoclasts and interestingly in fibroblasts from patients with I-cell 
disease (lysosomal storage disorder), thereby extending the pattern of physiological and 
pathological conditions in which these enzymes may be involved (Santamaria et al., 1998, 
Kornfeld and Mellman, 1989). 
There are many different cathepsins and the relevant features are summarised in Table 2-11 
below.
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Cathepsin 
type 
PH optimum Involved in Inhibitors 
A 5.2-5.7 
Muscular dystrophy, Skeletal muscle. 
Cleaves sequentially C-terminal hydrophobic residues. 
- di Isopropyl fluorophosphates (DIPF) 
- phenylmethane-sulphonylfluoride (PMSF) 
B 3.5-6.0 
Degradation of tissue proteins in the lysosomal system. 
Possesses dipeptidyl carboxypeptidase activity. 
- 4-Chloromercuribenzoic acid (PCMB) 
- iodoacetamide (IAM) 
- N-ethylmaleimide (NEM) 
- leupeptin 
C 7.7 
Muscular dystrophies and polymyositis. Splits  
dipeptide naphthylamides and  removes dipeptides 
from amino terminus 
- iodoacetic acid (IAA) 
D 2.8-5 
degradation of intracellular and 
endocytosed proteins (myelin) 
- pepstatin 
E 2.5 
found in bone marrow, polymorphonuclear 
leukocytesand macrophages 
- pepstatin 
F 4.5 
degrades cartilage proteoglycan at pH 4.5 - α2-macroglobulin 
- whole egg white 
G 
7.5 
 
digests a number of proteins such as 
prothrombin and elastin, and cleaves some synthetic 
chymotrypsin substrates 
- soybean trypsin inhibitor (STI) 
- α1 proteinase inhibitor (α1PI) 
- α1 antychimotrypsin,  chymostatin 
- diisopropylphosphofluoridate (DIPF) 
H 6.8 
hydrolyses blocked synthetic substrates such as 
benzoylarginine naphthylamide (BANA) 
and substrates with free oL-amino groups such as 
arginine naphthylamide 
- 4-Chloromercuribenzoic acid (PCMB) 
- iodoacetamide (IAM) 
- N-ethylmaleimide (NEM) 
I 6.5-7 BANA hydrolase - leucine chloromethane 
J 6.8 
hydrolyzes only a synthetic substrate, 
benzyloxycarbonyl-Phe-Arg-aminomethylcoumarin 
(Z-Phe-Arg-AMC)  
- 4-(hydroxymercuri)BenzoicAcid (PHMB) 
- α1 proteinase inhibitor (α1PI) 
- ATP 
- Ca++ 
K 6.2 Bone remodelling. Hydrolyses various synthetic - leupeptin 
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substrates such as Z-Arg-Phe-AMC, Z-Arg-Arg-AMC 
and Bz-Val-Lys-Lys-Arg-AMC.  
- potassium ions 
L  
splits cytosolic proteins, collagen, myosin, actin, 
tubulin, calmodulin, insulin, glucagon and many 
enzymes 
- leupeptin 
- benzyloxycarbonyl-Phe-Phe-diazomethyl ketone 
M 7 associated with lysosomal membranes - leupeptin 
N 3.5 Cleaves N-terminal peptides of native collagen - N/A 
P 5-6 
processing of propolypeptides - 4-Chloromercuribenzoic acid (PCMB) 
- leupeptin 
R 7-8 
hydrolyses casein and most of the ribosomal proteins - di Isopropyl fluorophosphates (DIPF) 
- soybean trypsin inhibitor (STI) 
- α1 proteinase inhibitor (α1PI) 
S 3.5 
antigen presentation: digests haemoglobin and other 
proteins.  
- z-Phe-Phe-diazomethane 
T 7 
catalyses the conversion of 
multiple forms of tyrosine aminotransferase 
- thiol blocking reagents 
W  
immune response: cytotoxic effector cell compartment 
and natural killer cells 
- peptide based inhibitor 
Z (or X)  
Intracellular protein turnover - Gly-Phe-Gly-semicarbazone 
- Proteinase Inhibitor E 64 
Table 2-11 Cathepsin A to T data adapted from (Agarwal, 1990). Cathepsin W data adapted from (Ondr and Pham, 2004). Cathepsin Z adapted 
from (Santamaria et al., 1998) 
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Cathepsin Z 
The behaviour and monitoring of this specific protease is of particular interest in this project as it 
is believed that it might be responsible for target protein (GAA) degradation during the 
bioprocess.  
Cathepsin Z (or X) is a cysteine endopeptidase part of the papain family. It is well established 
that the different cysteine proteases in this family are synthetized as preproezymes, which are 
processed to the corresponding proenzymes and targeted to the lysosomes by the M6P signal 
attached to them. The enzymes are further processed to mature forms consisting of either a single 
polypeptide chain or a two chain form composed of heavy and light chains linked by a 
disulphide bond (Berti and Storer, 1995). However in some cases, the precursors of these 
lysosomal enzymes escape from this processing pathway and continue along the secretory route, 
entering storage granules and being finally released into the extracellular space (Kornfeld and 
Mellman, 1989).  
It is believed that Cathepsin Z expression is linked to overexpression of lysosomal GAA. This 
could be due to the transport mechanism, mannose–6–phosphate receptor being overloaded with 
GAA, which induces CatZ and other lysosomal proteins being secreted as well. The commercial 
form of GAA, having the GILT tag is likely more sensitive to CatZ and other proteases due to 
potential clipping. Therefore overexpression of GAA/GILT results in CatZ expression which 
impacts stability of the target molecule.   
2.2.7 Detection of product and impurities 
Downstream purification is by definition the process of removal of impurities from the process 
stream in order to purify the target molecule to levels established by appropriate regulatory 
agencies. In the biopharmaceutical industry, this level is set extremely high, and failure to meet 
regulatory requirements on protein purity and stability can have serious consequences on patient 
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safety and drug effectiveness and overall business reputation, which will have a tremendous 
economic impact on the manufacturer.  
Host cell protein (HCP) release during production of therapeutic proteins is a critical quality 
attribute that must be monitored and reduced to acceptable levels during the production of a 
biotherapeutic protein (Bracewell et al., 2015). Being able to control HCP release during harvest 
and their removal via downstream processing is thus an important component of the 
manufacturing of such molecules and assurance of the ability of processes to achieve safe levels 
of HCP must be reported to regulatory authorities. Typical purity targets for a mAb type include 
<100 ppm HCP, <10 ng/dose DNA and  <5% product aggregates (Chon and Zarbis-Papastoitsis, 
2011). Some HCPs are known to be co-purified with the recombinant protein target, whilst 
others, specifically proteases, are reported to lead to product degradation (Gao et al., 2011). 
The physical properties of particulates  in the bioprocess stream are exploited during the 
downstream process to achieve separation and thus purification. During the first stages of 
primary clarification of CHO culture, usually the cells are separated from the media via 
centrifugation and filtration. These techniques are not very selective and separate particles only 
based on mass. In this instance for example, cells are easily removed via continuous 
centrifugation based on the great difference in mass between them and the proteins suspended in 
the media.  
As purification moves forward and the process stream is constantly more and more clarified 
there might not be as many radical differences between proteins and nucleic acids in solution and 
finer separation techniques are required. One of the most common and powerful separation 
techniques used in biopharmaceutical industry is chromatography.  
Chromatography is a powerful tool for the purification of biomolecules. “It aims at exploiting 
every little difference in the chemical and physical properties of molecules to effect the 
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separation of a mixture into individual compounds. These include differences in chemical 
reactivity, polarity and molecular size” (Ravindranath, 1989). There are several techniques used 
to separate molecules based on properties such as molecular charge, hydrophobicity, size and 
affinity. By using a combination of two or more of these techniques it is possible to achieve very 
high levels of protein purity.  Before moving forward however, it is important to briefly define 
such properties:  
Isoelectric point. It is the pH at which the molecule has a neutral charge. This quality allows 
separation through ion exchange chromatography (IEC). The pH of the mobile phase plays a 
very important role for sample retention as a change in pH over the isoelectric point (pI) would 
shift the charge of the protein. As explained later in greater detail, this technique  separates large 
proteins, small nucleotides and aminoacids on the basis of their charge. 
Hydrophobicity. “it’s the property of a molecule to repel from a mass of water” (Ben-Naim, 
1980). Separation based on this property takes advantage of hydrophobic interactions between 
molecules. “Hydrophobic regions (which are non-covalent and non-electrostatic) of a molecule 
may be attracted to non-polar regions of another molecule” (Ravindranath, 1989). 
Chromatography technique based on this property is hydrophobic interaction chromatography 
(HIC). When a sample containing a mixture of proteins is applied to a HIC column in high salt, 
hydrophobic and hydrophilic regions interact with the resin and bind to it. The salt interacts with 
water molecules to reduce solvation of the protein molecules in solution (Porath, 1986). As salt is 
gradually decreased, hydrophobic regions become exposed and are absorbed by the mobile media 
and therefore start eluting. The more hydrophobic the molecule, the less salt is needed to promote 
binding. 
Size. Protein size is determined by the number of amino acids forming the polypeptide and by 
the way the protein is folded. This quality allows separation in size exclusion chromatography 
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(SEC), in which molecules larger than the beads average pore size travel around them come out 
of the column first. Smaller molecules diffuse into the gel structure and are retained by the 
stationary phase and elute in order of decreasing molecular size. 
Affinity. Affinity it’s a method of separating biochemical mixtures based on a highly specific 
interaction between antigen and antibody, enzyme and substrate, or receptor and ligand. It’s the 
most selective type of separation technique as it takes advantage of ‘highly specific affinities that 
certain molecules naturally have for certain substrates, mainly enzyme-substrate, antibody-
antigen and receptor-hormone’ (Ravindranath, 1989). The process is reversible and it is possible 
to break the disulphate covalent bonds to release the antibody during elution. 
2.2.7.1 The issue 
It is hypothesized that the issue in this particular process of purification of recombinant human 
acid alpha glucosidase (rhGAA) is that some proteases naturally produced by CHO cells in 
culture might have similar physical properties in common with GAA such as size and isoelectric 
point and therefore could be harder to separate than most other impurities.  The presence of such 
proteases in one or more stages of purification and possibly even in the drug product  could have 
a detrimental effect on the target protein quality. 
During GAA production using a CHO culture, eventual proteases present in the process stream 
will be screened using an array of analytical techniques described below. Known proteases will 
be recognised using immunoassays, unknown ones will have to be identified using mass 
spectrometry.  
2.2.7.2 Analytical assay development 
Detection, quantification and identification of the components of the matrix at each different 
stage of the purification process will be achieved with ad-hoc analytical assays described below.  
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Immunoassays 
In order to ensure that the developed cell line is producing the target molecule, one of the first 
assays that will have to be performed is for GAA detection. As this is a well-known protein, 
GAA antibody is commercially available and running an immunoassay such as ELISA or 
AlphaLISA would be quite straightforward. This assay takes advantage of the immunogenic 
reaction that naturally occurs between antigen and antibody. Generally, microtiter plate wells are 
coated with immobilised antibody specific to GAA. Sample is added and eventually present 
antigen binds to the plate. A detection antibody specific to the antigen is added to the plate, a 
secondary antibody specific to the primary antibody is then added. The secondary antibody 
carries an enzyme bound to it. Enzyme substrate is finally added to the solution, which makes 
the solution change colour. The colour wavelength can be measured by a spectrophotometer and 
concentration of original antigen is therefore determined. This technique reveals presence and 
amount of a particular protein in a solution, and it’s useful when the protein of interest is known. 
In order to determine if other unknown proteases are present however, it is necessary to screen 
the solution using other techniques such as 2D gels or western blot analysis.  
Electrophoresis 
2D gel electrophoresis is a useful technique used to separate a diverse mix of proteins. An SDS-
PAGE gel is loaded with a mix of proteins, and are separated as they move through it. The 
advantage of this technique over regular SDS-PAGE is that it allows separation based on two 
different molecular properties such as mass and charge, which is handy when diverse molecules 
are hard to separate because for example have all the same mass. With this technique, a mix of 
peptides could be separated by charge first and by size on the second axes. Generally, gels are 
then stained to make proteins visible using Silver or Comassie Blue staining. Proteins are usually 
treated with a reducing agent prior to electrophoresis in order to break disulphide bonds and 
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favour the formation of linear structures. The other advantage of this technique over 
immunoassays is that it allows for recovery of material for further analysis. The protein of 
interest can in fact be ‘cut-out’ of the gel and identified using other techniques such as mass 
spectrometry (MS).  
Western blot 
Western blot is usually used in conjunction with a developed electrophoretic gel. The gel 
containing the mix of proteins separated by a specific property is subject to a perpendicular 
electric field, which moves the proteins outside of the gel. A membrane usually made of 
nitrocellulose or polyvinylidene difluoride (PVDF) is placed just next to it, and proteins bind 
non-specifically to it in a process called ‘blocking’. This membrane then is subject to a process 
similar to ELISA. The membrane is incubated in a solution with a primary antibody specific to a 
particular protein, washed and finally incubated with a secondary antibody specific to the 
primary antibody, linked to an enzyme specific to a substrate. Once the substrate is added, a 
change in colour reveals where the specific protein of interest is located. This process can be 
repeated several times with different antibodies to identify all proteins present. The material that 
does not react with any known antibody can then be collected and analysed via MS. Information 
source (Abcam, 2012) 
Enzymatic activity 
Enzyme activity is another metric that needs to be assessed as this measurement gives important 
information on enzyme kinetics with a particular substrate and is related to enzyme purity, as the 
value becomes larger as the enzyme is purified. Reaction rate however stays the same or might at 
times increase due to removal of eventual inhibitors from the process stream. The activity is 
generally measured in µmol mg-1min-1 
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In an article by (Reuser et al., 1978) GAA activity towards substrates such as glycogen and 
maltose was measured. 10µl of cell homogenate was mixed with maltose (50µl of 10g/l, Baker, 
Phillipsburg, N.J.) or glycogen (50µl of 50g/l Gibco, Grand Island, N.Y.) as substrate. Both were 
dissolved in 0.2M potassium phosphate-citrate buffer, pH4.4. After incubation and heating for 2 
min at 1000C the amount of released glucose was determined by adding 200µl glucose reagent 
according to (Koster et al., 1976).  Results showed that enzyme activity for infantile Pompe 
disease was 1%, and late onset Pompe disease was between 7 and 22% compared to healthy 
patients GAA activity.   
This assay will be used to determine the presence and activity of multiple proteases in different 
stages of purification by measuring conversion rates of specific substrates. 
GAA diagnostic assay 
Most enzymatic activity assays work by measuring colorimetric change due to the enzymatic 
degradation of a substrate. This approach is not feasible for GAA quantification as the presence 
of unrelated α-glucosidases (predominantly maltase-glucoamylase) can interfere with absolute 
GAA quantification. Acarbose, an amylase inhibitor, was used in a study by Okumiya et al to 
quench activity of other amylases and was proven capable of measuring accurately GAA activity. 
This method is now diagnostically used in the clinics to test suspected Pompe patients’ blood. 
Due to its reproducibility and rapidity, it was adapted to measure GAA amount in in-process 
samples.   
Zymography 
Zymographic techniques allow detection of proteases and some other hydrolytic enzymes 
following electrophoresis in various types of gel matrices” (Lantz and Ciborowski, 1994). 
Zymography is a versatile two stage technique involving protein separation by electrophoresis 
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followed by detection of proteolytic activity. It is useful as it allows the determination of enzyme 
activity using a SDS PAGE electrophoretic gel. In this process, polypeptides are not treated with 
a reducing agent neither are boiled in order to retain original active structure. After 
electrophoresis SDS is removed from the gel with the use of a detergent such as Triton X-100 
and the gel is stained using Comassie Blue. Enzyme activity indicated by “zones  of lysis, where 
proteolytically active bands have degraded the  substrate  in  the  indicator  gel,  are  visualized  
as  clear  zones against an opaque background  on dark-field illumination or as clear zones  
against  a dark blue background  after staining  of the gels with Comassie Brilliant Blue R-250” 
(Lantz and Ciborowski, 1994). 
Identification Assay 
One of the workhorses of analytical chemistry is Mass Spectrometry (MS). This technique has 
multiple applications in drug development ranging from protein characterisation to glycan 
analysis. There is a wide array of MS variations and it is not the intention of this work to go 
through all of them.  
MS is based on the principle that charged particles that travel through a magnetic field, are 
subject to a deviation of their path that is dependent on their mass. The mass spectrum produced 
of a polypeptide acts as a sort of fingerprint as it is unique to each one of them. 
A mass spectrometer is generally composed by four modules: an ion source, which excites the 
atoms in the molecule, an extraction system, a mass analyser and a detector. 
There are two approaches in protein characterisation using MS. The most common one is to 
digest the protein in fragments using specific protease and analyse them in a process called 
‘bottom up’. The information gathered by single peptides can be used to gain knowledge on the 
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full peptide. The other one is to run through the MS intact proteins and this process is nicknamed 
‘top down’. 
Peptide Mapping is a good example of the bottom up technique and although time consuming it 
is frequently utilised to analyse the primary structure of complex therapeutic proteins such as 
monoclonal antibodies. “Biomolecules of interest are subject to a protease, usually trypsin or 
Lys-C, that enzymatically cleaves the protein in specific peptides, which are then separated by 
LC and analysed by MS. During this process proteins are denatured (unfolded), reduced (to 
break disulfide bonds) and carboxymethylated (to prevent reformation of bonds). Mixture is then 
washed and digested and injected into the MS” (Dick et al., 2009).  
TEM imaging 
Transmission Electron Microscopy technique has been used for the past 80 years to acquire high 
resolution images of biological samples. It works similarly to a light microscope, although it uses 
electrons as "light source" and their much lower wavelength makes it possible to get a resolution 
a thousand times better than with a light microscope. In this work this technique will be used to 
acquire images of GAA producing CHO cells and compare them with a Null strain. Due to its 
high resolution it will be possible to visualise cells lysosomes to assess whether GAA over-
expression has an impact on lysosomes phenotype.  
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2.3 Objectives 
2.3.1 Production of stable CHO cell line for material generation. 
The production of a stable CHO cell line expressing GAA gene was the first goal of this project, 
and constituted the bulk of the first year MRes research project. This cell line was useful during 
the entire course of the EngD project as it was used to produce material to develop and optimize 
the purification process. This process took place in conjunction with University of Kent School 
of Biosciences labs.  
2.3.2 Development of assays for detection of product in the bioprocess stream 
Analytical assays had to be developed aimed at the detection and quantification of the product 
(GAA) levels at the different process stream steps. These assays were immuno, gel-
electrophoresis, western blots, zymography and enzymatic activity based. Tandem Mass Spec 
identity assays were also used to confirm identity of the product. 
2.3.3 Bioprocess mimic 
The development of the fermentation and downstream purification process had to closely mimic 
the process already in place at BioMarin, in order to ensure the maintenance of same conditions 
that cause CHO cells to produce specific proteases during the bioprocess. The downstream 
bioprocess was constituted of a series of two chromatography steps (IEX and HIC) after 
clarification of harvest cell culture fluid.  
2.3.4 Characterization of cell stress and its impact on protease production 
It is believed that the overexpression of GAA in recombinant CHO cells causes cell stress and 
over production of proteases such as cathepsin B, Z and others. A series of assays were used to 
compare recombinant vs. its original Null (untransfected) counterpart to identify differences in 
lysosomal phenotype, amount and type of proteases and their localisation in the cell structure. 
Images of lysosomes were be taken with Transmission Electron Microscope (TEM) and different 
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tandem MSMS techniques and zymography were used to identify and quantify HCP presence 
throughout different bioprocess steps.
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2.4 Project estimated timeline / Gantt chart 
An estimated project timeline is included for reference in Table 2-12 below: 
 
Table 2-12. Gantt chart of estimated project timeline.
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3 Materials and methods 
3.1 Cell line generation 
3.1.1 Cloning 
This section describes the process involved in cloning the human GAA gene into pcDNA 3.1 and 
pcDNA5/FRT vectors. This constitutes the first step of generation of stable CHO cell cultures. A 
list of all materials and reagents used in plasmid cloning is included in Table 3-1 below. 
Materials and 
Reagents 
Product 
code 
Manufacturer Description 
Abe 1 RE n/a  Restriction enzyme 
Agar A5054-250G Sigma  
Agarose A9539500G Sigma  
Ampicillin A9518-25G Sigma Ampicillin sodium salt 
Ase 1 RE ER0911 Thermo Scientific Restriction enzyme 
DH5 competent 
cells 
n/a n/a  
DNA stain S33102 Invitrogen For electrophoresis 
FreeStyle MAX 
CHO 
K900020 Thermo Fisher Expression system 
Gel Extraction Kit 28704 Qiagen Qiaquick Gel Extraction Kit 
Human GAA gene SC125512 Origene Homo Sapiens glucosidase, alpha, acid 
(GAA) transcript variant 1 as transfection 
ready DNA in vector  pcmv6-XL6 
Hyperladder 1KB plus Bioline For electrophoresis 
Ligase enzyme M180A Promega T4 ligase 
Loading buffer bio-37045 Bioline For electrophoresis 
MiniPrep kit 27104 Qiagen Qiaprep Spin Miniprep Kit 
MaxiPrep kit A2393 Promega Pureyield™ Plasmid Maxiprep System 
NaCl S3105-65 Fisher Scientific  
Not 1 RE 10889026 Roche Restriction enzyme 
pcDNA 3.1 vector V790-20 Invitrogen  
pcDNA 5/FRT 
vector 
V6010-20 Invitrogen  
Sal1 RE 11745-635 Roche Restriction enzyme 
TAE A1416 AppliChem Tris base, acetic acid and EDTA 
Top10 Competent 
cells 
C404010 Invitrogen Chemically competent 
Triptone 211705 BD  
TSAP enzyme M991A Promega Thermosensitive alkaline phosphatase 
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Table 3-1. Materials and reagents list. 
3.1.1.1 Media preparation 
The following media were scaled up or down as needed for different experiments.  
200ml LB Agar.  Mix: 
2.0 g Triptone, 3.0 g NaCl, 3.0 Agar, 1.0 g Yeast Extract, 200ml milliQ water. 
Autoclave, let cool to about 500C, add ampicillin, pour aseptically into new petri dishes 
100ml LB media. Mix: 
0.5 g Yeast Extract, 1.0 g NaCl, 1.0g Triptone 
Autoclave, let cool to about 500C, add ampicillin. 
3.1.1.2 Digestion  
The purpose of digestion is to allow the vector to open at a determined restriction site point, 
where the GAA gene is to be inserted.  
 Both vectors are digested with Not1 RE, however only the GAA-XL6 construct is digested with 
both Not1 and Ase1 REs. This allows for easier purification of the gene later on from the 
electrophoretic gel, as it cuts the XL6 vector (vector used by Origene for shipment of the GAA 
gene) in segments of less than 1000 bp, which do not locate closely to the GAA DNA band.  
Reaction mix Table 3-2 below is placed in a 0.5ml tube, vortexed, incubated 2hr in a 370C water 
bath followed by 20 minutes at 650C to inactivate the enzymes. The amount of DNA was 
Yeast Extract 09182-1KG Fluka  
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calculated by measuring absorbance at 260nm using a Nanodrop-N1000.
 
Table 3-2. Digestion reaction mix volumes in (μl), Buffer O 50 mM Tris-HCl (pH 7.5 at 37°C), 
10 mM MgCl, Thermo Fisher. 
3.1.1.3 DNA Purification 
This step allows the separation of DNA segments, which are then purified and ligated. A 1% 
agarose gel is made (1 g agarose in 100 ml water), microwaved until boiling, allowed to cool 
down to about 500C and mixed with 5µl of DNA stain. 10µl of sample is mixed with 10µl of 
loading buffer and pipetted into the gel alongside the 1kb hyper-ladder. The gel is run for 75 
minutes at 80V.  
Gene and vector bands are purified out of the gel using the Qiagen Gel Extraction kit (product 
code 28740).  
The protocol developed by the manufacturer was used, a copy of which is  attached into the 
bibliography (Qiagen, 2013). DNA was eluted into 20µl H2O, concentration checked by 
spectrophotometry (A260 - NanoDrop N1000) and frozen to -200C. 
3.1.1.4 Dephosphorylation  
Dephosphorylation is conducted in presence of thermo sensitive alkaline phosphatase (TSAP) 
enzyme, which “catalyses the removal of 5´ phosphate groups from DNA, thus preventing the re-
circularization and re-ligation of linearized cloning vector DNA during ligation” (Promega, 
2013b). This is only carried out with vectors (pcDNA3.1 and pcDNA5/FRT). 
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In 0.5µl tube 1µg of vector DNA, 5µl of 10X buffer, 1µl TSAP were mixed, vortexed and 
incubated 15 minutes at 370C, followed by 15minutes at 740C to inactivate the enzyme. The 
samples were ready for ligation. 
3.1.1.5 Ligation  
In this step each vector is ligated with the GAA gene. Two dilutions per ligation were used, a 1:1 
and 1:3, and also a negative control 1:0 (vector with no insert) to ensure ligation happened 
correctly.  
The reactions take place in 0.5ml tubes. The volumes are reported in Table 3-3 below. 
(µl) 1:1 1:3 1:0 
 pcDNA3.1 + GAA 
Vector 5 5 5 
Insert 5 15 0 
Buffer 2 3 2 
Enzyme 1 1 1 
Water 7 6 12 
 pcDNA5/FRT + GAA 
Vector 5 5 5 
Insert 5 15 0 
Buffer 2 3 2 
Enzyme 1 1 1 
Water 7 6 12 
Table 3-3. Ligation reaction volumes in µl. 
Tubes were vortexed, spun and incubated overnight at 40C. 
3.1.2 Genetic material characterization  
3.1.2.1 Via restriction enzyme (RE) digestion 
Both constructs (pcDNA3.1+GAA and pcDNA5/FRT + GAA) were digested with RE Sal1 to 
check for the direction of insertion. 1 μg of DNA was mixed with 0.5 μl of Sal1 enzyme, 2.5 μl 
SuRE/Cut Buffer H (cat# 11417991001 Sigma Aldrich USA) and water to reach 15 μl total 
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reaction volume. Reaction mixtures were incubated at 370C 1h and 20min 650C. Digested 
reaction mixtures were run on 1% agarose gel at 100 mV for 1 h. 
3.1.2.2 Via sequencing 
The DNA samples to be sequenced (two pcDNA 3.1 and two pcDNA 5/FRT) were diluted in 
water to100 ng/ml. 10 μl of sample and the purchased primers were submitted to the Wolfson 
Institute for Biomedical Research at UCL for sequencing.  
3.1.3 Transformation 
The selected plasmids were amplified using One Shot® TOP10 Chemically Competent E. coli 
(cat#C404010 Thermo Fisher). This procedure allowed using E. coli cells as highly an efficient 
cloning and plasmid propagation system. The amplified genetic material was then extracted and 
purified using PureYield™ Plasmid Maxiprep System (Promega).  
The manufacturer’s protocol was followed (cat#C404010 Thermo Fisher): LB agar Petri dishes 
containing 100 µg/ml ampicillin were plated aseptically. Prior to transformation Top 10 cells 
were thawed on ice and aliquoted. Ligation reaction mix was added at different ratio (1:0, 1:1 
and 1:3), aliquots were then incubated on ice for 30 minutes followed by thermal shock (30 sec 
at 420C in water bath) to allow inclusion of plasmid. Finally 200µl was plated and incubated 
overnight at 370C. 
The next day, single colonies were picked aseptically and put in 5ml LB media at 370C agitated 
at 250rpm for 8 hours and eventually transferred to 400ml LB ampicillin+ media in the same 
condition overnight. The next day growth was observed, cells were spun down and DNA 
purified via Maxiprep. The extracted DNA was diluted in 1 ml RNAse free water and stored at -
200C. This material was used for transfection into mammalian cells. 
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3.1.4 Transient Transfection  
A FreeStyle MAX CHO expression system kit was acquired from Thermo Scientific. The 
manufacturer protocol was followed: a vial of FreeStyle™ CHO-S® (cat# R80007 
ThermoFisher) cells was thawed out in a water bath and transferred aseptically into a 125ml 
flask containing 30ml of FreeStyle™ CHO Expression Medium with 8mM L-glutamine. The 
flask was incubated at 370C 8%CO2 overnight. The next day cell viability was assessed using a 
Beckman Coulter ViCell.  
CHO-S cells were sub cultured for five passages (approximately 2 weeks) before proceeding 
with transfection to allow complete recover from thawing. As they reached 1.5 106 cells/ml they 
were passaged to 0.3 106 cells/ml. Viability always stayed above 95%. Approximately 24h 
before transfection cells were passaged to 106 cell/ml. 
On transfection day, purified DNA material (from transformation 3.1.3) was filter sterilised, 
concentration was determined via NanoDrop and 37.5 µg were mixed with OptiPRO SFM media 
according to manufacturer. 
The plasmid preparation in media was gently mixed and added to the transfection reagent, 
incubated 15 minutes and slowly added to the cells. The flask was again incubated at 370C 
8%CO2 for one week, 1ml culture samples were taken every day and frozen for later analysis. On 
day of western blot analysis, frozen samples were thawed, spun at 13000rpm 10 min, supernatant 
the decanted and cell pellet sonicated to release the cell content. Target protein production was 
assessed via western blot (materials and methods 3.2.3) 
3.1.5 Stable transfection 
The pcDNA5/FRT-GAA construct was used to transfect the CHO Flp-In (cat# R75807, Thermo 
Fisher Scientific USA) commercially available cell line that had been previously adapted to grow 
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in chemical defined CD-CHO media (ThermoFisher) + 8mM glutamine, using PEI 
(Polyethylenimine linear, cat#9002-98-6 Sigma Aldrich USA)  as a transfection agent and the 
pOG44 Flp-Recombinase Expression Vector (cat# V600520 Thermo Fisher Scientific USA) in a 
(1:9):3 ratio (3µg of plasmid DNA added to 27µg of pOG44, incubated 5 minutes at RT, 
followed by 90µg of linear PEI).  
The cells were incubated in CD-CHO media (Thermo-Fisher Scientific, USA) and passaged to 
0.3 106 cell/ml when they reached 3 million cells per ml, this was done three times over the 
course of 18 days to ensure the cells were fully recovered from thawing. Viability was always 
maintained above 95%. 24 hours before transfection the cells were seeded at 0.5 106 cell/ml so 
that they would be at the desired concentration of 106 cell/ml at time of transfection. On the day 
of transfection the concentration of plasmid pcDNA/FRT A and B (from 3.1.3 Transformation) 
and pOG44 was assessed via NanoDrop at 260nm. As per protocol, the ratio of plasmid DNA to 
pOG44 to PEI was (1:9):3. In this case 3µg of DNA were added to 27µg of pOG44, incubated 
for 5 minutes at RT, followed by 90µg of linear PEI added, and vial vortexed and incubated for 5 
min at RT. This solution was then added drop by drop to culture in flasks. Freshly transfected 
cultures were incubated at 370C 8% CO2 125rpm in a spin tray incubator. The following day 
cells were spun at 300g 5 min and media changed with fresh media containing selection agent 
(500 µg/ml HygromycinB). Cell viability and count was assessed daily for three weeks, media 
was replaced by fresh HygB+ media every four days.  
3.1.6 Description of the Flp-In™ System  
The Flp-In™ System streamlines the generation of stable mammalian expression cell lines by 
taking advantage of a Saccharomyces cerevisiae-derived DNA recombination system. This DNA 
recombination system uses a recombinase (Flp) and site-specific recombination (Craig, 1988, 
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Sauer, 1994) to facilitate integration of the gene(s) of interest into a specific site in the genome 
of mammalian cells.    
In the Flp-In™ System, three different vectors are used to generate isogenic stable mammalian 
cells lines expressing your gene(s) of interest. The first major component of the Flp-In™ System 
is the pFRT/lacZeo target site vector that is used to generate a Flp-In™ host cell line. The vector 
contains a lacZ-Zeocin™ fusion gene whose expression is controlled by the SV40 early 
promoter. A FRT site has been inserted just downstream of the ATG initiation codon of the lacZ-
Zeocin™ fusion gene. The FRT site serves as the binding and cleavage site for the Flp 
recombinase. The pFRT/lacZeo plasmid is transfected into the mammalian cell line of interest 
and cells are selected for Zeocin™ resistance. Zeocin™-resistant clones are screened to identify 
those containing a single integrated FRT site. The resulting Flp-In™ host cell line contains an 
integrated FRT site and expresses the lacZ-Zeocin™ fusion gene (see the Figure 3-1 below). 
Note: Integration of the pFRT/lacZeo plasmid into the genome is random.   
The second major component of the Flp-In™ System is the pcDNA5/FRT expression vector into 
which the gene of interest will be cloned. Expression of the gene of interest is controlled by the 
human CMV promoter. The vector also contains the hygromycin resistance gene with a FRT site 
embedded in the 5' coding region. The hygromycin resistance gene lacks a promoter and the 
ATG initiation codon.    
The third major component of the Flp-In™ System is the pOG44 plasmid which constitutively 
expresses the Flp recombinase (Broach et al., 1982, Broach and Hicks, 1980, Buchholz et al., 
1996) under the control of the human CMV promoter.  
The pOG44 plasmid and the pcDNA5/FRT vector containing your gene of interest are 
cotransfected into the Flp-In™ host cell line. Upon cotransfection, the Flp recombinase 
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expressed from pOG44 mediates a homologous recombination event between the FRT sites 
(integrated into the genome and on pcDNA5/FRT) such that the pcDNA5/FRT construct is 
inserted into the genome at the integrated FRT site (see the figure below). Insertion of 
pcDNA5/FRT into the genome at the FRT site brings the SV40 promoter and the ATG initiation 
codon (from pFRT/lacZeo) into proximity and frame with the hygromycin resistance gene, and 
inactivates the lacZ-Zeocin™ fusion gene. Thus, stable Flp-In™ expression cell lines can be 
selected for hygromycin resistance, Zeocin™ sensitivity, lack of ß-galactosidase activity, and 
expression of the recombinant protein of interest.    
72 
 
 
Figure 3-1  Diagram of the Flp-In™ System. The figure illustrates the major features of the 
Flp-In™ System as described. For a brief description about FRT sites and the mechanism of 
Flp-mediated recombination, see published reviews (Craig, 1988, Sauer, 1994). With 
permission.  
3.1.7 Cell line cloning and selection 
360 clones were set up in 6 x 96 well plates (60 usable wells per plate). Transfected stable 
culture was subjected to serial dilution in order to reach a cell concentration of approximately 
73 
 
360 cells in 36ml total volume (1 cell per 100 μl aliquot per well) of CD-CHO media containing 
500 μg/ml  HygromycinB.  100µl aliquots were dispensed aseptically into the plate wells and a 
sterile cover placed over the wells. Plates were incubated at 370C 5% CO2 and monitored daily 
by optical microscopy for five weeks. Wells where doubling was observed, were transferred into 
increasingly larger volumes to 24 well plate, then to 6 well plate and finally to 125 ml flasks. 
Emerging clones were compared based on target product production and growth performance. 
Titer levels were assessed via GAA diagnostic assay (3.2.5.2) and western-blot analysis (3.2.3) 
Viability and growth performance were assessed via Vi-cell™ XR Cell Viability Analyser 
(Beckman Coulter, High Wycombe, UK). 
3.1.8 Lab scale fermentation  
The selected clone was thawed using standard protocol and resuspended in 30ml prewarmed CD-
CHO under moderate agitation at 370C 5%CO2 using single use sterile bottom baffled cell 250ml 
cell flasks After overnight incubation 250µg/ml of Hygromycin B was mixed into the broth and 
cell viability and count assessed via ViCell. Cells were left in incubation conditions until they 
reached a cell number > 12 10^6 cell/ml (8 days circa). Harvest would then follow. 
3.1.9 Cell banking  
Cell banking was  performed according to standard procedure as per (Stacey and Masters, 2008) 
under sterile conditions.  
An actively growing cell line in CD-CHO Hyg+ media was checked via ViCell for viability and 
cell count. After ensuring viability was > 95% and cell count was above 10^7 cells/ml, the 
following protocol was followed. 
• Determine volume of freezing medium based on number of aliquots to be prepared with 
each aliquot containing 1ml of cells in freezing medium.  
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• Freezing medium composition: 10% cryoprotectant dimethyl sulfoxide (DMSO), 90% 
CD-CHO. 
• Determine volume of cell broth needed to achieve required cell number.  
• Vol needed (ml) = desired concentration (cell/ml) x total volume (ml) / starting 
concentration (cell/ml) 
• Transfer measured volume needed into centrifuge tube and spin 10min 2000g, discard 
supernatant. 
• Resuspend pellet gently into freezing medium, aliquot into prelabelled cryo tubes.  
To achieve the highest levels of survival, vials were placed into Mr. Frosty (Thermo Scientific) 
containing isopropyl alcohol for controlled cooling overnight into -70oC freezer, and transferred 
into liquid nitrogen the next day for indefinite storage. 
3.2 Product characterization 
3.2.1 SDS-PAGE  
NuPAGE® Novex® Bis-Tris Gels (ThermoFisher Scientific USA), 4-12%, 1mm 12well precast 
gels were used for protein separation.  
Materials/equipment needed:  
- 1X MOPS running buffer (prepare from 20X MOPS stock)  
- Appropriate ladder to cover range of expected protein size 
- Pre-set 700C water bath 
- Vortex  
- XCell SureLock™ Mini-Cell. 
- 0.5ml capped vials 
- Deionized water  
- NuPAGE LDS sample buffer 
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For non-reduced sample preparation mix 0.5µg of protein was added to 2.5µl 4X LDS Sample 
buffer in plastic vials. Up to 7.5µl of deionized water to reach 10µl reaction volume. Briefly and 
vortex for few seconds. Samples were placed in a water bath for 10min. Material was then 
transferred to the gel well and the protein ladder loaded.  
Assemble XCell SureLock™ Mini-Cell following manufacturer specifications, add 600ml 1X 
MOPS to lower buffer chamber and 200ml to space in between gels (use dummy gel if running 1 
single gel). Place lid over gel chamber, attach electrodes and set gel to 200V constant, 50min run 
time.  
At the end of the run, the gel was removed by opening casing gently, then placed in weight boat 
and stain by pouring 50ml readymade Comassie blue solution over the gel and agitate gently for 
4h up to overnight. The gel was destained by multiple washes in de-stain solution (40% 
Methanol, 10% Acetic Acid). Destained gel was then scanned for image analysis or stored for 
further use. Alternatively SYPRO® Ruby Protein Gel Stain (Thermo Fisher Scientific, USA) 
could be used. SYPRO is a highly sensitive, ready-to-use fluorescent stain for the detection of 
proteins separated by polyacrylamide gel electrophoresis (PAGE), no destaining is required. 
3.2.2 Protein absorbance – NanoDrop  
Protein concentration reading was needed at multiple stages throughout the project. Two 
instruments were used for this purpose. Thermo Fisher Scientific Nanodrop ND1000 and Tecan 
multimode microplate reader. 
NanoDrop absorbance range goes from 220nm to 750nm. Its main benefit is sample volume 
requirement as it needs only 1µl of material to produce reproducible and fast result.  
3.2.3 Detection of product – Western blot  
GAA presence in samples was assessed via western blot analysis 
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Invitrogen XCell II blot module was used for western blot analysis. This kit includes the cassette 
for gel electrophoresis and membrane protein transfer which connects to power block via 
dedicated electrodes. Before the transfer of proteins from SDS-PAGE to membrane can happen, 
the SDS-PAGE gel must be run under standard conditions to separate protein mixtures based on 
charge and size. For the materials and protocol concerning gel running, refer to 3.2.1 SDS-PAGE. 
This section assumes the gel is already ready for transfer (gel staining-destaining not required for 
protein transfer to membrane). 
Day 1: 
SDS_PAGE 
- Thaw proteins and ladder on ice. 
- Prepare MOPS Running Buffer (1x) (dilute from stock), store at room temperature (RT). 
- Prepare master mix of SDS sample buffer (3X) and dilute 1:10 DTT (1DTT: 10SDS) in it 
(DTT from 30X to 3X) Do not need to add Β-MEtOH, is already in DTT (prepare in excess). 
- Pipette X µL protein (50µg) and X µL of SDS/DTT3X mix (mix: total→ 1:3) into Eppendorf 
tube. 
- Vortex samples, quickly spin and heat samples at 700C for 10 min.  
- Vortex and spin one more time to collect volume at the bottom of the vial 
- Pipette samples in NuPAGE® Novex® Bis-Tris Gels (Thermofisher scientific USA), 4-12%, 
1mm 12well precast gels, add appropriate prestained ladder  
- Fill cassette with 0.6L MOPS  running buffer (1x). 
- Run gel at 200 V for 50min 
Transfer 
- Keep gel in cassette soaked in running buffer until ready for transfer 
- Prepare  1X Transfer buffer from 20X Nupage (for 1L: 50ml 20X Nupage, 1ml antioxidant, 
100ml MeOH, 849ml RO water) 
- Soak blotting pads in transfer buffer and push out air bubbles with a spatula 
- Prepare PVDF membrane: cut membrane to match gel size. Never touch membrane directly: 
use wrapping paper and gloves. Pre-soak membrane 30sec in 100% MeOH and place in 
transfer buffer together with blotting pads. 
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- Follow manufacturer protocol instructions from page 10 to page 16 of XCell II™ blot 
Module, Manual part no. IM9051. Rev. Date: 14 December 2009. Transfer at 30V 1h. 
(https://tools.thermofisher.com/content/sfs/manuals/blotmod_pro.pdf) 
Blocking 
- Prepare 100 mL (per gel) blocking solution (non-fat milk 5% in PBS-T) and store at 40 C. 
- Discard gel 
- With protein side facing up, cut upper right corner of the membrane to mark membrane 
orientation, cut membrane to size. 
- Place each blot in 50 mL blocking solution in a weight boat, agitate for 1h at RT. 
Primary Antibody incubation 
- Primary anti-GAA rabbit monoclonal antibody was purchased from Abcam (cat.# ab137068 
(Abcam, 2013), working dilution (1:1000) 
- Prepare primary antibody solution in milk 5% in PBS-T(10ml;10µl) 
- Place blot into solution with protein side facing up, shake at 40C overnight. 
Day 2: 
- Wash blots in PBS-Tween 20 (0.2%) for 3x 10 min changing buffer between intervals 
Secondary Antibody incubation 
- Secondary anti rabbit polyclonal HRP-linked antibody was purchased from New England 
Biolabs (NewEnglandBiolabs, 2013) 
- Prepare secondary antibody solution in milk 5% in PBS-T(10ml;10µl) 
- Incubate membrane 1h RT with secondary antibody mix under moderate agitation 
- Wash blots in PBS-Tween 20 (0.2%) 3x 10 min changing buffer between intervals. 
Detection  
- Use SigmaFast Diaminobenzidine (Sigma-Aldrich, 2014) detection reagent (DAB). 
- Mix reagent pills (gold and white) in 5ml RO water. 
- Drop reaction mix onto membrane 
3.2.4 Identification of product – MALDI TOF MSMS 
Mass Spectrometry was used to identify the product in the cell culture supernatant. Digested 
samples were analysed using a Bruker UltrafleXtreme MALDI-TOF-TOF mass spectrometer 
(Bruker Coventry UK) 
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Samples were first run on a 12%Bis-Tris SDS gel in order to separate proteins based on 
molecular weight. Bands were then excised one by one using a scalpel and subjected to in gel 
tryptic digestion overnight at 4OC in digestion buffer (25µl sequencing grade modified trypsin 
(cat# V511 Promega USA), 470µl H2O, 5 µl N4HCO3 1M, 50µl acetonitrile).  
Sample excision and digestion protocol: 
Spot Excision 
- Wash the gel with water (2 x 10 mins). 
- Excise spot/band of interest with clean scalpel cutting as close to the edge of the spot as 
possible. (It is important to reduce the amount of background gel). 
- Cut the excised spot into small squares (~ 1 x 1 mm) and transfer into a 0.5 m1 microfuge 
tube. 
Reduction and Alkylation 
Always use freshly prepared NH4HCO3 (prepare a 100 mM stock and dilute as necessary). 
- Wash the gel particles with 100 ml of 50 mM NH4HCO3:acetonitrile (1:1) for 15 min. Spin 
down and remove the liquid. 
- Add 100 ml acetonitrile and leave for 15 min. until the gel pieces have shrunk (they become 
white and stick together). 
- Spin and remove all liquid. 
- Swell the gel pieces in 10 mM DTT in 50 mM NH4HCO3, adding enough liquid to cover the 
gel (ca 50 ml). Incubate for 30 min. at 56 °C. 
- Spin down the gel pieces and remove excess liquid. Shrink the gel pieces briefly in 
acetonitrile. 
- Remove acetonitrile and add 55 mM iodoacetamide in 50 mM NH4HCO3, adding enough 
liquid to cover the gel (ca 50 ml). Incubate for 20 min. at room temp. in the dark. 
- Spin down the gel pieces and remove iodoacetamide solution. 
- Wash gel pieces with 100 ml of 50 mM NH4HCO3 for 15 min. Spin gel pieces and remove 
all liquid. 
- Repeat step 8. 
- Shrink gel pieces with acetonitrile. Spin and remove all liquid. 
- Dry gel pieces in vacuum centrifuge. 
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In-gel Digestion 
- Rehydrate the gel pieces in 20 ml digestion buffer (10 mM NH4HCO3, 10% acetonitrile) 
containing 10 ng/ml of trypsin at 4 °C (on ice) for 30 min. (After 15 min. check samples and 
add more trypsin solution if all the liquid has been absorbed by the gel pieces). 
- Remove the remaining supernatant. Add 10 ml of the digestion buffer without trypsin to 
cover the gel pieces and keep wet during enzyme cleavage. 
- Leave samples at room temperature overnight. 
Extraction of Peptides 
- Add 5 ml acetonitrile and sonicate for 15 mins. 
- Spin down gel pieces and collect the supernatant in a 0.5 ml microfuge tube. 
- Add 10 µl 50% acetonitrile with 5% formic acid and sonicate for 15 mins. 
- Spin down gel pieces and collect the supernatant. 
- Pool the supernatants. 
- Retain the gel pieces until the supernatant has been analysed by mass spectrometry. 
 
0.5µl of sample and standard was placed on the MALDI plate and allowed to dry, followed by a 
droplet of 1ul of Super-DHB matrix. As the matrix dries, it forms a clean crystalized layer over 
the sample which immobilizes the peptides. MALDI plate was inserted in the instrument and 
appropriate method selected. MALDI-TOF-TOF was conducted using an UltrafleXtreme 
MALDI-TOF instrument (Bruker, Coventry, UK) in positive ion reflector mode and 50% laser 
power and MS-MS was conducted on the ten most intense peaks for each target spot. Generated 
peptide masses with an ion score exceeding the threshold set for p < 0.05 were interrogated using 
the Mascot algorithm (matrix-science.com) to search all taxonomies in the SwissProt database. 
Instrument run setup options: fixed modifications, carbidomethyl (C); variable modifications, 
oxidation (M); mass values: monoisotopic; protein mass: unrestricted; peptide mass tolerance: 
+/− 100 ppm; fragment mass tolerance +/− 0.5 Da. Instrument MALDI-TOF-TOF 
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3.2.5 Quantification of product  
3.2.5.1 Via AlphaLISA 
This assay allows identification of a specific antigen in a relatively quick and reproducible way. 
When the antigen of interest is recognised by its specific antibody, it forms a complex in which 
an acceptor and a donor beads are present and adjacent. Only when this complex is formed, 
excitation of donor bead by fluorescent light at 680nm, causes the attached acceptor bead to emit 
light at 615nm which is detected by the AlphaScreen analyser. Reaction mixture composed of 
samples containing antigen, biotinylated antibody and acceptor beads is added to wells of a 96 
well OptiPro plate, and incubated 1h at RT and then donor beads are added. After 30min 
incubation, the plate is read.  
Since the manufacturer does not provide already made detection kit for GAA, the assay had to be 
developed and optimised. This involves choosing the right antibody pair, biotinylating one of the 
two antibodies, and calibrating analyte sensitivity and response. The AlphaLISA development 
guide was followed (PerkinElmer, 2012).  
Materials:  
Item Manufacturer Catalogue 
AlphaLISA Acceptor beads Perkin Elmer, Inc. (1mg)    6772001 
AlphaScreen Streptavidin-coated 
Donor beads 
Perkin Elmer, Inc. (1mg)    6760002S 
Antibody 1: anti-GAA rabbit 
monoclonal 
Abcam ab137068 
Antibody 2: anti-GAA rabbit 
polyclonal 
Sigma-Aldrich Co. SAB2100872 
Microplates: ½ AreaPlate-96 Perkin Elmer, Inc. 6005560 
TopSeal-A Adhesive Sealing Film Perkin Elmer, Inc. 6005185 
ChromaLink™ Biotin Antibody 
Labelling Kit 
SoluLink Inc. B-9007-105K 
NHS activated biotinylation 
reagent 
SoluLink Inc. B1001-105 
Carboxymethylamine 
hemihydrochloride (CMO) 
Sigma-Aldrich Co. C13408 
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Sodium cyanoborohydride Sigma-Aldrich Co. 152159 
Zeba desalting columns Pierce (ThermoFisher Scientific 
Inc.) 
89889 (2 mL) 
Proclin-300 Sigma-Aldrich Co. 48912-U 
Tween-20 Pierce (ThermoFisher Scientific 
Inc.) 
28320 
Casein 5% Alkali-soluble 
solution 
Novagen (EMD Chemicals Inc.) 70955 
Dextran 500 Sigma-Aldrich Co. D1037 
Triton-X100 Pierce (ThermoFisher Scientific 
Inc.) 
28314 
Streptavidin-Sepharose beads GE Healthcare, Inc. 17-5113-01 
Table 3-4 PerkinElmer AlphaLISA reagents 
 
Figure 3-2 AlphaLISA principle. In presence of analyte, the complex donor bead/acceptor bead 
forms and excitation of donor bead causes release of O2 which transfers to acceptor bead and 
emit light at 615nm. Adapted from PerkinElmer (PerkinElmer, 2014) 
3.2.5.2 GAA diagnostic assay    
This method was used in this work to detect and measure amount of GAA in different clonal 
lines.  
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The GAA diagnostic assay developed by the University of Kumamoto Japan (Okumiya et al., 
2006) is used in the medical field to detect presence of GAA in leukocytes of people suspected 
of being affected by Pompe disease. This method employs glycogen and 4-methylumbelliferyl-α-
D-glucopyranoside as substrates for measuring GAA activity and incorporates acarbose to 
eliminate the interference of unrelated α-glucosidases (predominantly maltase-glucoamylase). 
After allowing GAA to degrade the substrates present in solution, an alkaline buffer is added to 
the reaction mix to stop GAA activity. This causes 4-methylumbelliferone to fluoresce at 
different wavelengths from unhydrolysed substrate, thereby permitting its measurement in 
presence of vast excess of unhydrolysed substrate.  
Reagents. 
• Buffer: 0.15M citrate/phosphate buffer pH 4.0 
• Substrate: 4-methylumbelliferyl-α-D-glucopyranoside 250mg (MW 338.31, Sigma Aldrich). 
Dissolve 250mg substrate in 503ml of buffer by warming to 80oC. Store stock substrate at -
20oC. 
• Inhibitor:  Acarbose 1g (MW 645.6, Sigma Aldrich). Dissolve 1g acarbose in 442.6 ml 
buffer to give 3.5mM solution. 
• Standard: Stock standard solution. Dissolve 176mg 4-methylumbelliferone (MW 176 Sigma 
Aldrich) in 1L H2O. Dissolve 100ul stock standard solution in 19.9ml distilled water to give 
working standard (1nmol per 200µl). 
• Stopping reagent: 1M glycine buffer pH10.4. Dissolve 75g glycine and 58g sodium chloride 
in 1l H2O. Add 55.7ml of this solution to 44.3ml 1M sodium hydroxide.  
• Substrate preparation: Dilute 250µl 3.5mM acarbose in 249.75ml stock substrate solution to 
give substrate working solution containing 3.5µM acarbose. 
Method. 
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• In 2ml Eppendorf vials prepare standard, blank and samples for analysis in triplicate.  
• Blank: 5µl H2O + 100µl substrate working solution 
• Sample/standard: 5µl sample/standard + 100µl substrate working solution  
• Cover plate and incubate at 37oC for 15-120min (time must be optimized)  
• Add 1ml stopping reagent, mix. 
• Transfer 500ml from each tube in 96well flat bottom polypropylene plate and read 
fluorescence at 360-480nm. 
3.3 Fermentation and downstream processing 
3.3.1 Harvest 
Cells were grown under batch culture conditions in 500ml bottom-baffled shake flasks 
containing 125ml of CD-CHO media (with 250µg/ml hygromycin B). Flasks were incubated 
under moderate agitation at 370C 5% CO2, until they reached at least 10 million cells/ml (8 days). 
Cell number and viability was checked daily using a ViCell (Beckman Coulter USA). On harvest 
day, cell broth from each flask was transferred to multiple 50ml conical tubes and spun at 2000g 
for 10 minutes to pellet the cells. The supernatant was pooled and it was filtered through a 
0.22µm Stericup® (Merck Millipore USA). Harvest Cell Culture Fluid (HCCF) was then 
concentrated 4 fold using multiple 10000MWCO (up to approximately 30ml)  
3.3.2 Capture step – Anion Exchange chromatography 
A GE AKTA Avant 25 (GE Healthcare Life Sciences USA) system was used to set up the anion 
exchange chromatography capture step. The column used was a GE CaptoQ HiTrap 1ml, 
equilibration buffer 50mM Sodium Acetate pH6.0 (Buffer A), elution buffer 1M Sodium 
Chloride in 50mM Sodium Acetate pH6.0 (Buffer B) at a flowrate of 1 ml/min. Concentrated 
HCCF was diluted 1:4 into equilibration buffer to adjust to optimal conductivity and favour 
binding of target material to resin. 30 ml loading volume at a time was loaded onto column using 
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AKTA sampling port, followed by 14CV wash (100% buffer A), 40CV linear gradient elution 
(0-35% buffer B), 5 CV strip (100% Buffer B) and regeneration (10 CV 0.5 M NaOH, 5 CV 
buffer A, 10 CV 20% EtOH). 2ml fractions of column wash and eluate were collected and 
absorbance at 280nm monitored throughout the whole run.  
3.3.3 Intermediate step – Hydrophobic interaction chromatography 
3.3.3.1 Binding condition screening 
This step was performed at BioMarin Pharmaceutical Inc. laboratories with Dr. John Henstrand’s 
group assistance. GAA reference material was used (BMN 103, 2.09 mg/ml).  
Resins 
B) Butyl Sepharose 4FF (GE Healthcare, USA cat# 17098001) 
P) Phenyl Sepharose 6 Fast Flow (High Sub) (GE Healthcare, USA cat# 17-0973-03) 
Buffer A 
a) 50 mM sodium acetate 1.0 M Sodium Chloride pH 5.0 
b) 50 mM sodium acetate 1.5 M Sodium Chloride pH 5.0 
c) 50 mM sodium acetate 2.0 M Sodium Chloride pH 5.0 
d) 50 mM sodium acetate 1.0 M Ammonium Sulphate  pH 5.0 
e) 50 mM sodium acetate 1.5 M Ammonium Sulphate  pH 5.0 
f) 50 mM sodium acetate 2.0 M Ammonium Sulphate  pH 5.0 
Buffer B 
50 mM sodium acetate pH5 .0 
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Procedure 
2mg reference protein was bound to two resins in six equilibration buffers (Buffer A). Binding 
and recovery was assessed by spinning reaction mixture in micro centrifuge 5min 12000g and 
determining protein concentration of supernatant via NanoDrop N1000. Reactions were 
performed in 1.5ml Eppendorf tubes.  
• Binding 
T = 0h  
Mix 200µl of resin (80% slurry) in 1ml Buffer A, add 200µl 10mg/ml protein (2mg) in 1.5 ml 
Eppendorf tube. 
Incubate 40C under moderate agitation overnight. 
T = 12h 
Spin and determine supernatant concentration 
• Wash 
Wash 3 times with 1 ml Buffer A, vortex, spin and collect supernatant. Determine concentration 
after each wash. 
• Elution 
Resuspend beads in 1 ml of Elution buffer 1 (75% A + 25% B), vortex, spin, determine 
concentration of supernatant. Repeat with Elution buffer 2: (50% A + 50% B) and Elution buffer 
3: (25% A + 75% B). 
• Strip 
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Resuspend beads in 1 ml Buffer B, vortex, spin and determine protein concentration of 
supernatant. Repeat the strip step three times total.  
3.3.3.2 Separation method details 
This step was run on AKTA Avant 25 (General Electrics) using an in-house packed (At 
BioMarin laboratories) column containing Butyl Sepharose 4FF (Fast Flow) resin. The packed 
column measured 8cm in bed height, and 0.34cm radius giving a total bed volume (V) = 8cm (h) 
x 0.342cm (r) x π = 2.94ml. Equilibration buffer 1M Ammonium Sulphate pH 5.0 (Buffer A), 
Elution buffer 50mM Sodium Acetate pH 5.0, flowrate 1ml/min.  
The anion exchange eluate fraction was buffer exchanged in Buffer A using Amicon 
10000MWCO spin filters, then 4CV loaded on the column using AKTA sampling port followed 
by 14 CV wash (100% buffer A), 40CV linear gradient elution (0-35 % buffer B), 5CV strip 
(100 % Buffer B) and regeneration (10 CV 0.5 M NaOH, 5CV buffer A, 10 CV 20 % EtOH). 2 
ml fractions of column wash and all elution peaks were collected and absorbance at 280 nm 
monitored throughout the whole run. 
3.4 Impurities characterization and cell stress 
3.4.1 Zymography 
Novex™ 12 % Zymogram Casein Protein Gels (cat# EC6405BOX Thermo Fisher Scientific 
USA) were used to visualise protease presence pre- and post- capture step in Null (CHO-S 
cat#R80007 Thermo Fisher) and GAA CHO cells. Samples were first denatured in SDS buffer 
and separated based on size similar to a standard SDS-PAGE gel, then they were renatured by 
incubating the gel in non-ionic detergents (renaturing buffer, Invitrogen) to re-establish 
enzymatic activity. The gel was then incubated overnight at RT in developing buffer (Invitrogen 
USA) which adds divalent metal cations required for enzymatic activity. The following day the 
gel was stained with Comassie blue and de-stained in 40 % MeOH, 10 % acetone. Regions of 
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protease activity appear as clear bands against a dark blue background where the protease has 
digested the substrate. 
Sample and system preparation:  
After determining samples’ protein concentration by absorbance at 280 nm, 10 µg are mixed 
with 5µl of provided Tris-Glycine SDS Sample Buffer 2X (LC2676), and the sample mix is 
brought to 10 µl volume using HPLC grade water. Heat is not required, as it would permanently 
denature proteases in samples. 
1L of 1X Tris-Glycine SDS running buffer is prepared by diluting 100ml of 10X buffer 
(LC2675) into 900ml of di-ionized water. 
Place empty gel in XCell SureLock® Mini-Cell (Thermo Fisher Scientific, USA), lock in place 
and add about 700ml of 1X Tris-Glycine running buffer according to manufacturer. Add 10ul of 
samples to gel wells and appropriate molecular weight standard. 
Run gel at 125V constant for 90 minutes. Expected current should be 30-40 mA/gel. 
As gel is running prepare 1X renaturing and developing buffers from stock 10X solution.  
Remove gel from casing and place it in 1X renaturing buffer for 30min at room temperature with 
gentle agitation, then decant buffer and replace with 1X developing buffer. Incubate at 37 OC 
overnight with gentle agitation. Next day proceed to Comassie blue staining and de-staining 
(40 % MeOH, 10 % Acetic Acid). Bands containing proteases are displayed in white over a blue 
background. 
3.4.2 CHO HCP - AlphaLISA  
Commercially available CHO HCP quantitation kit (cat# AL301C Perkin Elmer, Waltham MA 
USA) was used to quantify total HCP.  Kit components  
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Materials:  
Item Specifications  
AlphaLISA Anti-CHO HCP Acceptor beads 
stored in PBS, 0.05% Proclin-300, pH 7.2 
50 µL @ 5 mg/mL (1 brown 
tube, white cap) 
Streptavidin (SA)-coated Donor beads stored 
in 25 mM HEPES, 100 mM NaCl, 0.05% 
Proclin-300, pH 7.4 
200 µL @ 5 mg/mL (1 
brown tube, black cap) 
Biotinylated Antibody Anti-CHO HCP stored 
in PBS, 0.1% Tween-20, 0.05% NaN3, pH 7.4 
50 µL @ 500 nM (1 tube, 
black cap) 
AlphaLISA CHO HCP (1 µg), lyophilized 
analyte * 
1 tube, clear cap  
AlphaLISA HiBlock Buffer (10X)  10 mL, 1 small bottle 
Microplates: ½ AreaPlate-96 Cat# 6005560 
TopSeal-A Adhesive Sealing Film Cat# 6005185 
Table 3-5. Perkin Elmer CHO HCP AlphaLISA reagent list 
Protocol: 
Prepare 1X AlphaLISA HiBlock Buffer: add 2.5 mL of 10X AlphaLISA HiBlock Buffer to 22.5 
mL H2O. 
Prepare CHO HCP analyte standard dilutions: reconstitute lyophilized CHO HCP (1 µg) in 100 
µL H2O. Prepare standard dilutions as follows (change tip between each standard dilution): 
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Table 3-6 CHO HCP standard curve preparation. *Standards diluted in cell culture medium.  
Prepare 2.5X AlphaLISA Anti-CHO HCP acceptor beads + biotinylated Antibody Anti-CHO 
HCP mix (25µg/ml). Add 50 µl of 5mg/ml AlphaLISA Anti-CHO HCP acceptor beads and 50 µl 
of 500mM Biotinylated Antibody Anti-CHO HCP to 9900 µl 1X AlphaLISA HiBlock buffer 
Prepare 2X Streptavidin coated Donor beads. Under subdued light add 200 µl of 5 mg/ml Donor 
beads to 12300 µl of 1X AlphaLISA HiBlock Buffer 
In 96well ½ area microplate add: 
• 5 µl of each analyte standard dilution or sample in triplicate. Use 5 µl of sample diluent 
as blank. 
• Add 20 µl of the 2.5X mix (freshly prepared) 
• Incubate 60 min at RT 
• Add 25 µl of a 2X streptavidin coated Donor bead (subdued lighting)  
• Cover with black  TopSeal-A Adhesive Sealing Film 
• Incubate 30min at RT 
• Read in EnVision AlphaLISA reader 
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Data analysis: 
Calculate the average count value for the blank wells. Generate a standard curve by plotting the 
AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both 
axes. No additional data transformation is required. Analyse data according to a nonlinear 
regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable 
slope) and a 1/Y2 data weighting (the values at maximal concentrations of analyte after the hook 
point should be removed for correct analysis). Read from the standard curve the concentration of 
analyte contained in the samples. If samples have been diluted, the concentration read from the 
standard curve must be multiplied by the dilution factor. 
3.4.3 HCP identification and quantification via tandem MSMS  
3.4.3.1 MALDI TOF LC-MS/MS 
For digestion, GAA harvest HCCF and IEX fractions were suspended in 50 µl 8 M urea, 100 
mM ammonium carbonate. Next, 2 µl 450 mM dithiothreitol (DTT) was added and the mixture 
incubated at room temperature for one hour. This was followed by incubation with 20 µl of 100 
mM iodoacetamide (IAM) for 15 min at room temperature to achieve carbidomethylation of the 
sample. Urea was diluted by the addition of 128 µl MilliQ water prior to incubation at 37◦C for 1 
h with 5 µg modified sequence grade trypsin (Promega, Southampton, UK).  
For separation via liquid chromatography (LC), samples were applied to a C18 Acclaim 
PepMap100 (Thermo, UK) 75 µm internal diameter x 15 cm (C18, 3 µm, 100A) for on-line 
reverse phase HPLC (NanoLC Ultimate3000, Thermo UK). Elution was performed with a linear 
acetonitrile gradient (solvent A = 0.05% TFA, solvent B = 0.05% TFA, 90% acetonitrile) in a 40 
min cycle at a flow rate of 300 nl/min. LC was coupled to a fraction collector (Proteineer fcII, 
Bruker, Coventry, UK), dividing eluates into 120 fractions and mixing with matrix solution (α-
cyano-4-hydroxycinnamic acid (CHCA), Sigma UK, reconstituted according to manufacturer’s 
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guidelines in 89% acetonitrile, 0.1% TFA) prior to being spotted onto a MALDI-TOF target 
plate (MTP AnchorChip600384 T F, Bruker, Coventry, UK).  
MALDI-TOF-TOF was conducted using an UltrafleXtreme MALDI-TOF instrument (Bruker, 
Coventry, UK) in positive ion reflector mode and 50% laser power and MS-MS was conducted 
on the ten most intense peaks for each target spot. Generated peptide masses with an ion score 
exceeding the threshold set for p < 0.05 were interrogated using the Mascot algorithm (matrix-
science.com) to search all taxonomies in the SwissProt database. Acquisition software was set up 
as follow: fixed modifications, carbidomethyl (C) and variable modifications, oxidation (M); 
mass values: monoisotopic; protein mass: unrestricted; peptide mass tolerance: +/− 100 ppm; 
fragment mass tolerance +/− 0.5 Da. Instrument MALDI-TOF-TOF. 
3.4.3.2 High resolution nano LC-MS/MS 
Eluate fractions post anion exchange from three cell lines (GAA Cell line1, CHO-S Null and 
mAb producing) were screened via nanoLC tandem MS to determine HCP profile and presence 
of product. LC-MS/MS analysis was undertaken by first digesting samples with trypsin as 
described below, separating digested peptides on UPLC and lastly injecting them into the mass 
spectrometer.  
For digestion, post-IEX column eluates fractions were concentrated via 10000 MWCO 
concentrators (Millipore USA) by a factor of four. 50 µl of sample were mixed with 8 M urea in 
100 mM NH4HCO3 + 1 µl 450 mM DTT. This was allowed to incubate at RT for 1 h and 
followed by 15 min incubation at RT with 10 µl 100 mM iodoacetamide. Final protein 
concentration was determined with NanoDrop at 280 nm. The urea concentration was then 
diluted with 64 µl of HPLC grade water. Digestion with trypsin was performed for 1 h at 37OC 
by adding to each sample 4 µg of sequencing grade Trypsin (Promega V5111 USA). A 2 mg/ml 
BSA (Thermo Fisher, USA) stock solution was used as a quantitation standard. 50 fmol of BSA 
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was prepared by serial dilution and spiked into each sample prior to separation to allow for label 
free quantitation.  
For peptide separation,  10ul of sample was injected in triplicate onto a HSS T3 Acquity column 
(Waters, USA) 75 μm internal diameter  x 15 cm (1.8 μm, 100 A) for on-line reverse phase 
UPLC (Acquity M-Class, Waters, USA).  Elution was performed with a linear gradient from 3 to 
40% B over 40 mins; (buffer A: 0.1% formic acid in water. Buffer B: 0.1% formic acid in 
acetonitrile) at a flow rate of 300 nl/min. The M-class mass spectrometer was coupled via a 
nanospray source to a Synapt G2-Si (Waters, USA) and data was collected in HDMSe mode.  
Data was analysed using Progenesis QIP and searched against SwissProt using MSe Search and 
a false detection rate of 4%. Progenesis QIP software provided resulting data in the form of 
normalised average abundance (molar equivalent) of each specie matched in SwissProt database 
in triplicate readings. Average of each triplicate was calculated eliminating eventual outliers. 
Average abundances were converted to mass by multiplying them by the respective molecular 
weights. Score and probability values were used to avoid identification of false positives. In 
particular Anova (p) probability factor threshold was set at 0.1max, which means that at p of 0.1, 
there is a 10% chance of false positive being identified.  
Species were checked individually against UniProt database using accession IDs to determine 
biological functions (proteolytic activity). Isoelectric point was calculated using ExPASy pI 
calculator online tool (ExPASy. Compute pI/Mw tool). Hydropathicity index (GRAVY) was also 
calculated based on amino acidic sequence. Relative percentage of each protein out of the total 
were also calculated and used for resulting bubble graph diagram. 
3.4.4 Lysosomal protein production pathway: TEM imaging 
We know that only a small portion of produced GAA is secreted, while the vast majority is 
directed into the cell preacidified compartment and eventually ends up in lysosomes where it 
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fulfills its role of converting glycogen into glucose. In order to assess the morphological 
differences of lysosomal structure and content in GAA overexpressing cells, highly detailed 
images of its lysosomes were taken with transmission electron microscope and compared to 
lysosomes from the originating Null cell line. 
Cell preparation. One vial of GAA Clone 1 and Null CHO were thawed into 30ml of prewarmed 
CD-CHO under sterile conditions following standard thawing protocol. After 24 incubation at 
370C 5% CO2 mild agitation, 250 mg/ml hygromycin B was added to the GAA Clone 1 flask but 
not to the Null. Flaks were placed back in incubator for 3 days and growth monitored daily. Cells 
were eventually passaged back to 0.3 10^6 cell/ml in fresh media and re incubated. Cell viability 
and number was monitored for the following 7 days, after which a small aliquot (150ul) was 
taken for TEM sample prep  
Sample preparation. Cell culture aliquot was spun at 15k g for 15 minutes, supernatant decanted 
and pellet resuspended in primary fixing solution.  
Primary fixation 
• Resuspend pellet in 2% paraformaldehyde, 1.5% glutaraldheyde in 0.1M cacodylate 
buffer pH7.3 for 1h 
• Wash in 0.1M  cacodylate buffer 
• Resuspend in 1% Osmium tetroxide in 0.1M  cacodylate buffer 7.3pH, incubate 1h at 
4OC 
• Wash in 0.1M  cacodylate buffer 5 min 
• Incubate in 0.5% uranyl acetate for 20min 
• Wash in H2O for 5 min 
• Wash in 0.1M  cacodylate buffer for 5 min 
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• Wash in H2O for 5 min 
Dehydration  
• Wash in 25% EtOH 5 min 
• Wash in 50% EtOH 5 min 
• Wash in 70% EtOH 5 min 
• Wash in 90% EtOH 5 min 
• Wash 4 times in 100% EtOH 5 min in Analar and dry 
Epoxy Resin 
• Prepare resin (12 g agar, 8 g dodecenylsuccinic anhydride, 5 g methyl nadic anhydride, 
0.65 ml N-benzyldimethylamine, Sigma Aldrich USA) 
• Mix 2 part polypropylene oxide and 1 part resin for 1h 
• Apply to sample for a minimum of 4h. Overnight incubation preferred 
• Let harden for 24 h at 600C 
Ultra-thin sections are cut at 70-80 nm using a diamond knife on a Reichetr ultracut E microtome. 
Sections are collected on a 200 mesh copper grids. 
Sections are stained with uranyl acetate and lead citrate. 
Viewing and photography done on a Joel 1010 transmission electron microscope using Orius 
Gatan camera system. 
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4 Chapter one 
Production of a stable CHO cell line for target product generation. 
4.1 Introduction 
This chapter focuses on the generation of a stable Chinese Hamster Ovary (CHO) cell line 
expressing the target protein GAA. This initial step was necessary in order to establish a method 
of target protein production that would supply material for investigation for the whole length of 
the doctorate project and beyond. The generation of an independent cell line producing stably 
GAA was necessary to provide material for further investigation and optimization of the specific 
downstream process that the manufacturer BioMarin runs in their facility with product BMN 701 
(GAA). 
The process of generation of a stable CHO involved multiple steps. Initially the human 
recombinant GAA gene was purchased and cloned into a vector plasmid using standard 
molecular biology techniques. This involved cutting the plasmid with appropriate restriction 
enzymes, cloning the gene into the vector and transforming competent E. coli cells in order to 
generate multiple copies of the genetic material. Antibiotic selection was then used to ensure that 
only the cells that inherited the gene were brought forward. Nucleic acid from competent cells 
was then purified using a Miniprep kit. The material extracted was tested via agarose gels to 
ensure gene insertion had happened correctly. Base sequencing was also performed to establish 
that no errors were present on the newly formed plasmid.  
The purified genetic material was then used to transfect CHO cells. Before attempting stable cell 
line transfection and selection, we decided to transiently transfect CHO cells to test whether they 
could produce functional GAA. As explained in detail later on, stable clone generation is a far 
lengthier process compared to transient transfection as it involves integration of recombinant 
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material into host genome, however it is also a necessary step for long term studies as a stable 
clone produces target product indefinitely. After confirming via western blot that transiently 
transfected CHO cells were able to secrete GAA, we proceeded with stable transfection. The 
process took three attempts, each one taking between 6 to 8 weeks.    
The last step in this process was to select the high producer cell line to bring forward. This was 
done via one round of limiting dilution cloning (LDC) and the generated lines production and 
growth performance was compared. 
4.2 Plasmid generation 
The generation of a CHO cell line producing the therapeutic enzyme GAA involved multiple 
steps ranging from plasmid cloning to bacterial transformation to genetic material 
amplification, multiple rounds of transient and stable transfection and finally cell clone 
selection. Early in the project we decided to use site-specific gene integration expression 
system Flp-In/FRT to overcome location effect of random recombinant DNA integration into 
host genome, considerably shortening the clone selection process. pcDNA/3.1 plasmid was 
also used as a back-up transfection strategy as it allows for efficient forward-orientation 
multiple cloning site via selectable marker (Geneticin®). Human GAA gene was purchased 
from Origene and cloned into the plasmids. The newly generated genetic material was used to 
transform TOP10 chemically competent cells to amplify it. Mini prep allowed for genetic 
material purification and transfection into CHO host could begin. The data presented here 
below shows a series of agarose gels and gene sequencing to characterize the genetic material. 
It ultimately confirms that only pcDNA/FRT plasmid successfully received the gene without 
errors. This plasmid was then used to transfect mammalian cells.  
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4.2.1 Cloning GAA into plasmid vectors 
This first experiment was designed to open the two vectors (pcDNA3.1 and pcDNA5/FRT) using 
specific REs to allow cloning of GAA into both pcDNA/FRT and pcDNA/3.1. After digesting 
both vectors with Not1 and the GAA carrying vector (pCMV6-XL6) with both Not1 and Ase1 to 
linearize them, samples were loaded onto a 1% agarose gel and run for 75minutes at 80V. 
Results are shown in Figure 4-1 below.    
    
      
Figure 4-1: Linearized plasmids on agarose gel, from left: 1kd hyperladder, GAA, pcDNA 5/FRT, 
pcDNA 3.1, pOG44, 1kd hyperladder.  (notebook 106: 22/04/13).  GAA construct was digested 
with Not1 and Ase1 REs. Not1 excised the gene out (top band) and Not1/Ase1 combination cut 
the rest of the vector in smaller bands (four lower bands). Gel shows one clear band at around 
4k bp and four smaller bands between 0.8k and 1.5k bp. This is consistent with what was 
L         GAA           FRT            3.1          pOG44                  
L         
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expected out of the digestion of the GAA-XL6 construct from Origene. Both vectors and pOG44 
were cut once by Not1 RE to achieve linearization. The gel shows bands at around 5k, also 
consistent with expected results (pcDNA3.1: 5428bp, pcDNA5/FRT: 5070bp).  
The DNA was purified with gel extraction kit, dephosphorylated using TSAP and ligated 
(pcDNA3.1 + GAA and pcDNA5/FRT + GAA) using T4 ligase enzyme as explained in section 
3.1.1.3 DNA Purification, 3.1.1.4  Dephosphorylation and 3.1.1.5 Ligation in materials and 
methods above.  
4.2.2 Transformation  
Transformation is the process by which genetic information, in this case the construct (vector + 
GAA gene), is introduced into competent cells for replication. Upon successful transformation, 
competent cells replicate the nucleic acid of interest. The cells were grown on selective medium 
(ampicillin), because vector carried resistance gene this antibiotic, therefore cells that were able 
to grow had inherited a copy of the construct.  
Different competent cells were used for this experiment, however only Top10 from 
ThermoFisher worked. The membrane of competent cells is made chemically leaky, so that 
under specific conditions (heat shock of 30 seconds at 420C) they allow genetic material to cross 
it.  
OneShot Top 10 chemically competent cells were transformed using genetic material produced 
with ligation step. Transformed cells were plated on LB agar + ampicillin plate and incubated 
overnight at 370C. Next day the plates were taken out of the incubator and cell colonies were 
clearly visible for both constructs. Alongside the two samples of interest, positive and negative 
controls were also plated. 
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Positive control was provided by the manufacturer in the form of a plasmid (pUC19 Control 
DNA), which is used to verify the efficiency of the competent cells. Plates showed growth. 
As a negative control the competent cells were plated without genetic material. No cells grew on 
selective media proving the fact that cells need to inherit vector carrying antibiotic resistance in 
order for them to grow. 
Two single colonies per plate were aseptically picked and incubated into 5ml of LB-Amp media, 
at 250rpm 370C overnight. Next morning tubes were harvested and DNA purified via Miniprep 
for subsequent testing (sequencing and size confirmation).  
4.2.3 Direction of insertion  
During ligation it is not possible to control the direction of insertion of the genetic material into 
the vector. As a result, during transformation, some cells will acquire the plasmid with the gene 
inserted the correct way, and some will receive the plasmid with the gene inserted the other 
(wrong) way around. As only the gene inserted the right way will produce a functional protein, 
direction of insertion must be assessed. This was done by selecting a RE capable of cutting the 
genetic material within the gene (preferably not in the middle) and elsewhere in the vector 
(outside the gene), to avoid creating bands of similar sizes which are hard to distinguish on an 
electrophoretic gel. By checking band size after digestion, it was possible to determine if 
insertion happened correctly. 
According to NEBcutter online digestion tool (Vincze et al., 2003) few REs cut both constructs 
twice in convenient locations: 
pcDNA3.1 + GAA Band sizes (bp) pcDNA5/FRT + GAA Band sizes (bp) 
Pfl M1 7.3/1.8 Pfl M1 7.3/1.8 
Sal I 5.7/3.5 Sal I 5.3/3.5 
Ahd I 7/2.1 Ahd I 6.7/2.1 
Stu I n/a Psh AI n/a 
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Sac II n/a n/a n/a 
Table 4-1 Restriction enzymes compatible with both constructs. NOTE: Pfl MI cuts twice in the 
gene, therefore not usable. 
Both Sal I and Ahd I cut the plasmid in convenient locations and create bands of different 
enough molecular sizes. Sal I was selected as the more economical between the two.  
 
Figure 4-2. Sal 1 digestion of constructs to check for direction of insertion. 
As seen in Figure 4-2, in pcDNA 3.1 + GAA construct, Sal I produces two bands of 3.5 and 5.6 
bp if direction of insertion is right, and two bands at 4.6 and 4.5 bp if direction is wrong. In 
pcDNA 5/FRT + GAA construct, Sal I produces two bands of 3.5 and 5.3 bp if direction of 
insertion is right, and two bands at 4.6 and 4.2 bp if direction is wrong. So essentially we expect 
to see two separate bands if right or two overlapping bands if wrong.  
Construct 3.1 + GAA FRT + GAA 
direction right wrong right wrong 
Sal I 
3.5 4.6 3.5 4.6 
5.6 4.5 5.3 4.2 
Table 4-2 Estimated construct sizes (in kb) after digestion with Sal I  
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Before checking for direction of insertion however, it was important to check that the re-
linearized plasmid molecular weight matches what expected. To do this, a simple 2 point 
digestion with Not1 RE was performed to open the plasmid (Figure 4-3 below), and digestion 
product was run on a 1% agarose gel.  
 
 
Figure 4-3. Size confirmation.  L 1 kb ladder; 1 pcDNA3.1 A, 2 pcDNA3.1 B, 3 pcDNA 5FRT A; 
4 pcDNA 5FRT B. (notebook 106: 07/05/13). Data shows: pcDNA3.1 A: one band at around 6k 
bp. pcDNA3.1 B: two bands at around 6k bp and 4k bp.  pcDNA5/FRT A: two bands at around 
6k bp and 4k bp. pcDNA5/FRT B: two bands at around 6k bp and 4k bp. 
L       1        2      3        4       L  
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The result in Figure 4-3 above was consistent with what expected and proved that the construct 
contains both vector and gene. Digestion of pcDNA3.1 A did not work as only one band was 
observed. The reason for this became clear with sequencing later on.  
At this point, we digested the two constructs with Sal I restriction enzyme to check for direction 
of insertion. Results are in the Figure 4-4 below. 
 
Figure 4-4 Gene Insertion direction. left to right: (L) hyperladder; (1) pcDNA/3.1A, (2) 
pcDNA/3.1B, (3) pcDNA/FRT A, (4) pcDNA/FRT B. (notebook 106: 12/05/13). Data shows 
pcDNA3.1 A: one band at around 2.5k bp and one band at around 4k bp; pcDNA3.1 B: one band 
at around 2.5k bp and one band at around 4.5k bp; pcDNA5/FRT A: one band at around 2.5k bp 
and one band at around 5.5k bp; pcDNA5/FRT B: one band at around 2.5k bp and one band at 
around 5.5k bp        
Although the numbers are slightly lower than what expected (Table 4-2), the fact that all 
constructs show two clearly separated bands is a clear indication that all four constructs received 
the gene in the correct direction. This was however confirmed with sequencing below.  
4.2.4 Gene sequencing 
The last step of ensuring that the gene was in fact inserted the correct way is via sequencing. The 
Wolfson Institute for Biomedical Research at UCL provided this service to students and 
  L       1       2       3      4       
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members of staff on campus. The resulting data was provided on .ab1 files and analysed BioEdit 
Sequence Alignment Editor (Hall, 2013) 
In order to run a sequencing reaction a primer or a set of primers had to be created. Primers are 
short DNA sequences (15-30 nucleotides) that are used to align the DNA polymerase onto the 
section of the DNA of interest. In each reaction it is possible to sequence around 1000 bases, and 
generally only the section between base 50 and base 800 are accurately sequenced. For a GAA 
gene of around 3500 bases, 5 primers were therefore necessary. Primers were designed to align 
to the sequence on the vector just before the beginning of the gene and ending close enough to 
the end of the gene, so that part of the adjacent vector sequence is included. This was done to 
ensure the gene was inserted the right way and presented no errors. 
When multiple primers are to be used in one sequencing reaction they need to have similar 
melting temperature (Tm), which is defined as “the temperature at which one half of the DNA 
duplex will dissociate to become single stranded and indicates the duplex stability”. 
(PrimerBioSoft, 2013). In other words Tm represents the temperature at which the double DNA 
filament opens up to allow DNA polymerase to start replication. Tm can be calculated using one 
of the many online tools (Promega, 2013a) or by the following formula:   
Tm (
0K) = [ΔH / ΔS + R ln(C)], Or Tm (0C) = [ΔH/ ΔS + R ln(C)] - 273.15, where:  
ΔH (kcal/mole) change in Enthalpy. In the above formula the ΔH is obtained by adding up all the 
di-nucleotide pair enthalpy values of each nearest neighbouring base pair; ΔS (kcal/mole) change 
in Entropy obtained by adding up all the di-nucleotide pair entropy values of each nearest 
neighbouring base pair (PREMIER Biosoft, USA) 
The following custom primers were designed and purchased from Invitrogen. Details are listed 
in Table 4-3 below. 
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Name GAA1 GAA2 GAA3 GAA4 GAA5 
Sequence TAATACG
ACTCACT
ATAGGG 
TACAAGC
TGGAGAA
CCTGAG 
AGTGGA
ACGACCR
GGACTAC 
ACAACAG
CCTGCTC
AGTCTG 
TGTCTCC
AACTTCA
CCTACA 
Yield (OD) 2 2 2 2 2 
Mol. Weight 6126 6176 6152 6063 5973 
Tm C (at 5pmoles/µl) 48 52 54 54 50 
Extinction coefficient 230.4 235.4 227 212.7 203.3 
Percent CG 0.4 0.5 0.6 0.6 0.4 
µg per OD 26.6 26.2 27 28.5 29.4 
nMols per OD 4.3 4.2 4.4 4.7 4.9 
Table 4-3 Custom primers specifications. 
In Figure 4-5 below there we present a graphical representation of the resulting analysis. Blue 
bars represent regions coded by respective primers; orange sections represent GAA gene. 
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Figure 4-5. Graphical representation of sequencing results, blue bars represent regions coded 
by respective primers; orange sections represent GAA gene. Both pcDNA5/FRT + GAA A and B 
constructs received the complete gene in the correct direction. Both pcDNA3.1 + GAA A and B 
constructs did not receive the gene, or got it the wrong direction. 
It is interesting to note how in construct pcDNA3.1 A, sequencing started on vector just before 
insertion point and continued after insertion point, proving that the gene is completely absent. 
However, in construct pcDNA3.1 B no alignment points were found, sign that either primers 
didn’t find complementary sequences or that the genetic material is degraded. This explains why 
pcDNA3.1A size and direction of insertion agarose gels results were wrong. 
For these reasons, only pcDNA5/FRT + GAA construct was used for subsequent experiments. 
4.3 Transfection into mammalian CHO 
An initial round of transient transfection was necessary in order to confirm that a CHO host 
could produce active GAA of the correct size. This process has the benefit of being a relatively 
quick way to generate material for research, compared to stable transfection. The downside is 
that as the genetic material is not integrated into the host genome, it is not replicated during cell 
division and is therefore lost after few generations. Western blot analysis confirmed that GAA 
was being produced in transient clones from day 2 for at least 5 days.  
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4.3.1 Transient transfection 
 
Figure 4-6. Schematic representation of a transient transfection cycle. 
Transiently transfected cells were incubated for 5 days. Viability and cell count was assessed 
daily and 1 ml culture samples were taken to determine product production via western-blot. 
Both FRT constructs (A and B) showed similar doubling time (around 30 hours) and viability 
(>96%) as shown in Figure 4-7 below. 
108 
 
 
Figure 4-7. Transient transfection cultures growth curves. Cells were incubated for 5 days in 
60ml CD-CHO media in 250ml cell flasks. Viability and cell count were assessed daily via 
ViCell (Beckman Coulter USA) and broth aliquots were taken to determine product production 
via western-blot. Both FRT constructs (A and B) showed similar doubling time (around 30 
hours) and viability (>93%). Polynomial equation fitting. FRT A: y = 0.295 x2 - 0.077x + 1.015, 
r² = 0.994; FRT B: y = 0.311x2- 0.171x + 0.981, r² = 0.994   
Product production was qualitatively assessed also via western blot. Both pcDNA/FRT A and B 
reach maximum titer at day 3. 
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Figure 4-8. Western blot analysis of GAA production from day 1 to day 5 after transient 
transfection. Monoclonal rabbit anti-GAA 1:1000 working dilution was used 
(NewEnglandBiolabs, 2013). Both transfection reactions are represented per each day. Left 
pcDNA/FRT A, right pcDNA/FRT B. Three GAA isoforms are visible roughly at 95, and 120 and 
130 kDa in both samples. These sizes are not common for GAA, they could perhaps be not fully 
processed isoforms of GAA. They are however recognized by anti-GAA monoclonal antibody. 
Having confirmed that the transient transfection produced the expected results, stable 
transfection and clone selection followed. 
4.3.2 Stable transfection  
In order to stably express the target protein for an indefinite amount of time, a CHO FlpIn cell 
line was stably transfected with GAA recombinant gene. Stable transfection has the advantage 
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over transient transfection of producing recombinant cell lines that carry the transfection plasmid 
integrated into the genomes, ensuring a constant production of target protein.  
Integration of recombinant DNA in host cell line genome normally happens randomly which 
means that expression level is unpredictable due to position effects (Huang et al., 2007). To 
overcome this, the site specific FRT/FLP system was used. This type of recombination offers an 
alternative strategy to develop high producing and stable clones in a reproducible and predictable 
manner. The key is to target the FRT sequence to chromosomal locations where there is a high 
rate of transcription and gene amplification, and the amplified genes can be maintained (Huang 
et al., 2007). The vector carrying the FRT gene also carries hygromycin gene resistance allowing 
for selection pressure using Hygromycin B antibiotic. The FRT/Flp-In system relies on 
availability of Flp recombinase, which greatly improves the recombination efficiency in 
mammalian cell lines by a process called site-specific recombination.  The recombinase was 
produced by pOG44 plasmid, which was added to the reaction mix at the time of transfection.  
In this experiment, two transfections were attempted using pcDNA5/FRT+GAA constructs (A 
and B) prepared. Transfection efficiency was evaluated using two controls: one control lacked of 
pOG44 (-P) which prevented the production of FLP recombinase needed for the first cell 
divisions; a second control lacked the transfection plasmid all together making it impossible for 
it to proliferate under selection pressure. The four samples are summarised in Table 4-4 below. 
Sample Cell line Plasmid pOG44 PEI 
 A Flp-In pcDNA/FRT A ✓ ✓ 
 B Flp-In pcDNA/FRT B ✓ ✓ 
-P  -pOG44 (first control) Flp-In pcDNA/FRT A  ✓ 
 U  un-transfected (second 
control) 
Flp-In  ✓ ✓ 
Table 4-4 Stable transfection reaction mixtures.  
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Cell viability of stably transfected cells was tracked over a period of 3 weeks.  
 
Figure 4-9 Stable transfection cell viability curve. For transfection 3µg of plasmid DNA was 
added to 27 µg of pOG44, incubated 5 min at RT, followed by 90 µg of linear PEI at a (1:9):3 
ratio. Vial was vortexed, incubated 5 min at RT and added drop by drop to culture in flasks. 
Freshly transfected cultures were incubated at 37 0C 8% CO2 125rpm spin tray incubator. The 
following day cells were spun at 300g 5 min and media changed with fresh media containing 
selection agent 500 µg/ml HygromycinB. Cell viability and number was assessed daily for three 
weeks, media was replaced by fresh HygB+ media every four days. Only FRT-A transfected 
CHO FlpIn viability improved after foci generation (day11). Data shows that as selection 
pressure is applied via HygB addition, cell viability for all reaction mixtures decreases sharply. 
Eventually only transfected cells from reaction FRT-A were able to pick up again and viability 
reached normal levels after day 20.  Cells transfected with FRT B construct and both controls 
did not survive selection pressure.  
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During initial stages of stable transfection, the FRT plasmid carrying the target protein sequence 
and antibiotic hygromycin B resistance was added to the reaction mix and entered the host cells 
aided by PEI detergent. After 24h, hygromycin B selection agent was applied to all four reaction 
mixtures which caused cell viability to drop in all four samples. On day 11 viability of FRT A 
sample started increasing again reaching normal levels at day 20, while none of the other 
samples survived selection pressure. A possible explanation to this result is that at first, 
transfection supposedly happened only in sample A and B but not to either control, since they 
were lacking either the plasmid itself or the pOG44 plasmid. At this stage, in both transfected 
samples, the number of cells that acquired the plasmid, and therefore hygromycin resistance, was 
still incredibly smaller compared to the total number of cells present. For this reason the 
transfected cells samples, as a whole, seemed to perish as selection pressure was applied. After 
11 days however, the number of cells with a copy of the plasmid, started to equal the number of 
cells lacking it as most of the latter ones perished. This is when the first foci were seen. In the 
following days, while all the remaining untransfected cells continued to die, the transfected ones 
increases in number and the viability raised again. By day 19 FRT A sample viability 
approached 100%.  
At this stage the FTR A sample was composed by a number of cells that have inherited the FRT 
plasmid. While most of them should be high producers due to FRT presence, this was still a 
heterogeneous population. Cell line cloning and selection was therefore necessary to select for 
high producer clones lines. 
4.4 Cell line selection  
4.4.1 Clone generation 
Limiting dilution cloning (LDC) was performed on transfected cell pool that survived selection 
pressure. This technique was used in order to create clonal lines from the heterogeneous 
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population of clones generated during transfection and evaluate clonal target molecule 
production. The technique involved diluting the cells in a way in which in each well of a 96 well 
plate there was a chance of having 1 or less cells. After dilution and plating, cells were 
monitored to assess cell division and growth. 6 x 96 well plates were used for this experiment. 
The outer perimeter of wells was filled with a solution of water and ethanol in order to prevent 
contamination from outside and evaporation from within the plate. This left 60 wells per plate 
usable and therefore 360 wells in total (100 µl per well, 36 ml total volume). On the day of the 
procedure, the cell count from FRT A sample (from stable transfection) was 0.7 106 c/ml 
(viability > 97%). Assuming a final concentration of 1 cell per well (100µl aliquot), the total 
number of cells needed was 360 in 36 ml of media. At the current concentration, half microliter 
of cells contains 360 cells, a volume too small to be prepared accurately. A series of serial 
dilution was therefore set up in order to get to the right dilution in a more precise way. Dilutions 
were setup as follow: 
Dilution Neat 1:10 1:10 1:10 1:2 
Number of cells 700000 70000 7000 700 350 
Volume (cells + media) ml 1 0.1 + 0.9 0.1 + 0.9 0.1 + 0.9 0.5 + 0.5 
Table 4-5 serial dilution preparation for LDC in CD-CHO media. 
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After performing the serial dilution, the last aliquot containing approximately 350 cells was 
diluted in 36 ml of media containing 500 μg/ml HygromycinB, 100 µl aliquots were dispensed 
aseptically into the plate wells and sterile cover placed. Plates were incubated at 37 0C 5% CO2. 
For the following 5 weeks the wells were monitored daily using an optical microscope to see 
whether clones started doubling. Evaporating media was added as needed.  
In total only six clones proliferated and they were transferred into increasingly larger volumes of 
media in 24 well plate, then in 6 well plate and finally into 125ml flasks.  A schematic 
representation of LDC is shown in Figure 4-10 below.  
 
Figure 4-10 Schematic representation of foci generation via LDC. The heterogeneous FRT A 
population that survived selection pressure was put through one cycle of LDC to generate clonal 
lines. Out of 360 clones attempted only six showed doubling during the first five weeks of 
observation. Those six were transferred to gradually larger volumes up to 30ml flasks. Only 
three clones survived cell banking (clone 1, 2, 5).  
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4.4.2 Clone comparison 
Clones were assessed for growth performance and target molecule production. Among the six 
viable clones from LDC, only three were ultimately viable after cell banking (freeze-thaw cycle). 
Viable clones (clone 1, 2 and 5) were revived from liquid nitrogen and expanded in 125ml flasks 
in CD-CHO media under moderate agitation at 37 0C 5% CO2. Cells were passaged to 0.3 10
6 
cell/ml when they reached above 3 106 c/ml for four times. These values were chosen based on 
expert advice from other laboratory users. On the last passage, cells were monitored daily for cell 
number and viability by ViCell until they reached 15 106 c/ml. This allowed the calculation of 
doubling times and growth performance (Figure 4-11 top). The clones were then passaged one 
last time and grown until the viable cell concentration reached 5 106 cells/ml. They were then 
harvested, spun to separate cells and the supernatant was micro filtered through 0.22um filter. 
Samples titer was assessed via the GAA diagnostic assay (Figure 4-11 bottom) and qualitatively 
via western blot (Figure 4-12). A suitable candidate was chosen based on good balance between 
growth performance and target molecule production levels. 
Note. For assay development refer to 5.2 – Western blot and 5.4.2 – Quantification of 
Quantification by GAA diagnostic assay.  
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Figure 4-11. CHO GAA clone selection process. (top) doubling time and growth performance 
was assessed via Vi-cell™ XR Cell Viability Analyser; (bottom) GAA amount was assessed via 
diagnostic GAA assay (Okumiya et al., 2006). Although clone 2 had the best titer (0.24 g/l), 
clone 1 was chosen because of fairly good titer (0.18 g/l) and best growth performance (15 
million cells 6 days after passage). Medium used ThermoFisher scientific CD-CHO with 250 
µg/ml HygB, viability >93% at day 6. For assay development refer 5.4.2 Quantification by GAA 
diagnostic assay. 
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Figure 4-12 Western blot analysis of GAA production of heterogeneous pool (P) and clone 1, 2 
and 5. All but untransfected cell sample (U) show similar amount of GAA produced. Three 
isoforms (76, 92, 106KDa) are visible. Monoclonal rabbit antiGAA antibody (1:1000 w.d.) was 
used (cat.# ab137068 (Abcam, 2013). For assay development refer to 5.2 – Western blot 
4.5 Chapter conclusions 
In this chapter the generation of a mammalian clonal cell line stably expressing human acid 
alpha glucosidase (GAA) is described. This was necessary in order to provide a well defined  
material throughout the duration of the project to develop and optimize the purification process 
for this therapeutic enzyme in accordance with the overall goals of this project. 
The human GAA gene was purchased from Origene and cloned into a pcDNA/FRT plasmid, to 
be used in conjunction with site specific recombination Flp-In CHO expression system. A series 
of agarose gels and sequencing experiments confirmed correct integration of GAA into the 
vector and the proper formation of the vector. This was used to transiently transfect a CHO cell 
line, and GAA production was successfully confirmed via western blot over a five-day lab scale 
batch fermentation at 250ml scale. Although enzyme production was not quantified at this stage, 
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we visually confirmed GAA presence in transiently transfected cells. The generated plasmid was 
then utilised to stably transfect a suspension adapted CHO Flp-In mammalian cell line, targeting 
the FRT transcription site for site directed mutagenesis. This process greatly shortened cell clone 
selection process by eliminating location effect commonly associated with random gene 
integration. Antibiotic selection pressure was applied to transfected cells and eventually foci 
carrying gene and antibiotic resistance emerged.  
The heterogeneous cell population deriving from the process was subjected to LDC to generate 
clonal cell lines. Generally, two rounds of LDC are suggested to generate true clonal lines, 
however in the interest of time only one cycle was performed. This process resulted in three 
viable clones out of 360 attempted.  The three clones were expanded and GAA presence, titer 
and cell culture growth and performance determined. Titer determination was performed using a 
GAA diagnostic activity assay. Out of these three (clone 1, 2 and 5) clone 1 was chosen as 
candidate for future studies as it showed an acceptable titer (0.18g/l) and better growth 
performance when compared to the other two.   
This is precisely the reason why Flp-In/FRT system was used: although the number of clones 
generated is quite low, they all produce good levels of target product. 
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5 Chapter two  
Product characterization 
5.1 Introduction 
In this chapter, we describe the development of the analytical assays needed to characterize the 
targeted molecule produced by the stable GAA producer CHO clone 1 generated in the previous 
chapter.  
Gel electrophoresis was used visualize the target molecule and other species present in clarified 
harvest. Western blot was utilized to identify GAA by anti-GAA mAb recognition and to gather 
information on its molecular weight. Identity of the target molecule was further confirmed via 
tandem mass spectrometry. Amylase activity assay (EnzCheck) was used to determine activity of 
target molecule and lastly immunoassay (AlphaLISA) and a fluorescence based assay (GAA 
diagnostic) were utilized to determine concentration of GAA in harvest and through the 
purification process. EnzCheck and AlphaLISA did not give successful results.  
The features that have been evaluated are summarised in Table 5-1 below: 
 SDS-
PAGE 
Western 
blot 
MSMS EnzCheck AlphaLISA GAA 
diagnostic 
Size ✓ ✓ ✓    
Presence ✓ ✓ ✓  ✓  
Activity    ✓  ✓ 
Identity   ✓    
Amount     ✓ ✓ 
Table 5-1. List of analytical techniques described in this chapter and their purpose.  
Size via SDS-PAGE 
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One method for measuring GAA size is via gel electrophoresis. This method is expected to show 
target molecule size based on the principle that linearized molecules travel through the mesh of a 
polyacrylamide gel while subjected to an electrostatic current with a speed proportional to their 
size. By running alongside a ladder of proteins of known MW it is possible to determine protein 
of interest size.  This assay is however prone to misinterpretation especially in early clarified 
harvest samples due to the large number of impurities present. 
Due to its simplicity this method was used also to determine presence of GAA at different stages 
of the downstream process.  
Different GAA isoforms have been seen at different stages of production with the main one 
being at around 110KDa. Other GAA forms have also been reported in literature with sizes 
ranging from 70KDa to 105KDa  (Reuser, 1985) 
Presence and size via Western blot 
Size and presence of the target molecule is more easily determined when the target protein can 
be seen clearly next to a molecular standard free from other impurities. Western blot’s main 
advantage over SDS-PAGE is that the target protein is designed to be the only specie recognized 
by the pair of specific primary-secondary antibodies and as a result, it is the only band that 
appears on the PVDF membrane after incubation next to the molecular standard. The assay is 
however much more labor intensive than SDS-PAGE as it involves transferring proteins from gel 
onto a membrane, multiple washes and incubations with different antibody solutions. Assay 
optimization is also important as protein transfer time and antibodies working solutions must be 
determined. 
Identity via MSMS 
MALDI TOF MSMS is mostly used to acquire information on identity (and size) of the 
molecular species of interest via peptide ionization and time of flight analysis to create a peptide 
map fingerprint. This technique is labor intensive as it involves separating protein mixture via 
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SDS-PAGE, excision of single protein bands, peptide digestion using trypsin and spotting 
samples onto the MALDI plate for analysis. It also requires high technical know-how necessary 
to operate a mass spectrometer and data analysis. It is however the only technique that can 
provide information on identity of the peptides analysed by sequence comparison with online 
protein databases such as SwissProt.  
Activity via EnzCheck 
Activity of the produced target protein was assessed via EnzChek® Ultra Amylase Assay Kit 
(Thermo Fisher Scientific USA). This assay contains a proprietary starch derivative (DQ ™) 
labeled with BODIPY® FL dye to such a degree that fluorescence is quenched. In presence of 
amylase (GAA is an amylase), the substrate is degraded, quenching is relieved and as a result 
fluorescence is emitted. By measuring with fluorescence microplate reader the resulting signal, it 
is possible to determine the amount and activity of enzyme, as signal will be proportional to 
activity of amylase. One drawback of this assay is that the substrate is not specific to GAA only 
but also to beta and gamma amylases present. 
Quantification via AlphaLISA.  
Determination of the amount of target protein is of critical importance throughout the whole 
bioprocess. Developing an assay capable of determining target molecule concentration in a 
reliable and high throughput fashion will help determine titer levels and downstream process 
strategy.  
The AlphaLISA immunoassay is a high throughput fluorescence based immunoassay in which 
signal is proportional to amount of analyte in solution. Primary and secondary antibodies are 
immobilized onto a donor and acceptor beads and the presence of analyte allows formation of a 
close association of the two beads which leads to emission of light at 615nm as explained in 
materials and methods (section 3.2.5).  
122 
 
Since the manufacturer does not provide already made detection kit for GAA, the assay had to be 
developed and optimised. This involved biotinylation of antibody, choosing the right antibody 
pair and calibrating analyte sensitivity and response. The AlphaLISA development guide was 
followed (PerkinElmer, 2012).  
Quantification via GAA diagnostic assay.  
Quantification of GAA can also be determined via the alternative activity method developed by 
Okumiya group (Okumiya et al., 2006). This assay is used in the clinics to detect presence of 
GAA in patients’ blood and it is specific to GAA, which puts it at a clear advantage over other 
activity assays (such as EnzCheck) that detect generic amylase activity in samples. Activity is 
measured by fluorescence deriving from substrate degradation (glycogen and 4-
methylumbelliferyl-α-D-glucopyranoside 4MU-αGlc). Specificity is achieved by incorporation 
of acarbose to eliminate the interference of unrelated alpha-glucosidases (predominantly 
maltase–glucoamylase).  
This assay was used to determine GAA concentration in clarified harvest of different clones for 
cell line selection.  
5.2 Target molecule size and presence. 
The purpose of this experiment is to compare the clarified harvest material from the GAA 
producing CHO selected in section 4.4.2 (Clone 1) to the originating Null culture in order to 
show that the GAA CHO line over-expresses the target protein.  
After growing both strains in 30ml of CD-CHO media in bottom baffled cell flasks for 8 days, 
cells were transferred to centrifuge tubes and spun. Supernatants were concentrated via Amicon 
10000MWCO. 50µg of protein per sample was prepared according to protocol and run on the gel 
below (Figure 5-1).  
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This gel shows clearly the presence and size of the target protein at around 110KDa in the GAA 
CHO Clone 1. By running the sample alongside a control of the original cell line (Null CHO-S) 
we can observe that the 106KDa band corresponding to GAA is being strongly overexpressed in 
the cell supernatant during fermentation. 
 
Figure 5-1 gel electrophoresis NuPAGE™ Novex™ 4-12% Bis-Tris (ladder cat# 26614 Thermo 
Fisher, USA) SYPRO ruby stained. Concentrated clarified cell culture supernatants. Sample 1 is 
GAA CHO Clone 1, sample 2 is the originating Null CHO-S. Data shows one clear band at 
around 110KDa in GAA CHO sample. This is believed to be over-expressed GAA. Null sample 
shows no such band. 
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GAA size and presence in the clarified harvest can also be assessed via western blot. This 
technique was also used to detect presence of target protein in chromatographic fractions as 
explained in the following chapter.  
For this western blot experiment a clarified harvest sample from CHO Clone 1 was concentrated 
using a 10000MWCO and run on a SDS-PAGE gel alongside a sample of pure GAA drug 
substance provided by BioMarin pharmaceuticals Inc. Proteins were transferred to a PVDF 
membrane by applying a voltage of 30V for 1h.  
After transfer, the membrane was washed in PBS-T 5% milk three times for 10 minutes each, 
then incubated overnight at 4oC with the primary mAb in a solution of PBS-T 5% milk under 
gentle agitation. Next day the membrane was washed again in PBS-T 5% milk three times for 10 
minutes each and the incubated for 1h in a solution of secondary Ab PBS-T and 5% milk under 
gentle agitation. SigmaFast Diaminobenzidine (DAB) tablets were used for detection. 
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Figure 5-2 Western blot. Proteins transferred to PVDF membrane from Bis-Tris 4-12% Gel, 
ladder cat# 26614 Thermo Fisher, USA. Primary anti-GAA rabbit mAb (w.d.1:1000 Abcam cat.# 
ab137068),  Secondary anti rabbit polyclonal Ab HRP-linked (w.d. 1:1000). Sample 1 is GAA 
drug substance reference (BioMarin, lot# 11132013), sample 2 is the GAA CHO clone 1 
clarified harvest. Data shows one prominent band in CHO clone 1 harvest at just above 100 
KDa. Accidental use of unstained ladder meant that bands had to be handwritten using gel as 
reference. 
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5.3 Target molecule identity 
So far we have gained information on the target protein presence and size. The data seen so far 
tells us about the presence of a 100 to 110 KDa protein overexpressed in clone 1. While it is 
probable that this is recombinant human GAA, it must be proved by an orthogonal identity 
method. Mass spectrometry is usually the go-to method to determine protein identity by 
providing peptide fingerprint of the protein of interest and matching it to a peptide sequence 
database such as SwissProt.  
For this experiment, the most visible band in sample 1 (at around 110 KDa) from SDS-PAGE gel 
Figure 5-1 was excised with a scalpel for further analysis. The gel fragment was processed via 
the protocol included in materials and methods (3.2.4 Identification of product – MALDI TOF 
MSMS) and digested with modified sequencing grade trypsin. After application of 0.5 µl of 
sample and standard to the MALDI plate followed by 1 µl of Super-DHB matrix, the plate was 
processed via mass fingerprint first and then the 10 most prominent peaks processed again via a 
second round of MS where the ion-trap first performed MS measurements on all intact peptide 
ions, and then in a second scan it performed a MS/MS experiment on the ten largest peptide 
signal peaks. 
The additional sequence information provided by tandem MS can be extremely powerful, 
sometimes enabling definite protein identification to be made on the basis of a single peptide.  
However, tandem MS spectra of multiple peptides that arise from digestion of a given protein 
provide greater opportunity for obtaining definitive identification. 
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Figure 5-3 MALDI-TOF-TOF on a UltrafleXtreme MALDI-TOF instrument (Bruker, Coventry, 
UK) in positive ion reflector mode and 50% laser power with MS/MS conducted on the ten most 
intense peaks for each target spot. Generated peptide masses with an ion score exceeding the 
threshold set for p < 0.05 were interrogated using the Mascot algorithm (matrix-science.com) to 
search all taxonomies in the SwissProt database. Fixed modifications: carbidomethyl (C); 
variable modifications: oxidation (M); mass values: monoisotopic; protein mass: unrestricted; 
peptide mass tolerance: +/− 50 ppm; fragment mass tolerance +/− 0.5 Da. Instrument MALDI-
TOF-TOF 
The Mascot results page shown in Figure 5-3 was automatically generated after analysis and 
database search were completed. It is divided in different sections.  
Section A at the top shows information on user identification, database searched (in this case the 
SwissProt database) and analysis timestamp are provided. Then follows a list of the species 
found in the sample in order of result confidence. LYAG_HUMAN (GAA) appears as first entry 
indicating that GAA was found in the sample mix in highest abundance. 
Section B shows the histogram representation of the protein score. In this result 
LYAG_HUMAN (GAA) scores at 156, quite a bit away from the ‘greyed out’ (uncertain) 
threshold.  
The protein score allows the software to judge whether a result is significant or not. From the 
Mascot website, the protein score is defined as ‘probability that the observed match is a random 
event’. The higher the score, the lower is the probability that the result is a random event. A 
score is reported as -10*LOG10(P), where P is absolute probability. In this case (Figure 5-3 B) a 
probability of 10^-15.6 scores at 156.  
An event is considered significant if it is expected to occur at random with a frequency of less 
than 5%. Events happening in the grey region are considered of no significance as their 
probability of being random identifications is higher than 5%. Events falling outside of this area, 
129 
 
such as the result shown in Figure 5-3 B, are non- random events. In this case GAA has a score 
which is well clear of the set threshold and as such is a clear result because it has a high score, 
leaving little room to doubt. 
Section C shows the parameters used for database search. These are the filters that are used in 
the generation of the result in order to exclude impossible matches.  
In this case sequencing grade modified trypsin (cat# V5111 Promega USA) was used as a 
peptide digestion enzyme. This enzyme works by hydrolysing peptide bonds at the carboxyl side 
of lysine and arginine residues. The enzyme is also modified by reductive methylation, rendering 
it resistant to proteolytic digestion (auto-proteolysis).  
Under fixed modification Carbamidomethyl (C) was selected as a result of the deliberate post-
translational modification introduced to cysteine residues by reacting with iodoacetamide 
(present in the digestion reaction mix). Under variable modifications Oxidation (M) was selected. 
‘Monoisotopic’ mass values or the mass of the first peak of the isotope distribution is selected to 
differentiate it from an experimental average mass value.  
Peptide mass tolerance of +- 50ppm was used to improve discrimination in peptide finger print 
and fragment mass tolerance of +- 0.5Da refers to MS/MS fragment ion matching. 
Section D reports matched sequence molecular weight, in this case 106112 Da, the probability 
score and emPAI (Exponentially Modified Protein Abundance Index), the index used for 
approximate label free quantitation of proteins (Ishihama et al., 2005). 
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5.4 Target molecule quantification 
5.4.1 Quantification by AlphaLISA 
The AlphaLISA technology, also referred as ‘no-wash ELISA alternative’, allows the detection 
of molecules of interest in serum, plasma, cell culture supernatants or cell lysates in a very 
sensitive, quantitative, reproducible, and user-friendly way. Almost, any sandwich assay can be 
developed to detect an analyte of interest. As shown in Figure 5-4 below, an anti-analyte 
antibody which is biotinylated binds the streptavidin Donor bead while another anti-analyte 
antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the 
complex forms bringing the beads into close proximity (AlphaLISA development guide 
(PerkinElmer, 2012) and the excitation of the Donor beads with light at 680nm provokes the 
release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor 
beads, resulting in light emission at 615nm wavelength. The fluorescent light signal is measured 
using a Perkin Elmer EnVision reader and is directly proportional to amount of analyte in 
solution.  
 
Figure 5-4 Perkin Elmer AlphaLISA assay. In presence of GAA in solution the polyclonal and 
monoclonal anti-GAA antibodies recognize different epitopes of the GAA molecule and bring 
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into close proximity the acceptor and the streptavidin coated donor bead. Once this complex is 
formed, excitation using light at 680nm causes transfer of an oxygen molecule to acceptor bead 
which triggers cascade of energy transfer which leads to emission of fluorescent light at 615nm 
wavelength. Signal is measured an EnVision AlphaLISA reader and signal is directly 
proportional to amount of GAA present in solution. 
The vendor sells a number of off-the-shelf detection kits for several widely used assay such as 
for human IgG and Host Cell Protein (HCP) and they all differ in the antibodies that recognize 
the specific analyte. GAA, being a therapeutic enzyme for a rare genetic disease, had no 
available ready to use detection kit at the time this work was performed, which meant a new 
assay had to be developed.  
Developing an AlphaLISA assay for a new analyte is a multi-step process which involves 
choosing the right pair of antibodies, biotinylation of one of the two antibodies, and conjugation 
of the other antibody onto the acceptor bead. Lastly, titration of biotinylated antibody is done to 
determine its working concentration. 
The function of the antibody pair is to recognize the analyte of interest and bring the acceptor 
and donor beads in close proximity. Both antibodies need to be specific to the analyte and must 
recognize different epitopes of the molecule. One of the two antibodies will have to be 
biotinylated and the other one should be conjugated to AlphaLISA Acceptor beads.  
5.4.1.1 Selection of antibody pairs 
In this experiment the pair of monoclonal and polyclonal anti-GAA (specified in section 3.2.5 of 
materials and methods) was chosen. AlphaLISA development guide recommends testing the two 
possible combinations such as:  
- biotinylated antibody A + antibody B-AlphaLISA Acceptor beads  
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- biotinylated antibody B + antibody A-AlphaLISA Acceptor beads 
In this work however only one combination was tested:  
Biotinylated polyclonal antibody + monoclonal antibody - AlphaLISA Acceptor beads. 
5.4.1.2 Biotinylation of polyclonal antibody 
Biotinylation is the process of attaching covalently biotin to a molecule. By attaching biotin to 
the polyclonal antibody, this will bind with the streptavidin found on the surface of the donor 
beads effectively securing the bead to the antibody, necessary step for the dual bead complex 
formation.  
For this purpose we used a biotinylation kit ChromaLink™ Biotin Antibody Labeling Kit from 
Solulink, USA (cat. B-9007-105K).  
Following manufacturer instructions we proceeded to buffer exchanging the polyclonal antibody 
to remove the 0.02% sodium azide it was stored in. This was achieved by using a 10000mwco 
dialysis cassette overnight against  PBS buffer. The next day the recovered antibody was further 
desalted using  Zeba™ Spin Desalting Columns (Thermofisher USA) and protein concentration 
was assessed by BCA assay at 3.62 mg/ml. This value was used with the Chromalink Biotin 
calculation tool in Table 5-2 below. 
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Table 5-2 ChromaLink Biotin (DMF-soluble) Protein Labelling Calculator. By entering protein 
concentration and molecular weight of the protein to be biotinylated, the tool outputs in bold the 
volume Anhydrous DMF (Dimethylformamide – used to solubilize S-HyNic, part of Solulink's 
proprietary linker technology) and the volume of ChromaLink Biotin (3.91µl) to add for the 
biotinylation reaction to take place. 
Mixing thoroughly 100 µl of antibody with 100 µl of anhydrous DMF with 3.91µl of 
Chromalink Biotin and incubating 2h at room temperature allows the antibody to bind covalently 
biotin.  
After incubation is completed, a second buffer exchange allows for biotin in excess to be washed 
out of reaction solution. The last step in this process is to measure the Molar Substitution Rate 
(MSR) to assess how efficient the biotinylation reaction has been. This is done by measuring 
absorbance of the sample at 280 and 354 using a NanoDrop UV reader and using the SoluLink 
E1% ChromaLink Biotin MSR Calculator .  
 
Table 5-3 Solulink E1% ChromaLink Biotin MSR Calculator. By entering volume of biotinylated 
protein recovered, absorbance at 280 and 354nm, and standard extinction coefficient (E1%) for 
human antibody, this tool calculates the MSR. In this experiment per each mole of antibody, 
close to 13 moles of biotin were incorporated.  
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5.4.1.3 AlphaLISA acceptor bead conjugation with the antibody 
Looking at Figure 5-4 showing the AlphaLISA principle, the analyte is recognized by one 
antibody biotinylated that will attach to the donor bead via biotin-streptavidin interaction, and by 
a second antibody conjugated to the acceptor bead. Here we discuss the process of conjugation 
of the monoclonal antibody to the acceptor bead. 
The protocol provided by PerkinElmer discusses the conjugation of 5mg of acceptor beads with 
a coupling ratio of 50:1 to the antibody. Due to limited amount of acceptor beads available, the 
protocol was scaled down to 10 fold. 
In a 0.5ml Eppendorf, 25µl of acceptor beads conjugated with 0.01mg (16.1 µl) of mAb (0.62 
mg/ml) in presence of Sodium cyanoborohydride and 100mM HEPES according to protocol and 
incubated 20h at 370C in the Eppendorf shaker. Beads are washed the next day using a low salt 
buffer provided by the vendor and stored at 40C in dark vial until use. Final concentration 50 
µg/ml. 
5.4.1.4 Determination of optimal biotinylated antibody concentration 
The last step in the AlphaLISA assay development is the determination of the optimal working 
concentration of biotinylated antibody for the reaction to take place as shown in Figure 5-5. This 
is done by adding increasing concentrations (0.1mM to 100mM) of biotinylated antibody to a 
fixed amount of sample (5ul of clarified cell culture material), in presence of acceptor beads 
coupled with anti-GAA mAb and streptavidin donor beads. This is done in a 384well 
AlphaPlate™ (cat. 6005350) using AlphaLISA Immunoassay Buffer (10X) (Cat No. AL000).  
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Figure 5-5. Titration curve for GAA detection assay prepared in 25mM HEPES pH 7.4. 5 µl of 
clarified cell broth were mixed with 10 µl of mAb coupled acceptor beads and 10µl of 
biotinylated polyclonal antibody serially diluted from 100 mM to 0.1mM and incubated 1h at 23 
0C. At completion of incubation, 25 µl of streptavidin coated donor beads were mixed into each 
well in darkness and incubated 30 min at 230C. Plate was read in PerkinElmer EnVision 
AlphaLISA reader (excitation 680nm emission 615nm).  
As described in the AlphaLISA development manual (PerkinElmer, 2012) a bell shape curve was 
obtained. The highest signal obtained (50 mM) indicates the hook point (highest signal before 
saturation of the bead binding capacity) of the biotinylated anti-GAA antibody. According to 
protocol, a sub-hooking concentration should be used as optimal working concentration. The 
working concentration is of the biotinylated antibody was therefore set as 25 mM.  
5.4.1.5 Results 
We used the prepared reagents to run an AlphLISA plate to measure amount of GAA in harvest 
of the three different clones generated in the clone comparison section (4.4.2) and compared 
them with data from the untransfected CHO cells.  
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Figure 5-6. GAA amount comparison in CHO untransfected (Null), clonal pool and clones 1, 2 
and 5. Samples prepared in triplicate on 96well half area microplate. 5 µl of clarified harvest 
from each culture mixed with 10 µl 25 mM biotinylated anti-GAA pAb mix and 10 µl acceptor 
beads coupled to anti-GAA mAb (50 µg/ml). After 1h incubation at r/t, 25 µl of streptavidin 
coated donor beads were added to each well in dark and seal-film applied. Plate was read after 
30 min incubation at r/t using AlphaLISA EnVision reader. Data shows comparable levels of 
GAA in all samples. 
Results shown in Figure 5-6 are in direct contrast with western blot and GAA diagnostic assay 
results presented in section 4.4.2. Data has previously shown the absence of GAA in Null culture, 
and its presence at different levels in pool and the three compared clones.  
Despite the time invested in developing this assay it was not possible to obtain consistent GAA 
results from it. This can be attributed to a combination of factors. 
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Firstly, it is recommended that both antibody combinations are tested for biotinylation and 
conjugation to acceptor beads. That is biotinylation of antibody A and conjugation of antibody B 
and the vice-versa. Due to limited amount of antibody available and limited supplier stock at the 
time, only one combination was tested (biotinylation of pAb and conjugation of mAb). This was 
perhaps not the optimal combination. 
Secondly, it would have been better to use pure GAA reference material instead of clarified cell 
culture material for developing the assay. As harvest is likely to contain large amount of HCP 
and other unknown substances that could interact with the AlphaLISA reagents and antibodies. 
BioMarin could not provide pure GAA reference material at the time the assay was being 
developed. Reference material would have also been useful for a spike study for quantification 
purposes. 
Subsequently, we became aware of an alternative assay for quantification of GAA (described in 
detail in the following section 5.4.2). This assay, employed in clinics to determine amount of 
GAA in patients’ blood, is based on a University Medical Center of Rotterdam study. We 
therefore decided that it would have made more sense to transfer this already working assay into 
UCL laboratories rather than continuing developing the AlphaLISA assay. 
5.4.2 Quantification by GAA diagnostic assay 
The search for an alternative method for the quantification of GAA lead to the adoption of a 
GAA diagnostic assay. This method is based on substrate degradation by GAA and unlike other 
amylase activity assay, it is specific to this enzyme thanks to the use of an alpha-glucosidase 
inhibitor. Currently this technique is used in clinics to test patients’ blood for levels of GAA in 
the diagnosis of Pompe disease.  
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The 2006 paper by (Okumiya et al., 2006) discusses how this method employs glycogen and 4-
methylumbelliferyl-α-D-glucopyranoside (4MU-αGlc) as substrates for measuring the lysosomal 
GAA activity, as previously also described in (Reuser et al., 1978) and (Van Hove, 1996) but 
incorporates acarbose to eliminate the interference of unrelated α-glucosidases (predominantly 
maltase-glucoamylase). In their study, the activity of GAA in mixed leucocytes from 25 Pompe 
patients and 30 healthy subjects was determined and they found that the addition of acarbose, an 
alpha-glucosidase inhibitor, created a clear separation between the patient and the control ranges. 
Assay principle 
At acidic pH, α-glucosidase hydrolyses the substrate 4MU-αGlc to 4-methylumbelliferone and 
glucose. Adding alkaline buffer stops the enzyme reaction and causes the 4-methylumbelliferone 
to fluoresce at a different wavelength from the unhydrolysed substrate, thereby allowing its 
measurement in the presence of a vast excess on unhydrolysed substrate. 
The addition of acarbose eliminates interference by unrelated α-glucosidases, predominantly 
maltase-glucoamylase. It has been shown that 3.0 µmol/l acarbose completely inhibits the 
maltase-glucoamylase activity but the lysosomal acid α-glucosidase by only 5%. 
Results:  
The aim of this assay is to determine the concentration of GAA in clarified harvest material from 
clone 1,2 and 5  and compare it to the GAA concentration in heterogeneous clone population 
(pool) and untransfected culture (Null) (section 4.4.2) 
First a serial dilution experiment using Biomarin pure GAA reference standard (2.09mg/ml lot# 
11132013) was set up to determine the signal to dilution curve range (Figure 5-7). This 
experiment allowed us to understand what dilution range would be appropriate for in process 
sample analysis. 
139 
 
From Figure 5-7 below, we show how the dilution factor and fluorescence signal response are 
linked by a power curve relationship (resulting equation y = 2E+06x-0.861). Reference material 
dilutions lower than 1:40 ratio resulted in saturation of the instrument absorbance limit (RFU 
65000). Following this experiment, we empirically decided that a dilution of 1:100 (20 mg/L) for 
the GAA reference material would place it somewhere in the middle of the power response curve.  
Figure 5-7. GAA Reference dilution response via diagnostic assay on BMG Fluorstar Galaxy 
fluorimeter. Reference material (2 mg/ml) was first diluted 1:10, then 1:2 dilutions 22 times 
in triplicate in assay buffer (range shown 1:40 to 1:640 or 50 to 3 mg/L). 5µl of each dilution 
was mixed with 100 µl substrate (4MU-αGlc pH4.0) and incubated at 37oC for 60 min. At the 
end of incubation period, the reaction was stopped with 1M glycine buffer pH 10.4. Plate was 
read in scan mode at 360-480 nm range, with absorbance peak at 420 nm. Data range 
selected shows power curve relationship (with equation y = 2E+06x-0.861) between fluorescent 
signal and dilution factor. Reference dilution factors lower than 1:40 saturated the 
instrument signal (instrument maximum signal is 65000 RFU)  
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Subsequently we tested clarified harvest from clones. As GAA amount in harvest is expected to 
be about 1/10th of the amount found in the reference (around 0.2mg/ml), the samples were further 
diluted 1:10 in order to allow GAA amount  to be similar in concentration to the reference. After 
diluting the samples in assay buffer they were prepared in triplicate the same way as the 
reference.  
 
Figure 5-8. GAA diagnostic assay, determination of GAA amount in clarified harvest from Null, 
pool and clone 1, 2 and 5. Samples prepared in triplicate and read on a flat-bottom 96well 
polystyrene plate via BMG Fluorstar Galaxy fluorimeter. Reference material (2.09 mg/ml) was 
diluted 1:100 in assay buffer, all other samples were diluted 1:10. 5µl of each dilution was 
mixed with 100µl substrate (4MU-αGlc acarbose pH 4.0) and incubated at 37oC for 60 min. At 
the end of incubation period, the reaction was stopped with 1M glycine buffer pH 10.4. The plate 
was read in scan mode at 360-480 nm range, with absorbance peak at 420 nm. RFU was 
normalized by subtracting blank value and resulting RFU values were used to calculate GAA 
concentration based on reference value [i.e. clone1 concentration: (clone 1 RFU x 2.09 / 
reference RFU)/10 = (29997 x 2.09 / 34002) / 10 = 0.18 mg/ml]. Error bars are ±1 standard 
deviation on triplicate measurement. 
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5.5 Chapter conclusions 
This chapter focused on the characterization of the target molecule GAA. The work here 
presented served as an important bridge between stable cell line generation (Result chapter one) 
and bioprocess design and characterization of impurities (Result Chapters three and four). 
Ensuring the stable cell line generated produced the expected molecule was critical before 
undergoing downstream development effort.  
As GAA is known to exist in different isoforms of molecular weights ranging from 70 to 
110KDa a series of analytical assays was put in place to characterize the target molecule and 
determine titer and molecular weight. While the main specie was found to be at 106KDa, other 
isoforms at different stages of maturity were also observed. 
As the mature GAA was expected to have a molecular weight of 106KDa, we first ran clarified 
harvest material from stable clone 1 on a SDS-PAGE to visualise the target molecule and host 
cell protein (HCP) profile and compared this with a Null culture clarified harvest. This 
experiment showed two broadly similar HCP profiles, with only visible difference being Clone 1 
having a clear band at around 110KDa mark. As shown later, most mammalian cell lines share a 
largely overlapping HCP profile it is therefore not surprising that the two samples looked so 
similar. The presence of the significant band at 110KDa was a clear indication that GAA is being 
over-expressed. This however needed to be confirmed with an identity or immuno based assay.  
Western blot in this case was a good additional assay for the confirmation of size and presence of 
the target molecule as it relies on specific anti-GAA antibodies to recognize GAA. Clone 1 
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clarified harvest was run alongside GAA pure reference on a SDS-PAGE gel and transferred 
onto a PVDF membrane. We then proceeded with incubation with the specific antibody pair and 
exposure to diaminobenzidine (DAB) tablets which revealed that the overexpressed band at 
around  100KDa seen in SDS-PAGE was in fact GAA.  
Identity confirmation was also provided by MS/MS analysis using MALDI-TOF-TOF on 
UltrafleXtreme MALDI-TOF instrument (Bruker, Coventry, UK). SDS-PAGE band of interest 
was excised, digested with sequencing grade porcine trypsin and analysed via tandem mass 
spectrometry, which confirmed the identity as GAA and molecular weight of 106KDa. 
After having demonstrated the size and identity of target molecule we wanted an assay that could 
determine GAA concentration in samples in a fast and reliable way. Although western-blot can 
be used semi-quantitatively, due to its fairly long running time (2 days per gel) it was deemed 
not appropriate for this purpose. We investigated AlphaLISA, another immunoassay based 
technique for the determination of GAA concentration in samples. The development of this assay 
however did not produce satisfactory results mainly because it relied on antibodies and a pure 
GAA reference not available at the time of development.  
Lastly we tried an enzymatic activity assay used in the diagnosis of Pompe disease from blood 
samples. This assay is capable of measuring GAA activity without interference from other 
amylases thanks to the addition of acarbose. This assay was transferred from the Royal Free 
Hospital Haematology Department and it was utilised to quantify GAA in clarified harvest of 
different clones for clone comparison purposes.  
Overall, the work presented in this chapter showed how stable clone 1 CHO produces around 
0.18 mg/ml of 106KDa GAA in 8 to 10 days of small scale (cell flask) fermentation in CD-CHO 
hygromycin+ media.  
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6 Chapter three  
Downstream Purification process 
6.1 Introduction 
So far we have generated a stable mammalian cell line producing therapeutic enzyme GAA and 
developed some of the assays needed to characterize the target molecule during production. We 
have established that harvest supernatant of 8 day old clone 1 culture contains approximately 
0.18 g/l of 106 KDa GAA. The theoretical pI was calculated as 5.4 and hydropathicity gradient 
(GRAVY) -0.129.  
The aim of this chapter is to present the work that went into the development of the two-step 
chromatographic GAA purification process. This process is designed to mimic sponsor company 
BioMarin Pharmaceutical GILT-tag (Glycosylation Independent Lysosomal Targeting) GAA 
purification process.  
The development of the purification process resulted in a two-step strategy based on exploitation 
of target molecule net charge first via anion exchange (IEX) using Capto-Q resin (GE) and then 
its hydrophobicity via hydrophobic interaction chromatography (HIC) using a butyl HIC resin. 
High throughput resin screening was used to help chose among different resins and binding 
conditions for the intermediate step.  
Some of the analytical assays developed in the previous chapter such as western blot and the 
GAA diagnostic assay, were used to assess GAA presence and concentration in elution fractions. 
Impurity and protease analysis of process samples at different stages of the bioprocess are also 
reported in this chapter. 
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6.2 Fermentation and harvest  
A cell bank vial (1 ml at approximately 107 cells) was thawed from liquid nitrogen in 370C water 
bath and quickly resuspended in 10 ml of fresh pre-warmed CD-CHO media. DMSO was 
removed by 2000 g, 5 min centrifugation and resuspension in 35 ml of pre-warmed media 
containing 250 µg/ml Hygromycin B in a 125 ml cell flask. They were  then incubated for 3 days 
in 370C 5% CO2 to allow recovery and passaged to 0.3 10
6 cell/ml in a 500ml shake flask 
containing 125ml CD-CHO (250µg/ml hygromycin B). Flasks were incubated under moderate 
agitation (125rpm on orbital shaker) at 370C 5% CO2, until they reached at least 10 million 
cells/ml (6-8 days). Cell number and viability was assessed daily using a ViCell (Beckman 
Coulter USA). On harvest day, cell broth from each flask was transferred to multiple 50ml 
conical tubes and spun at 2000g for 10 minutes to pellet the cells. The supernatant was pooled 
and it was filtered through a 0.22µm Stericup® (Merck Millipore USA). An equal volume of 
buffer A-P (50 mM sodium acetate, 20 mM sodium phosphate, 1 M NaC1 adjusted to pH 5.2) 
was added to reduce the pH and inhibit phosphatase activity. This mixture was stored at -200 C 
until purification.  
6.3 Capture step– anion exchange chromatography 
The capture chromatographic step is designed to isolate, concentrate and stabilize the target 
protein.  
IEX separates large proteins, small nucleotides and aminoacids on the basis of their charge. IEX 
media have charged functional groups that bind molecules with an opposite charge. Bound 
molecules are eluted from the medium by displacement, via the application of an increasing 
concentration of a similarly charged molecule. Proteins have numerous functional groups that 
can have either positive or negative charges. By adjusting the pH or the ionic concentration of 
the mobile phase, proteins can be separated. IEX is used for capture of the target protein from 
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bulk impurities from large-volumes, as an intermediate purification step, or as a final step for 
high resolution purification to remove impurities. 
Proteins carry a charge based on the pH of the environment. The pH at which a molecule has no 
net charge is called its isoelectric point (pI). GAA theoretical pI based on its aminoacid sequence 
was calculated as 5.4 (ExPASy - SIB Swiss Institute of Bioinformatics) therefore at a pH above 
5.4 the protein should carry a net negative charge and bind to an anion exchanger. Vice versa at 
pH below pI the protein should carry a net positive charge and bind to a cation exchanger. 
Although technically both exchangers could have been used by working at pH range 6-7 for the 
anion exchanger or between 4-5 pH for cation exchanger, keeping the target molecule in the 
cation exchanger low pH range, would expose it to proteolytic degradation threat. For this reason 
we decided to go for anion exchange separation. 
Anion exchange resins come in two types: strong and weak. The main difference between the 
two is that in strong anion exchangers the number of charges remains constant regardless of the 
buffer pH. These types of resins retain their selectivity and capacity over a wide pH range. 
Quaternary ammonium (Q) is an example of strong anion exchanger and its functional group is -
N+(CH3)3. Weak anion exchangers in contrast, display pH-dependent behaviour and so deliver 
optimal performance over only a small pH range. When the pH of the buffer no longer matches 
the acid dissociation constant (pKa) of the resin functional group, these resins suffer significant 
capacity reduction. Diethylaminoethyl (DEAE) is an example of weak anion exchanger and its 
functional group is -N+(C2H5)2. Usually a strong ion exchanger is tried first due to its wider pH 
range of operation, weak exchangers are used when strong ones fail as selectivity of weak and 
strong ion exchangers often differ. 
Bead size had to be taken into consideration. As this is early in the purification process (e.g., first 
step - the capture stage), speed of sample processing is more important than resolution as the 
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volume is large and the target protein needs to be removed from harvest and stabilized. For this 
reason particle size (dp) was selected to allow low backpressure at high flow rates. Some of the 
commonly used large particle size resins available are Sepharose (90nm) and Capto (75nm) 
(both GE Life Sciences).  
Lastly, a small volume (1 ml) prepacked column (HiTrap) was used due to limited scale of the 
feed (lab research scale) and convenience.   
After all these considerations a HiTrap Capto Q 1ml IEX column was chosen for this step.  
A standard preloaded GE-developed linear gradient purification method was used as a starting 
method which provided good initial product separation with minor tweaking required. Resulting 
chromatogram is shown in Figure 6-1 below. 
6.3.1 Chromatogram 
 
Figure 6-1 Clone 1 clarified harvest anion exchange chromatogram. Acquired on GE AKTA 
Avant 25 column GE CaptoQ HiTrap 1ml, 1 ml/min flow rate, equilibration buffer 50mM 
Sodium Acetate pH6.0 (BufferA), elution buffer 1M Sodium Chloride in 50mM Sodium Acetate 
pH6.0 (BufferB).  30ml of Clone 1 were diluted 1:4 into equilibration buffer to favour binding. 
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After equilibrating column with buffer A for 10CV, 1.8 mg of material was loaded at 1 ml/min 
via sampling port. Salt concentration was kept at 0 until completion of flow through 
(approximately 20CV) and then for wash cycle (15CV). The NaCl concentration was increased 
in a linear gradient fashion over 40CV up to 400mM to elute the GAA. Elution peak showed a 
pre-peak. 1M NaCl for 10CV allowed tightly bound material to elute as well. Column was 
regenerated after each injection with 20CV 500mM NaOH. 2ml fractions were taken as shown 
during flowthrough (ft), elution (e) and strip (s). 
6.3.2 Fraction analysis 
The purpose of the following experiments was to demonstrate whether all GAA elutes in elution 
fraction or some is lost in the flow through or strip fractions.  
The 2ml fractions collected during the IEX chromatographic run were analysed via gel 
electrophoresis (Figure 6-2), western blot (Figure 6-3) and the GAA diagnostic assay (Figure 
6-4) for presence and quantity of target molecule.  
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Figure 6-2 gel electrophoresis NuPAGE™ Novex™ 4-12% Bis-Tris (ladder cat# 26614 Thermo 
Fisher, USA) Comassie blue stained (left) SYPRO ruby stained (right). Samples: fractions from 
Figure 6-1. ft1-4 (pooled flow through fraction 1 to 4), e1-4 (pooled elution fraction 1 through 4), 
s1 (strip), H (clarified harvest), e1-2 (pooled elution fraction 1 and 2), e3-4 (pooled elution 
fraction 3 and 4). Data shows GAA over-expressed (~110KDa) in H together with impurities of 
sizes covering the whole gel size spectrum. e1-4 shows qualitatively the degree of purification of 
the capture step. A protein of similar size (presumably GAA) is present in elution together with 
other proteins at ~175, 55 and 30KDa. Same samples were rerun and gel was stained via 
SYPRO ruby to confirm results and increase sensitivity.   
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Figure 6-3. Western blot of anion exchange fractions (chromatogram shown in Figure 6-1). 
After collection, fraction samples were concentrated using 10000MWCO filters and 20µg of 
protein was loaded on 4-12% bis-tris SDS-PAGE gel and separated according to MW. Proteins 
where then transferred to PVDF membrane from Bis-Tris 4-12% Gel, (ladder cat# 26614 
Thermo Fisher, USA). Primary anti-GAA rabbit mAb (w.d.1:1000 Abcam cat.# ab137068),  
Secondary anti rabbit polyclonal Ab HRP-linked (w.d. 1:1000). Ref sample is GAA drug 
substance reference sample 2.08 mg/ml (BioMarin, lot# 11132013). Chromatogram (from 
Figure 6-1) was copied on membrane to better show the fractions. Data shows how GAA can be 
seen present in varying concentration only in the four elution fractions and no GAA is observed 
in flowthrough and strip fractions. Elution fraction e3 seems to have the highest GAA amount, 
which corresponds to the peak in the chromatogram attached. The GAA bands were slightly 
below the expected molecular weight for GAA (106 KDa), however so was the reference 
standard. This can be attributed to the molecular weight standard being compromised or 
inaccurate. 
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Figure 6-4. GAA diagnostic assay determination of GAA amount IEX fractions from figure 6.1.  
Samples prepared in triplicate and read on a flat-bottom 96 well polystyrene plate via BMG 
Fluorstar Galaxy fluorimeter. Reference material (2.09 mg/ml) was diluted 1:100 in assay buffer, 
all other samples 1:10. 5 µl of each dilution was mixed with 100µl substrate (4MU-αGlc 
acarbose pH 4.0) and incubated at 37 oC for 60min as per described assay method. At the end of 
incubation period, reaction was stopped with 50µl 1M glycine buffer pH 10.4. The plate was 
read in scan mode at 360-480 nm range, with absorbance peak at 420nm. RFU was normalized 
by subtracting blank value and resulting RFU values were used to calculate GAA concentration 
based on reference value. 
As previously mentioned, the purpose of this step is to isolate, concentrate and stabilize the 
target protein. The figures shown in this section confirm the fact that the anion exchange step is 
able to capture the target molecule at low salt (pH 6.0). Elution occurs at a NaCl concentration 
between 200 and 400 mM.  
From gel electrophoresis image (Figure 6-2) we can see a comparison between clarified harvest 
and post IEX fractions. In both gels (Comassie and SYPRO stained), the elution fraction is 
visibly purer than the harvest and it clearly contains a protein of the same molecular weight as 
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the one seen in harvest sample. Although we cannot be sure from this experiment that the 
marked band is GAA, we can assert that the MW is around 110KDa, the expected MW for GAA. 
The flow-through sample, strangely, shows very little protein present, perhaps due to wrong 
sample loading concentration. This is in clear discordance with chromatogram showing 
flowthrough absorbance maxing out the UV detector.   
In order to identify the 110 KDa band in the elution fractions, the same samples were run again 
on a NuPage 4-12% BT gel and transferred onto a PVDF membrane for western blotting analysis 
(Figure 6-3). The processed membrane showed that the band seen in elution fractions from 
electrophoresis is in fact GAA as it is recognised by the specific monoclonal anti-GAA - 
secondary antibody couple linked to HRP. This also confirms that flow through and strip 
fractions are target molecule free.   
The GAA diagnostic assay was used to quantify eluting GAA and calculate step yield. From 
Figure 6-4, up to 0.2 mg/ml of GAA is present in the four fractions. Each fraction volume is 2ml. 
As the load volume was 10ml and the concentration of GAA in the load was 0.18 mg/ml, we can 
calculate mass balance and purification yield. 
Mass balance 
Load (In):  10ml x 0.18mg/ml = 1.8 mg 
Elution (Out):  4 x 2ml x 0.2mg/ml = 1.6 mg 
Percent recovery 
Mass out / mass in x 100 = 1.6 mg / 1.8 mg x 100 = 89% 
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6.4 Intermediate purification – hydrophobic interaction chromatography 
The intermediate purification objective is to remove most of the bulk impurities such as other 
proteins, nucleic acids, HCPs and lipids. An effective separation strategy is commonly based on 
the principle of exploitation of a combination of techniques with independent selectivity. In this 
instance, the target molecule was first purified based on its charge via anion exchange, leaving it 
in a mixture of similarly charged molecules, and co-eluting species as later shown. In order to 
further purify GAA, the subsequent separation had to be based on a different selectivity. 
Hydrophobic interaction was picked as a good candidate for intermediate purification as able to 
separate molecules based on hydrophobicity. This was also decided to mimic the sponsor 
company downstream process. 
HIC separation principle is complementary to ion exchange. Proteins are composed by amino 
acids, and amino acids can have either polar (hydrophilic) or non-polar (hydrophobic) side 
chains. The specific sequence of aminoacid determines protein folding structures. Depending on 
the type of side chains that are mostly exposed, the whole protein will acquire either polar on 
non-polar behaviour. When a sample containing a mixture of proteins is applied to a HIC column 
in high salt, hydrophobic and hydrophilic regions interact with the resin and bind to it. The salt 
interacts with water molecules to reduce solvation of the protein molecules in solution (Porath, 
1986). As salt is gradually decreased, hydrophobic regions become exposed and are absorbed by 
the mobile media and therefore start eluting. The more hydrophobic the molecule, the less salt is 
needed to promote binding.  
HIC solid phase is composed by resin beads with bound hydrophobic ligands. Bead size choice 
depends on application as it impacts resolving power needed and the pressure drop. For instance, 
larger beads are more suitable for capture to intermediate purification as they tend to have a 
lower pressure with impure and viscous samples, vice versa smaller beads are more suitable for 
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intermediate and polishing steps when the sample is mostly pure and more resolving power is 
required. In terms of ligands there are multiple types on the market with different levels of 
hydrophobicity and the two tested in this work are butyl and phenyl. A protein's adsorption 
behaviour is determined by the type of immobilized ligand. In general, straight chain alkyl 
ligands demonstrate hydrophobic character while aryl ligands show a mixed mode behaviour 
where both aromatic and hydrophobic interactions are possible (Hofstee and Otillio, 1978). The 
choice of ligand type is empirically determined following hydrophobic ligand order from GE. 
Degree of ligand substitution must also be taken into consideration as protein binding capacity 
increases with an increased degree of substitution of the immobilized ligand. With a high level of 
ligand substitution, the binding capacity remains constant; however, the affinity of the 
interaction increases (Jennissen and Heilmeyer, 1975). 
Lastly pH and temperature also have an impact on binding capacity of the resin as they can alter 
a protein conformation and therefore affect ionic interactions and hydrogen bonds between 
polypeptide chains. As seen in the next section a specific pH range was tested at room 
temperature. 
6.4.1 HIC development strategy 
The development of the HIC step was a particularly lengthy process as it did not produce 
satisfactory results due to the first principle approach strategy adopted. Most of the initial 
experiments were done using a ligand that turned out to be not the ideal one. Much time could 
have been saved had we used high throughput plates strategy from the beginning.  
The starting point of the method development was a paper by Van Hove (Van Hove et al., 1997) 
in which purification of GAA was achieved by binding target molecule onto Concanavalin A 
Sepharose 4B column and then loading the eluate onto a phenylsepharose HP column in 0.75M 
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ammonium sulphate pH 5.3. This was the first experimental run tested: IEX eluate was buffer 
exchanged using 10000 mwco concentrator spinner filters in 0.75M ammonium sulphate pH 5.3 
and loaded onto HiTrap Phenylsepharose low sub column. Elution was achieved by gradual 
decrease of conductivity, or in other words linear increase of the no-salt buffer (buffer B). The 
chromatogram expected elution region however showed little absorbance (data shown in next 
section). Due to the small amount of protein present in loaded sample, it was difficult to 
determine whether any binding occurred. To try to increase affinity we then switched the column 
with a higher degree of substitution Phenyl Sepharose HiTrap (high sub) (GE Healthcare, USA 
cat# 17-1355-01), with similar results. 
At this point, a more systematic approach was adopted and a screening experiment was set up: 
GAA was loaded onto the Phenyl Sepharose HiTrap (high sub) column using different 
equilibration buffers at different salt concentrations and pH levels (details in next section). A 
total of 13 conditions were screened, this however did not lead to satisfactory results. The small 
amount of protein loaded onto the column would not bind to the beads and was observed in the 
flowthrough peak.  
Different resins were then suggested for testing by BioMarin in a high throughput plate based 
format type of experiment. Binding of pure GAA material was tested using two types of resin 
(phenyl and butyl) in different salt buffers. This approach eventually led to successful result.  
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6.4.2 Screening of resins and binding conditions via AKTA 
6.4.2.1 First principle approach 
 
Figure 6-5. HIC chromatogram, Run 1: 0.75M ammonium sulphate pH 5.3. Blue: absorbance 
(mAu); green: % buffer B; brown: conductivity (mS/cm). IEX eluate fraction was buffer 
exchanged in Buffer A via multiple washes through 10000mwco Amicon filter keeping final 
volume constant. HIC method reagents: buffer A 0.75M ammonium sulphate pH 5.3, buffer B 
20mM acetate pH 5.3, flow rate 0.5ml/min, column HiTrap phenyl FF low sub (cat# 17-1353-01 
GE HealthCare) HIC method sequence: equilibration 5CV buffer A, injection 2ml via sample 
loop, wash 10CV buffer B, Elution  20% to 50% buffer B over 10CV, strip 100% buffer B 5CV, 
CIP 0.5M NaOH 5CV. Figure shows large portion of protein mixture does not bind. No elution 
peak visible. 
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Figure 6-6. HIC chromatogram, Run 2: GAA reference in 0.75mM ammonium sulphate. Blue: 
absorbance (mAu); green: % buffer B; brown: conductivity (mS/cm). Injection of GAA reference 
material diluted in buffer A. HIC method reagents: Buffer A 0.75M ammonium sulphate pH 5.3 
20 mM acetate, Buffer B 20mM acetate pH 5.3, flow rate 0.5ml/min, column HiTrap Phenyl FF 
low sub (cat# 17-1353-01 GE HealthCare) HIC method sequence: equilibration 5CV buffer A, 
injection 2ml via sample loop, wash 10CV buffer B, Elution  20% to 50% buffer B over 10CV, 
strip 100% buffer B 5CV, CIP 0.5M NaOH 5CV. Figure shows GAA reference does not bind 
under these conditions.  
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Figure 6-7. HIC chromatogram, Run 3: high-sub HiTrap Phenyl FF column used. Blue: 
absorbance (mAu); green: % buffer B; brown: conductivity (mS/cm). IEX eluate fraction was 
buffer exchanged in Buffer A via multiple washes through 10000mwco Amicon filter keeping 
final volume constant. HIC method reagents: Buffer A 2.0M ammonium sulphate pH 5.3, 20 mM 
acetate, Buffer B 20mM acetate pH 5.3, flow rate 0.5ml/min, column HiTrap Phenyl FF high sub 
(cat# 17-1355-01 GE HealthCare) HIC method sequence: equilibration 5CV buffer A, injection 
2ml via sample loop, wash 10CV buffer B, Elution  20% to 50% buffer B over 10CV, strip 100% 
buffer B 5CV, CIP 0.5M NaOH 5CV. Figure shows large portion of protein mixture still does not 
bind. As conductivity starts lowering proteins start coming off the column however no peak can 
be identified.  
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6.4.2.2 Binding buffer screening 
Buffer A Buffer B pH Initial conductivity (mS/cm) 
0.75 M AS 20 mM acetate 5.3 115 
1.0 M AS 50 mM NaP 5 140 
1.0 M AS 50 mM NaP 6 140 
1.0 M AS 50 mM NaP 7 140 
1.5 M AS 50 mM NaP 4 185 
1.5 M AS 50 mM NaP 5 185 
1.5 M AS 50 mM NaP 6 185 
1.5 M AS 50 mM NaP 7 185 
2.0 M AS 50 mM NaP 5 220 
2.0 M AS 50 mM NaP 6 220 
2.0 M AS 50 mM NaP 7 220 
Table 6-1. HIC binding buffer screening study of IEX eluate fraction. AS: ammonium sulphate, 
NaP: sodium phosphate. Column HiTrap Phenyl FF high sub (cat# 17-1355-01 GE HealthCare).  
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Figure 6-8 HIC binding screening study representative chromatogram (12 total chromatograms 
show similar profiles). Blue: absorbance (mAu); green: % buffer B; brown: conductivity 
(mS/cm). IEX eluate fraction was buffer exchanged in Buffer A (refer to table 6-1) via multiple 
washes through 10000mwco Amicon filter keeping final volume constant. HIC method reagents: 
Buffer A and B refer to table 6-1, flow rate 0.5ml/min, column HiTrap Phenyl FF high sub (cat# 
17-1355-01 GE HealthCare) HIC method sequence: equilibration 5CV buffer A, injection 2ml 
via sample loop, wash 10CV buffer B, Elution 20% to 50% buffer B over 10CV, strip 100% 
buffer B 5CV, CIP 0.5M NaOH 5CV. Figure shows very little protein in breakthrough fraction 
and no elution occurring. IEX peak absorbance is at around 100 mAu, but here it is only 1/10th 
of that. Probable protein loss during buffer exchange could be the cause of this.  
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6.4.2.3 Resin binding screening 
Having been unsuccessful in obtaining satisfactory separation using first principle approach we 
decided to screen alternative resins and buffers. This step was performed at BioMarin 
laboratories in Novato CA with Dr. John Henstrand’s group assistance. This study was designed 
to determine GAA optimal binding condition on two different resins and multiple salts. This 
procedure allowed for quick screening of multiple conditions using 96 well plate setting.   
 
Table 6-2 Resin binding screening experiment. Quantities refer to protein amount found in each 
1 ml sample and are expressed in μg (green to red relative good to bad performance). 2000 μg of 
pure GAA reference material (BMN 103; 2.0mg/ml; ε = 1.56) was mixed with 200 μl of 80% 
slurry of resin in 1 ml of the different equilibration buffers as per table, mixed and incubated o/n 
under gentle agitation at 4oC to allow protein binding. The next day tubes were spun and 
supernatant concentration determined via absorbance at 280 nm (T=12h), beads were then 
resuspended in 1 ml of fresh buffer A, mixed, spun and concentration of supernatant determined 
and step repeated 3 times (W1, W2, W3). Elution was performed by resuspending the beads in 1 
ml of elution buffers of decreasing salt concentrations E1 (75%A+25%B), E2 (50%A+50%B), 
E3 (25%A+75%B). For strip step beads were resuspended in 100% buffer B (no salt) 3 times as 
above (S1, S2, S3). The condition that yielded to the best protein recovery and least amount of 
loss was (A) 2M NaCl, (B) 50mM sodium acetate on Butyl Sepharose 4FF at pH 5.0. Conditions 
that did not show satisfactory results were not brought forward (blank spaces). 
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This experiment allowed the quick screening of 12 different conditions for binding of pure GAA 
onto HIC resin. After mixing 2mg of pure GAA reference material with the resin beads in 
specific equilibration buffer, o/n incubation and three wash cycles, only 5 conditions out of 12 
show >99% binding (highlighted in green under wash in Table 6-2). This showed that binding 
generally occurred better under NaCl than ammonium sulphate. The conditions that did not 
achieve >99% protein binding after three cycles of buffer A washing, were not brought forward 
(amber and red). After 3 cycles of elution at decreasing salt concentrations, GAA showed better 
unbinding from butyl rather than phenyl resin, with one condition achieving over 67% recovery 
(highlighted in green under elution). Lastly the strip cycle showed how out of the 5 experimental 
conditions, more GAA came off at this stage from phenyl >60%) vs butyl resin (<30%) 
indicating butyl performing overall better in binding and eluting GAA minimizing protein loss.  
Out of the 12 experimental conditions tested, the condition that yielded the best protein recovery 
and least amount of loss was binding in 2M NaCl and eluting in 50mM sodium acetate on Butyl 
Sepharose 4FF at pH 5.0. 
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6.4.3 Purification of IEX eluate on AKTA via HIC using resulting conditions from resin 
binding screening study.  
6.4.3.1 GAA Reference 
 
Figure 6-9. GAA reference material injection on Butyl Sepharose 4FF CV = 3 ml (GE 
Healthcare, USA cat# 17098001). Load: 5mg GAA diluted in 15 ml 2.0M NaCl, flow rate 1 
ml/min, wash 3CV, elution 0-100% 50mM sodium acetate 10CV, 1ml fractions collected.  
The separation conditions established via resin binding screening were tested on an AKTA 
Avant 25 using an in-house packed Butyl Sepharose 4FF (d = 0.66cm, bed height = 9 cm, CV = 
3ml) column.  
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First we injected 5 mg of pure GAA diluted in 15 ml of 2.0 M NaCl at a flow rate of 1 ml/min 
onto the column. Elution was performed via linear gradient from 0 to 100% buffer B (50 mM 
sodium acetate) over 10v CV.  The 33 1ml elution fractions collected were pooled together. 
Protein absorbance at 280nm was performed via NanoDrop and concentration determined to be 
0.084 mg/ml (ε = 1.56 (mg/ml)-1 cm-1).  
Protein recovery: 
Load (IN): 15 ml at 0.33 mg/ml = 5 mg 
Elution (OUT): 33 ml at 0.084 mg/ml = 2.77 mg 
% protein recovery: 100 x 2.77 / 5 = 55.4% 
The protein recovery calculated (55.4%) was slightly lower than resin binding screening 
experiment result (66.7%), This was probably due to experimental conditions not being 
comparable. Although high throughput screening was useful in selecting the right running 
conditions, results from the two systems cannot be fully comparable due to the different 
geometry and fluid dynamics of a plate microwell and a chromatographic column.  
6.4.3.2 IEX Eluate sample 
We then proceeded to injecting IEX eluate sample (from Figure 6-1).  The four 2 ml eluate 
sample fractions were pooled together and buffer exchanged into 2.0 M NaCl pH 5.3 using an 
Amicon 10000mwco spinner concentrator maintaining the final volume constant (8 ml). The 
sample was then injected onto the Butyl Sepharose 4FF column (CV 3ml) at a flow rate of 1 
ml/min. Column was washed with  3 CV of 2 M NaCl, followed by 10 CV of 0-100% linear 
grade elution with 50 mM sodium acetate to lower salt concentration (and buffer conductivity) 
164 
 
and allow protein to elute. Unlike previous attempts at purifying IEX eluate sample, this time a 
clear elution peak could be observed (Figure 6-10).  
The HIC elution fractions were pooled together and the sample was run on SYPRO ruby SDS-
PAGE gel to visually assess degree of purification compared to the capture step (Figure 6-11).   
 
Figure 6-10. HIC separation of GAA from IEX elution peak. Blue: absorbance (mAu); green: % 
buffer B; brown: conductivity (mS/cm). Butyl Sepharose 4FF CV = 3 ml (GE Healthcare, USA 
cat# 17098001). Load: 0.4 mg in 2.0M NaCl, flow rate 1 ml/min, wash 3CV, elution 0-100% 
50mM sodium acetate 10CV, 1ml fractions collected. 
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Figure 6-11. SYPRO ruby stained SDS PAGE comparison of H: HCCF sample, IEX elution pre-
peak (left) and main peak (right) and HIC elution peak. GAA protein band at 106KDa in HIC 
sample shows a higher degree of purity than the IEX GAA band.  
The chromatogram in Figure 6-10 shows a good degree of separation occurring under the 
running conditions selected, in contrast with all the previous runs. The elution fraction was run 
on a SYPRO ruby SDS-PAGE (Figure 6-11) which confirmed presence of GAA at 106KDa and 
increased overall feed purity. The purity of GAA after HIC was determined via LC/MSMS to be 
above 80% as shown later in section 7.4.3.  
6.5 Chapter conclusions 
The development of a purification process capable of removing the biotherapeutic enzyme of 
interest (GAA) from a CHO cell culture process stream was an important milestone of the EngD 
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project. The main goal of this process was to investigate protease and HCP removal at the two 
chromatographic steps while achieving an acceptable level of GAA purity. Although important, 
achieving highest purity of the target molecule was never the end goal of this process mainly 
because of the purely research nature of the project. The GAA produced through this process 
was never meant for human use but rather should be seen as an academic exercise to process 
development and HCP identification and removal activities. 
The harvest of a GAA producing clonal CHO cell culture, generated in results chapter one, was 
first clarified via centrifugation and filtration to remove whole cells and cell debris. The clarified 
Harvest Cell Culture Fluid (cHCCF) was then subjected to two rounds of chromatographic 
separation, first based on protein charge (capture IEX) then followed by protein hydrophobicity 
(intermediate HIC).  The final target protein purity was above 80% as assessed by MS (section 
7.4.3 Figure 7-10) 
In the first chromatographic step, Anion Exchange, protein charge was used to capture GAA 
from the process stream using a 1ml HiTrap capto-Q column on an Akta Avant 25. GAA 
presence in elution fraction was confirmed by western blot. The step protein recovery was 
calculated as 89% and purification yield 46%.  
For intermediate purification, Hydrophobic Interaction chromatography was investigated. After 
numerous failed attempts at separating GAA in IEX eluate on a Phenyl Sepharose 6FF HiTrap 
resin a resin binding study was set up at BioMarin laboratories. This experiment lead to the 
adoption of butyl resin instead of phenyl and determination of 2 M NaCl pH5.0 as the ideal 
equilibration buffer. IEX eluate was separated using the conditions determined in the screening 
experiment after being buffer exchanged into 2M NaCl. An SDS-PAGE gel of the HIC elution 
fraction was run next to the IEX elution fraction and HCCF sample and GAA was observed at 
106KDa molecular weight. Protein purity was measured at 82% via MS analysis (next chapter). 
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7 Chapter four 
HCP, proteases and cellular stress due to target protein overexpression.  
7.1 Introduction  
In the previous chapter we have discussed the development of the downstream process for the 
purification of GAA from cell line 1 harvest. The focus of this last chapter will be identification 
and quantification of HCP released by the chosen cell line, assessment of protease presence in 
the feed throughout the bioprocess and determination of whether GAA over-expression has an 
effect on general cell and lysosomal phenotype by acquiring high resolution images of affected 
organelles. 
This chapter is divided in four result sections ordered by assay type: qualitative protease 
characterization via zymography; HCP screening via immunoassay (AlphaLISA); protease 
identification via mass spectrometry; and lastly lysosomal phenotype characterization.  
Proteases present in in-process samples were at first qualitatively characterized via zymography. 
This technique was used early on in the project during the cloning to compare transfection 
strategies and their effect on protease release and later on to determine protease clarification 
performance of the capture step.  
Subsequently we proceeded with assay development for total HCP quantification via AlphaLISA. 
This assay was used to quantify HCP before and after capture chromatography to determine step 
yield. 
Once we had a good idea of the total amount of HCP present in the feed, we proceeded with 
identification of those HCP via mass spectrometry. We mainly focussed on HCP in GAA Clone 
1 HCCF and capture step eluate and compared eluates from different cell lines as explained later. 
For these sections three tandem MS techniques were employed: (1) in-gel tryptic digestion 
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MALDI MS/MS, (2) MALDI TOF LC-MS/MS and (3) label free high resolution LC-MSMS. 
The first revealed to be labour intensive and error/contamination prone and best suited for 
product identification rather than HCPs, the second was more high throughput due to separation 
via LC but reliant on approximate quantification by emPAI index, while the latter was high 
throughput as well as truly quantitative via label free quantitation through  direct comparison 
with a BSA standard reference. Other non-MS based strategies were considered for HCP 
identification, including Proteseeker by G-Biosciences, an assay based on exposure of protease 
mix to 12 different kinds of inhibitors together with colorimetric protease screening. This assay 
was attempted on IEX eluate fraction and however produced no satisfactory results. 
In the last result section of this chapter we present TEM acquired images of cells lysosomes to 
assess whether GAA over expression has an impact on their morphology and overall cell stress, 
which could relate to overall levels of secreted proteases. Different cell lines lysosomes were 
compared for reference.  
7.2 Qualitative protease characterization via zymography 
The purpose of this assay was to qualitatively assess presence and approximate molecular weight 
of proteases present in in-process samples. Zymography combines two analytical methods: 
protein separation based on molecular weight via gel electrophoresis and protease digestion of 
specific substrate (casein) within the gel resulting in white bands showing on blue gel 
background.  
Proteins in samples are linearized by the SDS in the sample buffer but not heat denatured in 
order to maintain their functionality. Linearization allows proteins to move through the gel mesh 
at a rate proportional to their molecular weight under the applied electrostatic current. At the end 
of the run, the proteins are renatured by incubating the gel in non-ionic detergents (Renaturing 
buffer, Thermo Fisher Scientific USA) to re-establish enzymatic activity. The gel is then 
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incubated overnight at RT in developing buffer (Thermo Fisher Scientific USA) which adds 
divalent metal cations required for enzymatic activity. The following day the gel is stained with 
Comassie blue and de-stained in 40%MeOH, 10%Acetone. Regions of protease activity appear 
as clear bands against a dark blue background where the protease has digested the substrate. 
There are several variants commercially available and they differ by substrate used. The ones 
used here were 12%Novex® casein (0.05%) zymograms gels (cat# EC64052BOX Thermo 
Fisher Scientific, USA).   
7.2.1 Protease distribution in transient and stable transfection cultures. 
The first study was done to compare protease content in transient and stable transfection clones 
from 4.3.1 and 4.3.2 
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Figure 7-1. Comassie blue stained zymogram gel of centrifuged harvested cell culture fluid 
(HCCF) of transient transfection (T.T. section 4.3.1) and stable transfection (S.T. section 4.3.2) 
cultures. Incubation time 72h at 37oC pH 5.0 under moderate agitation. Molecular weight 
standard Mark12 unstained (cat# LC5677, Thermo Fisher Scientific, USA). Data shows the wide 
range of proteolytic activity in both harvest samples, with heavier presence at around 80KDa 
molecular weight. Also stable transfection GAA clone 1 sample seems to have heavier 
proteolytic presence then its transient transfection counterpart. Note. Absence of 66.3 and 55.4 
KDa ladder marks makes data questionable. Note. GAA not being a protease is not visible in 
zymograms. 
7.2.2 Protease distribution in Anion Exchange Capture chromatography  
Following the capture step purification of HCCF of clone 1 (section 6.3.1), we wanted to 
determine protease presence in HCCF and ion exchange eluate fraction. Samples were buffer 
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exchanged into PBS and concentrated 4X in a 10000mwco spin concentrator. After determining 
sample total protein concentration via nano-drop, 5mg of protein was mixed with sample buffer 
as per protocol (material and methods section 3.4.1) and loaded onto the gel. At the end of the 
run the gel was incubated with renaturing buffer to allow proteins to renature and become active 
and then incubated for 72h in developing buffer pH 5.0 at 370C under moderate agitation.  Gel 
was finally stained in Comassie blue and destained in 40% MeOH 10% Acetic Acid.  
The original resulting data image (Figure 7-2 right) was enhanced (left) to better reveal the 
molecular weight standard. Image shows a general reduction in proteolytic activity from HCCF 
to eluate fraction, with the exception of a conspicuous amount left at 80KDa mark. This result is 
in accordance with later figures (Figure 7-3). According to MS identification data shown in 
result section 7.4.3 below (see also appendix 1 for complete HCP identification list), proteases of 
~80KDa size present in GAA IEX eluates are Dipeptidyl peptidase 3, a metalloproteinase and 
Prolyl endopeptidase a serine protease.  The implications of the presence of these two proteases 
coeluting with the product has not been evaluated due to lack of time and we think it would be 
valuable work to undertake in the future. 
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Figure 7-2 Comassie blue stained zymogram. Yellow tone added in image post processing to 
enhance ladder. Harvest (HCCF) from GAA Clone1 (300616) and IEX eluate were buffer 
exchanged into PBS and concentrated 4X, samples prepared as per manufacturer protocol. 
Incubation time in developing buffer was increased from over-night to 72h to increase sensitivity. 
Ladder EZ™-Unstained Protein Ladder Marker (Cat# PM001, Enzynomics, Korea). Data shows 
proteolytic activity in HCCF sample at wide range of molecular weights, with vast majority 
located at 80KD, later determined to be made up by Dipeptidyl peptidase 3, a metalloproteinase 
and Prolyl endopeptidase a serine protease. Similar pattern was observed to the HCCF harvest 
but with lower amounts. 
7.2.3 IEX protease removal by comparing GAA Clonal cell line to originating Null 
A further comparison of IEX protease removal was done by running HCCF and IEX eluate of 
the GAA producing clone selected and the originating Null cell line on a zymographic gel side 
by side. Both cultures were grown identically as previously discussed (section 6.2) in 50ml CD-
CHO and harvested. Resulting gel was developed for 72h in pH 5.0 at 37OC for increased 
sensitivity. Similarly to Figure 7-2, the gel in Figure 7-3 shows qualitatively the amount of HCP 
with proteolytic activity that the capture anion exchange step is able to clear from HCCF samples. 
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Specifically, going from HCCF to IEX eluate while most proteases are cleared from the process 
stream, a significant amount of proteases at 80kDa coelutes. MS analysis putatively identified 
this band as dipeptidyl peptidase 3 and prolyl endopeptidase. The gel also shows how the 
protease profile of a Null and an overexpressing CHO cell line are broadly similar, as further 
demonstrated in section 7.4.3 below.  
 
Figure 7-3 Comassie blue stained casein Zymogram. From left: Null HCCF (Null-H), Null IEX 
Eluate (Null-E), Cell line1 HCCF (C1-H), Cell line 1 IEX Eluate (C1-E). Protein samples are 
first separated according to molecular weight via gel electrophoresis, then renatured and 
incubated 72h in pH 5.0 at 37OC in the gel containing casein substrate and finally stained and 
de-stained. Areas that show proteolytic activity appear as white bands over dark background. 
Data shows that IEX is able to clear out the majority of proteases from HCCF to eluate sample 
except for some co-eluting ones at around 80 KDa. These were later identified via MS as 
Dipeptidyl peptidase 3 and Prolyl endopeptidase. Furthermore, amount of protease in GAA cell 
line 1 eluate seems to be less than amount of proteases present in Null eluate. Note: GAA, not 
being a protease, is not visible in zymography. 
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7.3 CHO HCP screening via AlphaLISA 
Host cell protein (HCP) release during production of therapeutic proteins is a critical quality 
attribute that must be monitored and reduced to acceptable levels during the production of a 
biotherapeutic protein (Bracewell et al., 2015). Being able to control HCP release during harvest 
and their removal via downstream processing is thus an important component of the 
manufacturing of such molecules and must be reported to the regulatory authorities. Typical 
purity targets include <100 ppm HCP, <10 ng/dose DNA and  <5% product aggregates (Chon 
and Zarbis-Papastoitsis, 2011). Some HCPs are known to be co-purified with the recombinant 
protein target, whilst others, specifically proteases, are reported to lead to product degradation 
(Gao et al., 2011). 
Historically, immunoassay based techniques such as ELISA have been used as high throughput 
methods to quantify HCP amounts during process development, manufacturing and in final 
product formulations. This approach has been important in the development of HCP assays and 
process development and product characterisation, however there are some inherent limitations 
with the use of ELISA. For example, the polyclonal antibodies used for detection are raised 
against the spectrum of HCPs found in the host cell (or in some cases mixed pools of cells), 
results are thus generally cumulative of all the HCPs present in a sample and cannot provide 
identification of single critical HCPs of interest, and only those HCPs which are immunogenic 
can be detected. These issues can be summarized as concerns as to whether all HCPs are being 
measured at all and with sufficient sensitivity (Bracewell et al., 2015, Zhu-Shimoni et al., 2014). 
For these reasons orthogonal analytical high throughput techniques are being developed based on 
peptide identity via mass spectrometry: the need to simultaneously quantify and identify HCPs in 
samples with greater sensitivity and precision, has resulted in the advancement of orthogonal 
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analytical techniques based on LC-MS/MS. High throughput monitoring of HCP via LC-MS/MS 
is becoming ever more common (Doneanu et al., 2012, Chiverton et al., 2016) 
Nevertheless, immunoassays remain a valid and well established technique for HCP quantitation. 
Perkin Elmer AlphaLISA, already used (although unsuccessfully) for product quantitation (see 
section 5.4.1 for assay principle), was revisited for HCP quantitation. In this instance, the 
development work performed for product quantitation was not needed due to the fact that the 
HCP quantitation kits are commercially available through the manufacturer. 
7.3.1 AlphaLISA standard curve 
According to the manufacturer protocol the standard curve for this assay uses a Four Parameter 
Logistic Fit (4PL) with 1/y2 weighting. The applied weighting is used to offset heteroscedasticity 
by taking into account the change in variance which occurs with an increase in signal. 
Heteroscedasticity refers to the circumstance in which the variability of a variable is unequal 
across the range of values of a second variable that predicts it. A four Parameter Logistic Fit 
(4PL) with 1/y2 weighting is represented by the equation 
𝑌 =  𝑑 +  
𝑎−𝑑
1+(
𝑥
𝑐
)𝑏
   Equation 7-1 
After preparing the standards in triplicate as per section 3.4.2, the plate was inserted into the 
EnVision AlphaLISA reader, excitation set at 680 nm and signal emission recorded at 615 nm.  
All standard readings were first corrected by the mean of the blank group measurements. The 
standard data points were then plotted (concentration vs. corrected measurement) and a Four 
Parameter Logistic Fit (4PL) with 1/y2 weighting was made through these points (source 
myassay.com) 
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Figure 7-4 CHO HCP AlphaLISA assay standard curve. AlphaLISA CHO HCP 12 point 
standard dilution prepared in triplicate as per section 3.4.2 in materials and methods using 
CD-CHO (cell media) as diluent. 5 µl of each standard dilution was mixed with 20 µl Anti-
CHO HCP acceptor beads + biotinylated Antibody mix in a 96 well ½ area plate and 
incubated 60 min at RT, then 25 µl of streptavidin coated donor beads were added to each 
well in subdued lighting. Plate sealed with black TopSeal and incubated at RT for a further 
30 min. Plate read in an EnVision AlphaLISA reader (680/615 nm ex/em). Resulting signal 
was averaged and corrected subtracting blank reading and fitted to Eq 7.1 (Calculated 
parameters for this curve: a = -1.81693; b = 1.24996; c = 0.000286492; d = 15673; R² = 1  
The CHO HCP analyte standard curve here presented showed acceptable intra replicate precision 
and broad dynamic range. Lower Detection Limit (LDL): 450 pg/mL; Lower Limit of 
Quantification (LLOQ): 1472 pg/mL (cat# AL301C Perkin Elmer). 
7.3.2 HCP quantification in capture step via AlphaLISA 
AlphaLISA was used to determine CHO HCP concentration in HCCF and IEX eluate fraction to 
determine purity. During this process we encountered difficulties in measuring accurately HCP 
in HCCF sample. Several plates containing HCCF and IEX eluate samples were run and 
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although HCP determination in IEX eluate was reliable, we couldn’t get reproducible data for 
HCCF samples. We noticed that the quantification of HCP in HCCF was constantly giving 
inexplicably low results, often a fraction of what found in the respective purified sample. Surely 
HCP amount in HCCF should have been at least equal if not higher than amount found in the 
purified sample. We tried an array of sample diluents for HCCF samples from water, PBS, cell 
culture media. This seemed to have no effect on the result.  
We then realised that this phenomenon had been described before in the literature and is known 
as ‘the hook effect’. The hook effect is caused by excessively high concentrations of analyte in 
solution simultaneously saturating both capture and detector antibodies. The high-dose hook 
effect occurs mostly (but not exclusively) in one-step immunometric (sandwich) assays, giving a 
decrease in signal at very high concentration of analyte (Fernando and Wilson, 1992). In these 
conditions, reactions can go into antigen excess and result in falsely decreased results and 
potential misdiagnosis. In one step two-site immunoassays where capture and detection antibody 
are added simultaneously, free analyte and analyte bound to the labelled antibody compete for 
the limited number of antibody-binding sites of the detector and in the presence of very high 
analyte concentration will decrease instead of increase label bound to the solid phase, decreasing 
the resulting signal (Cole et al., 2001). As a solution to this problem the authors suggest 
decreasing amount of analyte in solution.  
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Figure 7-5. With permission from (InTech). High-dose hook effect in Elecsys hCG+β assay - an 
excessive amount of hCG overwhelms the binding capacity of the capture antibody. This results 
in an inappropriately low signal that causes an erroneous “hooked” result (6200 IU/L) for a 
patient with an excessively elevated serum hCG+ β concentration of 1 030 000 IU/L.  
To overcome the hook effect a HCCF sample from Clone 1 culture was serially diluted in the 
1:100 to  1:256000  range in CD-CHO media (12 dilutions in triplicate) and mixed with acceptor 
beads, biotinylated antibody and donor beads in the same exact way it was done for standard 
curve preparation explained above (section 7.3.1). The resulting signal was then averaged among 
the triplicates, corrected by subtracting the blank and converted to concentrations via the 
standard curve generated, taking into account the dilution factors. A recovery dilution factor 
between 80-120% was used to pick results close to the mean value.  As seen in (Table 7-2) 
below only dilutions between 1:500 and 1:32000 were in the acceptable recovery range. This 
explains why previous attempts at determining HCP in HCCF samples failed, as sample dilutions 
were usually in the range 1:1 to 1:64, a range here shown to be outside acceptable recovery. This 
experiment allowed for the determination of HCP concentration in HCCF samples as 
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0.093mg/ml. The usable dilution range for future experiments was arbitrarily set between 1:1000 
and 1:8000 dilutions. 
 
Table 7-2. CHO HCP AlphaLISA HCCF serial dilution experiment. HCCF dilutions 1:100 to 
1:256000 were prepared in triplicate in CD-CHO media and mixed in acceptor beads, 
biotinylated antibody and donor beads as explained above. Standard curve run in same plate 
was used to determine HCP concentration in samples. Only concentrations that satisfied the 80-
120% recovery range (dilutions between 1:500 and 1:32000 in yellow) were used to calculate 
average HCP concentration. Total HCP concentration in HCCF sample prepared was measured 
at 0.093 mg/ml. The standard curve shown in section 7.3.1 is a representative one shown as an 
example. A unique standard curve is run with each plate and set of samples. The specific 
equation parameters are used with each set of samples for concentration calculations.   
Having established HCP concentration in GAA Clone 1 HCCF and its appropriate dilution range 
for AlphaLISA assay, a new purification was set up on the AKTA as previously shown (section 
6.3) and 2 ml fractions collected throughout the whole run (Figure 7-6). Fractions from each 
stage were pooled together and CHO HCP AlphaLISA was performed. A new plate 96 well ½ 
area plate was set up with standard curve dilutions and the 4 samples from one GAA clone 1 IEX 
purification: (H) HCCF load 7ml, (FT) Flowthrough (16 x 2ml fractions), (E) Eluate (7 x 2ml 
fractions), (St) Strip (1 x 2ml fraction). This data was used to measure IEX yield reported in 
section 6.3. 
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Figure 7-6. GAA Clone 1 HCCF IEX purification using AKTA avant. 2ml fractions collected as 
shown and used for CHO HCP quantitation via AlphaLISA assay. Separation details previously 
described in section 6.3.1. 
 Sample 
Sample Volume 
(ml) 
HCP 
concentration 
(mg/ml) 
HCP 
amount (mg) 
Tot HCP 
(mg) 
GAA 
concentration 
(mg/ml) 
IN HCCF 7 0.082 0.574 0.574 0.18 
OUT 
FT 32 0.005 0.160  (28%) 
0.564 
(98%) 
0 
E 14 0.022 0.308  (54%) 0.2 
St 2 0.048 0.096  (17%) 0 
Table 7-3. IEX HCP mass balance via AlphaLISA. HCP in samples was measured as described 
in table 7.2. GAA concentration determined in section 6.3.2 
181 
 
7.4 Protease identification via tandem mass spectrometry 
In this section we present results of three tandem MS techniques aimed at identification and 
reliable quantitation of HCP present in GAA HCCF and capture eluate fraction: (1) in-gel tryptic 
digestion MALDI MS/MS, (2) MALDI TOF LC-MS/MS and (3) label free high resolution nano 
LC-MSMS. 
The first MS technique was in-gel tryptic digestion MALDI MS/MS. This technique involved 
separation of proteins based on molecular weight on a SDS-PAGE gel, excision of visible bands, 
digestion of each band with trypsin, and spotting sample on a MALDI plate for MS/MS analysis. 
This methodology is labour intensive and inherently error prone for a few reasons: first of all, not 
all bands were found to contain only one protein but rather a complex mixture of proteins of 
similar molecular weights, this was especially true in an impure HCCF sample; also, low 
concentration HCPs could easily go undetected due to bands being too faint to see and excise; 
lastly, as this technique involved many steps, human contamination (mostly by keratin) became a 
serious issue.  
We then tried running the same samples on LC/MSMS using MALDI attached to fraction spotter. 
This technique relieved the analyst of the manually intensive gel digestion sample preparation. 
The benefit of this technique over the previous one was that the peptides digested by trypsin 
were separated by LC rather than the electrophoretic gel method. This resulted in a more 
reproducible and less labour intensive task. Elution fractions were spotted automatically onto a 
MALDI plate and run via tandem mass spectrometry. Quantification of species found was 
achieved via emPAI (Exponentially Modified Protein Abundance Index), the index used for 
approximate label free quantitation of proteins (Ishihama et al., 2005). Although peptide 
separation was sufficient resulting in identification of more of the HCPs present, quantification 
was still inherently approximate as based on protein coverage by the peptide matches in a 
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database search result (emPAI), rather than true positive quantitation via reference standard 
comparison. 
Lastly, the same samples were tested via a high resolution label free quantitative nano LC-
MSMS. This methodology still relies on robust LC peptide separation, however the relative 
quantification calculation of each protein identified through this type of analysis is achieved 
via direct comparison with a BSA reference standard spiked in the samples before sample 
injection. In order for quantification to be absolute there should be a reference standard per 
identified ion or protein species, a clearly unfeasible solution. 
7.4.1 HCP identification via In-gel tryptic digestion and MALDI MS/MS 
The aim of this experiment was to try to identify HCP present in HCCF and their distribution in 
IEX fractions flowthrough, eluate and strip, using the same technique utilized for product 
identification (section 3.2.4). This was important in order to determine which class of co-eluting 
proteases were responsible for product degradation. A GAA Clone 1 cell culture was expanded 
and harvested as previously shown (section 6.2). HCCF material was loaded onto CaptoQ anion 
exchange resin on AKTA Avant and separation was achieved as shown before (section 6.3). The 
four samples (HCCF, FT, E, St) were run on a NuPAGE® Novex® Bis-Tris Gels SDS-PAGE 
gel (Figure 7-7), excised with a scalpel, digested with sequencing grade trypsin and run on 
UltrafleXtreme MALDI-TOF instrument (Bruker, Coventry, UK) for MS/MS analysis. 
Generated peptide masses were interrogated using the Mascot algorithm (matrix-science.com) to 
search all taxonomies in the SwissProt database. 
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Figure 7-7. MALDI-TOF-TOF on excised in-gel trypsin digested GAA fermentation ion 
exchange purified fractions. Comassie blue stained SDS-PAGE gel containing load (HCCF) and 
IEX separated fractions (FT, E, St) of a Clone 1 GAA cell culture harvest. Gel sharpness and 
contrast were enhanced to facilitate visualisation of protein bands. The gel fragments were 
processed via the protocol included in materials and methods (3.2.4) and digested with modified 
sequencing grade trypsin. 0.5 µl of digested sample followed by 1 µl of Super-DHB matrix was 
applied onto MALDI plate. UltrafleXtreme MALDI-TOF instrument (Bruker, Coventry, UK) in 
positive ion reflector mode and 50% laser power and MS/MS was conducted on the ten most 
intense peaks for each target spot. Generated peptide masses with an ion score exceeding the 
threshold set for p < 0.05 were interrogated using the Mascot algorithm (matrix-science.com) to 
search all taxonomies in the SwissProt database. Fixed modifications: carbidomethyl (C); 
variable modifications: oxidation (M); mass values: monoisotopic; protein mass: unrestricted; 
peptide mass tolerance: +/− 50 ppm; fragment mass tolerance +/− 0.5 Da. Instrument MALDI-
TOF-TOF.  
Results reconfirmed presence of GAA (Lysosomal alpha-glucosidase) at around 110KDa in 
HCCF and eluate fraction. Interestingly human Cathepsin Z, the serine protease suspected of 
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degrading GAA in the process stream, was also identified in eluate fraction at around 28KD.  
Despite identifying a few other HCPs (i.e. 6 phospho beta galactosidase in FT and E fraction), 
this methodology was revealed to be of too low a resolution and prone to keratin contamination. 
Also, the overall amount of HCP identified (especially in HCCF) was unexpectedly low. This 
was due to the fact that protein bands on gel were hard to see and therefore excise and digest. In 
order to improve data quality digested peptides should have been separated via reverse phase 
HPLC, whilst reducing analyst interaction (thus reducing contamination), as discussed in the 
next section.  
7.4.2 HCP identification via MALDI TOF LC-MS/MS and quantitation via emPAI  
The aim of this experiment was to identify and quantify HCPs present in GAA harvest HCCF 
and IEX eluate fractions. The in-gel digested MSMS analysis from the previous section showed 
that a better peptide separation before MSMS analysis was necessary in order to improve data 
quality. Also, quantification was only possible by based on band intensity. The purpose of 
adding the LC function to MSMS analysis was to allow the digested peptides to be separated 
under more robust conditions than the gel electrophoresis. A GAA harvest HCCF and IEX eluate 
fraction samples were digested with sequencing grade trypsin in the presence of DTT and IAM 
and applied to a C18 Acclaim PepMap100 column for on-line reverse phase HPLC. Eluates from 
each sample were divided in 120 fractions and spotted onto a MALDI plate for MS/MS analysis. 
A Mascot generated emPAI index was used for relative quantitation of species identified as 
shown in Figure 7-8. 
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Figure 7-8. MALDI TOF LC-MS/MS HCP identification and quantitation via emPAI. GAA 
harvest HCCF (blue) and IEX eluate fraction (red) samples were digested with sequencing grade 
trypsin in presence of IAM and DTT, run on LC (NanoLC Ultimate3000) C18 Acclaim 
PepMap100 column (C18, 3 µm, 100A) (solvent A = 0.05% TFA, solvent B = 0.05% TFA 90% 
acetonitrile, 40 min cycle, flow rate of 300 nl/min) attached to fraction collector and spotted 
onto a MALDI plate for MSMS analysis on an UltrafleXtreme MALDI-TOF instrument in 
positive ion reflector mode and 50% laser power, MS-MS was conducted on the ten most intense 
peaks for each target spot. Generated peptide masses with an ion score exceeding the threshold 
set for p < 0.05 were interrogated using the Mascot algorithm (matrix-science.com) to search all 
taxonomies in the SwissProt database. Fixed modifications: carbidomethyl (C); variable 
modifications: oxidation (M); mass values: monoisotopic; protein mass: unrestricted; peptide 
mass tolerance: +/− 100 ppm; fragment mass tolerance +/− 0.5 Da. Instrument MALDI-TOF-
TOF. In total 335 and 127 HCPs were respectively identified for HCCF and IEX eluate, here we 
only reported those amongst the better known or that showed proteolytic activity. Species were 
ordered by ascending relative amount in the HCCF sample. 
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As shown in Figure 7-8 the emPAI index was used for quantification purposes of HCPs found in 
pre and post IEX purification of a GAA producing CHO culture harvest sample. emPAI 
(exponentially modified PAI) (Ishihama et al., 2005) is an identification-based algorithm for 
protein-abundance estimation, which is based on the number of observed peptides per protein 
normalized by the theoretical number of peptides, the so-called protein abundance index (PAI) 
(Rappsilber et al., 2002) and is generally used to get an idea of relative amounts of different 
species in a protein mixture. According to literature, although the emPAI is not as accurate as 
quantification using synthesized peptide standards, it is quite useful for obtaining a broad 
overview of proteome profiles (Shinoda et al., 2009).  
According to the data, IEX was able to reduce amounts of most HCPs present in feed, while 
retaining the target molecule (GAA). Cathepsin B and Z were also retained during purification 
and coeluted with the product. Actin, 40S ribosomal protein, heat shock protein 71KDa, 
Legumain, nucleobinding-1, elongation factor 2 were found in moderate quantity in post capture 
step eluate in accordance with label free quantitative LC-MS/MS data reported in the next 
section.  
7.4.3 HCP identification and quantification via high resolution nano LC-MS/MS  
Scientific principle and novelty: the mass spectrometer used, a high resolution Waters SYNAPT 
G2-Si, was part of the Biomolecular Science Facility at University of Kent. The main difference 
between the Synapt G2-Si and other high resolution mass spectrometry systems is that it utilises 
the extra dimension of ion mobility separation (dt) on top of the common chromatography (rt) 
and mass separation (m/z) technologies. This maximizes selectivity and confidence in the results. 
By combining step-wave with quant-off and tri-wave technologies this system provides a step 
change in analytical performance for qualitative and quantitative applications.  
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In this experiment we compared HCP content found in capture step eluate fraction of three 
different CHO cell lines. The GAA producer, a Null and a mAb producing were expanded and 
purified under the same conditions and IEX eluate fractions were screened using high resolution 
nanoLC tandem mass spectrometry. The resulting data is presented in Figure 7-9 and Table 7-4. 
The data is shown in a bubble graph generated by plotting the 50 most abundant species found in 
each cell line. These were ordered by calculated pI (ExPASy Compute pI/Mw tool, SIB Swiss 
Institute of Bioinformatics) on the X axis and by hydrophobicity index GRAVY (ExPASy 
ProtoParam tool, SIB Swiss Institute of Bioinformatics) on the Y axis. Bubble size (diameter) 
represents percent of a given protein out of the total mass and was calculated by multiplying 
normalized abundance (averaged among triplicate LC injections) by the protein molecular 
weight. Quantification calculation of each species found through this type of analysis was done 
via direct comparison with the BSA reference standard spiked in the samples right before sample 
injection. As previously mentioned, in order for quantification to be truly representative there 
should be a reference standard per each identified species, a clearly unfeasible solution. For this 
reason, we are confident of HCP ID being correct, even though absolute amounts of each specie 
could perhaps be not fully accurate. This was however a clearly better solution than relative 
quantification via emPAI index in MALDI TOF TOF in the previous section. 
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Figure 7-9 High resolution LC-MS/MS of IEX eluate. In blue target molecule GAA, in red HCPs 
with proteolytic activity, in grey all other HCPs. Data shows identification and quantification of 
HCP found in capture step (IEX) eluate fraction across the three cell lines: GAA cell line1 vs 
Null (top) and GAA cell line1 and Ab producing (bottom). Out of a total of 233 HCPs identified 
in the samples, 36 showed proteolytic activity. The first 50 more abundant species are reported 
per each cell line and ordered by calculated pI (ExPASy Compute pI/Mw tool, SIB Swiss 
Institute of Bioinformatics) on the X axis and by hydrophobicity index GRAVY (ExPASy 
ProtoParam tool, SIB Swiss Institute of Bioinformatics) on the Y axis. Bubble size represents 
percent of a given protein out of the total mass and was calculated by multiplying normalized 
abundance (averaged among triplicate LC injections) by the protein molecular weight.  Post IEX 
column eluate fractions were concentrated and digested with sequencing grade modified trypsin, 
50fmol of BSA was spiked in each digested sample before injection in LC to allow for label free 
quantitation. Separation via HSS T3 Acquity column (Waters, USA) 75 μm internal diameter  x 
15 cm (1.8 μm, 100A) on-line reverse phase UPLC (Acquity M-Class, Waters, USA). Elution by 
linear gradient from 3 to 40% B over 40 mins; (buffer A: 0.1% formic acid in water. Buffer B: 
0.1% formic acid in acetonitrile), flow rate 300 nl/min. Separated peptides were injected via 
nanospray source to a Synapt G2-Si (Waters, USA), data collected in HDMSe mode. Data 
analysed using Progenesis QIP and searched against SwissProt using MSe Search and a false 
detection rate of 4%. Complete list of HCP identified in all samples is included in supporting 
data LC-MS/MS HCP. 
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Table 7-4 Overlapping and unique HCPs. List of the 50 most abundant overlapping HCP common to all three cell lines (top) and four unique to 
GAA HCP (bottom). Values (calculated µg/ml) are ordered by abundance in GAA sample. HCP are considered ‘overlapping’ when present in at 
least two out of three cell lines. Concentration (µg/ml) is calculated by multiplying normalized abundance value by molecular weight divided by 
sample volume (10µl). Normalized abundance value based upon BSA standard. 
192 
 
193 
 
Figure 7-10 High resolution LC-MS/MS of IEX vs HIC eluate. In blue target molecule GAA, in 
red HCPs with proteolytic activity, in grey all other HCPs. Data shows identification and 
quantification of HCP found in intermediate step (HIC) eluate fraction of the GAA producing 
cell line. Only 20 species had a non-negligible normalized abundance reading (above 10 counts) 
and were ordered by calculated pI (ExPASy Compute pI/Mw tool, SIB Swiss Institute of 
Bioinformatics) on the X axis and by hydrophobicity index GRAVY (ExPASy ProtoParam tool, 
SIB Swiss Institute of Bioinformatics) on the Y axis. Bubble size represents percent of a given 
protein out of the total mass calculated as explained in Figure 7-9. In post HIC eluate, 82% of 
total protein consists of product. Among the rest the most abundant are Drebrin (3.6%), 
Neuraminidase (2.5%), 78 kDa glucose-regulated protein (2.1%) and Elongation factor two 
(2%). Complete list of HCP identified in all samples is included in supporting data LC-MS/MS 
HCP. 
As expected in the GAA producer, GAA was the dominating species in IEX eluate accounting 
for over 36% of the total by mass spectrometry. In the same GAA eluate sample, HCP quantified 
via AlphaLISA (PerkinElmer, MA USA) in section 7.3.2 accounted for approximately 54% of 
total protein. By comparison this enzyme accounts for approximately 2% by MS of the total 
species found in Null and mAb producing cell lines after IEX, further proof that basal GAA 
levels are found across many mammalian cells lines and that the GAA cell line is expressing 
recombinant material. Actin, clusterin, drebrin, elongation factor 2 and lysosomal protective 
protein (carboxypeptidase) were some of the more common HCP co-purifying due to their pI 
being within 1 unit of target molecule.  HCPs with similar hydrophobicity to GAA but over 1 pI 
unit difference were thought to be passenger molecules that co-purified, some most likely by 
‘product-associated’ interaction. This phenomenon of co-purification with the product due to 
interaction with the product itself (piggy backing), has been described previously for antibodies 
(Levy et al., 2014, Hogwood et al., 2016). In this category we found: neuraminidase (pI 6.82), 
the protease involved in cleaving glycosidic linkages in neuraminic acids; procollagen C-
endopeptidase enhancer 1 (pI 8.63) involved in cartilage and bone formation; 40S ribosomal 
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protein S6 (pI 10.83); cAMP-dependent protein kinase catalytic subunit gamma (pI 8.7) a kinase; 
dystroglycan (pI 9.4) a complex involved in numerous processes such as cell survival and 
migration and membrane assembly (source Uniprot.org).  
After intermediate purification HIC (Figure 7-10) GAA purity reached values of above 80%, 
while HCPs were greatly reduced. The top 5 HCP in order of abundance were Drebrin (3.6%), 
Neuraminidase (2.5%), 78 kDa glucose-regulated protein (2.1%) and Elongation factor 2 (2%) 
and Protein crossbronx (1%). Full HCP information can be found in supplemental information 
provided.   
In the antibody producing cell line IEX eluate, some of the most abundant species found were 
antibody as expected, which account for about 25% of the total. In the pI range between 5 and 6, 
where direct adsorption to the IEX resin is anticipated, other proteins found include: legumain, a 
protease involved in lysosomal protein degradation; thioredoxin a protein responsible for various 
redox reactions through the reversible oxidation of its active center, and proteases lysosomal 
protective protein and ferrochelatase. Outside the typical pI range for direct interaction and 
therefore candidates for piggy-backing through the process are: CYR61 (pI 8.49), which promotes 
cell proliferation angiogenesis and cell adhesion; neuroaminidase (pI 6.8), dystroglycan (pI 9.4) 
and 40S ribosomal protein S6 (pI 10.8).   
In the Null profile range of HCPs with pI between 4.5 and 6.5 we observed clusterin, lysosomal 
protective protein, Complement C3, thioredoxin (disulfide oxidoreductase), protocollagen C-
endopeptidase enhancer (peptidase), phosphoglycerate mutase (kinase), lysosomal protective 
protein (serine carboxypeptidase), legumain (lysosomal hydrolysis) and the common heat shock 
cognate protein 70 KDa (Xiaohui Lu, 2015).  HCPs with pI > 6.5 were identified as dystroglycan 
(pI 9.4), 40S ribosomal protein S6 (pI 10.8), matrix metalloproteinase-19 (pI 8.9). Interestingly 
most of the HCP identified in the pI > 6.5 range in this sample, were common with those found in 
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GAA and mAb producer, sign that their elution was not caused by product associated interaction, 
as product in the Null cell line is barely present. We believe that they might interact with another 
HCP that does interact with the resin.  
Importantly, the cysteine protease cathepsin B and Z were ubiquitously present in moderate 
quantity in all three cell lines. More precisely cathepsin B was 0.60 μg/mL or 0.62 % of total 
protein content in GAA producer, 1.85 μg/mL or 0.83% of total protein in Null and 0.04 μg/mL or 
0.20% of total protein in mAb producer. Cathepsin Z was 0.10 μg/mL or 0.10% of total protein in 
GAA producer, 0.41 μg/mL or 0.18% of total protein in Null and 0.01 μg/mL or 0.05% of total 
protein in mAb producer. This suggests these are not co-purifying with the products and are 
retained to some extent by the resin, or, that they also co-purify with another HCP that does 
interact with the resin.   
The view of sponsor company BioMarin is that CatZ expression is linked to overexpression of 
lysosomal GAA. Although this could not be independently verified, this phenomenon could be 
due to the transport mechanism mannose–6–phosphate receptor being overloaded with GAA 
which induces CatZ and other lysosomal proteins being secreted as well. The commercial form of 
GAA, having the GILT tag is likely more sensitive to CatZ and other proteases due to potential 
clipping. Therefore overexpression of GAA/GILT results in CatZ expression which impacts 
stability of the target molecule.   
With the exception of a small number of unique species found in excess in the GAA line and 
reported in the bottom part of Table 7-4, the HCP profile across the three cell lines was however 
found to be broadly similar and in agreement with other studies (Hogwood et al., 2016). A list of 
the 50 most abundant overlapping proteins common to all three cell lines is found in Table 7-4 
(top). This overlap in HCPs across many different cell lines has been studied extensively in two 
recent studies. In the first one (Tait et al., 2012), the authors compared HCPs in harvest 
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supernatants of day 10, 12 and 14 cultures generated by a Null cell line and a recombinant IgG4-
producing cell line and reported that whilst there were increases in HCPs, which they associated 
with viability decline later in culture, there were many similarities between the cell lines and days 
of harvest. In another study (Yuk et al., 2015), the HCP profile of three different Null cell lines 
was compared and it was reported that despite differences in CHO lineage, upstream process, and 
culture performance, the cell lines yielded similar HCP profiles. Furthermore, this study 
determined that about 80% of the most abundant 1000 proteins identified were common to all 
three lines.   
While the HCP profile in this study is largely similar across the three cell lines, some are unique 
only to the GAA cell line. Table 7-4 (bottom) shows the relative distribution and calculated 
concentration of the four species that were found to be particularly abundant in the GAA line and 
almost absent in the other two. These are: (1) actin (cytoskeletal protein ubiquitously expressed in 
all eukaryotic cells) where a relatively low amount was found in Null and mAbs lines, a much 
greater amount was found in GAA line material. (2) drebrin (related to actin polymerization) 
which was also present predominantly in the GAA cell line material. (3) Probable dual-specificity 
RNA methyltransferase RlmN (involved in RNA formation) and (4) EGF-containing fibulin-like 
extracellular matrix protein 1 (involved in cell adhesion and migration). We suspect that the 
disparity in amounts observed for these particular species might be due to a combination of two 
factors: the large amount of GAA in GAA producer sample could possibly be responsible for mass 
spectrometer detector sensitivity saturation, which could explain quantification discrepancies with 
the other two lines. This could also account for differences in the mAb cell line where a high 
concentration of mAb is present. Also, the competitive behaviour of different species onto the 
anion exchange resin could have affected the amount of target bound coeluting species. 
197 
 
7.5 Lysosome phenotype characterization 
Understanding the GAA production pathway in healthy mammalian cells is an important step in 
determining how GAA overexpression affects overall cell functionality. As discussed before in the 
GAA synthesis section (2.2.4.2), the newly formed polypeptide leaves the endoplasmic reticulum 
and goes through Golgi where M6P receptors bind to it and are responsible for its transfer into the 
preacidified compartment, before entering the lysosome. In this process only 10-20% of GAA fails 
to bind to the receptors and is secreted out of the cell through secretory granules (Kornfeld, 1987). 
GAA overexpression in recombinant production CHO cells is likely to have an effect on cell 
physiology and as a result a potential impact on HCP release and product degradation. As most of 
the GAA produced by cells ends up accumulating in the lysosome, we hypothesize differences in 
phenotype between lysosomes from a Null and a GAA producer CHO maybe apparent. For this 
reason we compared images of lysosomes from two cell cultures using Transmission Electron 
Microscopy (TEM).  
7.5.1 Investigating the lysosomal phenotype with TEM in GAA producing cells 
For this experiment we wanted to investigate whether GAA over-expression affected lysosomal 
morphology by comparing images of lysosomes from the recombinant GAA expressing cell line 
and the originating Null CHO cells. The resulting data is presented in Figure 7-11, Figure 7-12 
and Figure 7-13 and shows a clear difference in lysosomal phenotype between Null and GAA 
cells. While lysosomes are present in similar numbers (on average 18 per cell) and size (400 nm) 
in both cell types, they are generally full and dark in GAA overexpression cells and empty or 
mostly empty in Null cells. Specifically, over 72% of lysosomes are completely full (F) in the 
GAA cell line while only 8% present the same phenotype in the Null line. This trend was also 
observed when comparing lysosomes containing some (%HF – half full) to no (%E - empty) dark 
matter: only 17% of all lysosomes in the GAA overexpression cell line present this phenotype 
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versus 55% in Null. This data provides evidence that over expression of GAA leads to lysosomes 
becoming full and engorged. Potentially this could contribute to the overall cellular stress levels 
experienced by the cell. 
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Figure 7-11 Transmission Electron Microscope images of Null (A) and  GAA producer (B) cells. Cells were sampled at the same time from 
actively growing cultures, fixed and ultra-thin slices were prepared for TEM imaging (magnification 3000X). 33 images of single cells were 
taken per each sample. Lysosomes were counted and categorized based on content in Full (F), Half-Full (HF) and Empty (E). Images chosen 
for this figure are representative; all other images are included in supporting data “TEM images” 
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Figure 7-12. More TEM images of Null (top row) and GAA producer (bottom row) cells prepared as described in Figure 7-11 to highlight 
difference in lysosomal phenotypes. As previously shown lysosomes are dark and engorged in GAA producer and empty in Null. 
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Figure 7-13 TEM Lysosomes data collated and analysed in excel (A – Null; B – GAA). Values 
derived from 33 images per each cell line. 
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7.6 Chapter conclusions  
In this chapter we discussed the effects that overexpression of GAA from the CHO cell culture has 
on overall cell stress and how this relates to release of HCP and protease levels. This is important 
not only for potential product degradation caused by proteases but also for deciding the 
appropriate downstream processing strategy.  
A first qualitative assessment of protease level in clarified harvest and capture step eluate via 
zymography (Figure 7-3) revealed that IEX is able to remove significant amounts of proteases 
from the process stream but with a notable coeluting bands at 80KDa. MS revealed this to be 
composed of Dipeptidyl peptidase 3, a metalloproteinase and Prolyl endopeptidase a serine 
protease.  
Total HCP amount in the harvest and post IEX purification was quantified via immunoassay 
AlphaLISA, a non-wash higher throughput version of ELISA. This assay needed optimization to 
correctly quantify HCP in harvest due to the hook effect caused by high HCP concentration in 
harvest sample. HCP was determined to be around 0.09 mg/ml in harvest, 50% of which coeluting 
in IEX eluate fraction with GAA. By comparison HCP amount in post intermediate purification 
(HIC) accounted only for less than 20% of total protein as measured by MS. When comparing 
HCP amount in harvest determined via AlphaLISA to gel analysis images (i.e. Figure 5-1), it 
comes clear how AlphaLISA grossly underestimated the actual value, perhaps due to interference 
caused by cell media components. Limitations of as ELISA methods in the determination of HCP 
in harvest samples have been highlighted in (Wang et al., 2015, Zhu-Shimoni et al., 2014) and are 
thought to be due to a combination of underrepresentation of low abundance/immunogenicity 
species due to HCP heterogeneity and dilutional non-linearity caused by copurifying HCPs 
enriched in drug substance that may have limited antibody detection.  
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A proteomic approach was adopted in order to gather more information on the identity of the 
species found. Different tandem MS techniques were used to identify those HCPs eluting with 
GAA in the IEX eluate. After getting unsatisfactory results using in-gel tryptic digest MALDI 
MSMS and MALDI TOF LC/MSMS due to a series of issues, we used a high resolution nano-
LC/MSMS to compare the HCP profile of the GAA IEX eluate sample with a Null and a 
monoclonal antibody producer CHO purified in the same way. This revealed that GAA is the 
dominating eluting species (as expected) in the GAA CHO, while this protein accounts for around 
2% in the other two. Coeluting HCPs with a similar pI to that of the target protein were listed, 
together with other HCPs of pI value over 1 unit difference from GAA but eluting due to 
association to product or another coeluting HCP. Data was presented in bubble graph format in 
Figure 7-9 and Figure 7-10. This analysis also revealed that the great majority of HCP profile in 
the three CHO cultures IEX overlaps, as also noted by similar studies (Yuk et al., 2015, Hogwood 
et al., 2016).  
Cysteine proteases cathepsin Z and B were found in moderate quantity across the three cell lines 
IEX eluates suggesting that these do not co-purifying with the products and are retained to some 
extent by the resin, or, that they also co-purify with another HCP that does interact with the resin. 
Barely detectable amount of these two proteases were found in the subsequent HIC step eluate 
(less than 0.1% of the total protein), indicating that they were removed from the process stream in 
the HIC flowthrough. 
Lastly to visually assess the effect that product overexpression has on producing cells, we captured 
images of lysosomes, the organelles that store GAA, and compared them with images of Null cells 
using Transmission Electron Microscope. This revealed that the majority of lysosomes (72%) in 
the GAA producer were of dark and engorged nature indicating that stress deriving from target 
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molecule overexpression had detectable effects on phenotype of the cells. The origin of the dark 
matter in lysosomes has not been evaluated, although we believe GAA to be part of it. 
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8 Conclusions 
The work presented within this thesis has focused on a number of aspects of upstream and 
downstream processing. Much of this has been undertaken using methodologies for process 
development, allowing for product and HCP characterization at different steps of DSP. These 
investigations have benefited by the inclusion of analytical techniques for characterization 
purposes, with HCPs being pivotal process related impurities of interest. First, with reference to 
the research objectives defined in introduction, and as a means of summarizing the overall 
findings of this doctorate, a number of conclusions are drawn.  
Objective one: Production of stable CHO cell line for material generation. 
The generation of the mammalian cell line producing GAA was the first objective of the project 
and it was a necessary one in order for the rest of the work to take place. It started with the 
cloning of the GAA gene into a plasmid vector and the incorporation of the vector into a Flp-In 
CHO cell line. The Flp-In system was selected in order to shorten the clonal screening process 
due to its ‘site-directed recombination’, which facilitates integration of the gene of interest into a 
specific highly transcribed FRT site in the host genome, and allows all clones generated to 
produce considerable and comparable levels of recombinant product. Product production was 
first assessed via western blot of transiently transfected cultures. Stable transfection was then 
performed and clones were generated with limiting dilution cloning. Clones titer was lastly 
assessed using a GAA diagnostic assay and one clone was selected as candidate for material 
generation and downstream process development studies.  
The chosen clone (GAA 1) was able to generate 0.18 g/l of human GAA after 6 days of batch 
culture in a 1 litre cell flask. The cell count at harvest was 15 million cells per millilitre.  
206 
 
Objective two: Development of assays for detection of product in the bioprocess stream 
The aim of this chapter was to present the analytical techniques employed to characterize the 
product secreted by the clonal stable cell line generated in results chapter one. Before proceeding 
with downstream development and released HCPs characterization, it was important to ensure 
the correct isoform of GAA was produced and in what quantity.  The clarified harvest of the 
selected clone underwent a series of analysis to determine GAA presence, amount and identity. 
Comparison of GAA cell culture harvest with Null CHO line via gel electrophoresis highlighted 
the presence of a clear band at around 110KDa which was absent in the Null line. Analysis of the 
same sample by western blot, confirmed that the band at 110KDa was in fact recognised by anti-
human GAA antibody. Product identity was confirmed by tryptic digestion of the protein band of 
interest and running it via tandem mass spectrometry. Peptide matching to SwissProt database 
positively identified it as 106112 Dalton LYAG_HUMAN with good result confidence.  
GAA quantification was performed via a GAA diagnostic method used in clinics to diagnose 
presence of the enzyme in suspected Pompe patients. This method, unlike other enzyme activity 
assays, is specific to GAA thanks to the use of an alpha-glucosidase inhibitor. This permitted 
determination of clone 1 titer and was subsequently used to determine product content after 
purification steps.  
Objective three: Bioprocess mimic 
After having generated a stable cell line producing GAA and having developed the analytical 
assays to characterize the product, we proceeded with development of the purification process. 
Cell culture harvest was spun and filtered through a 0.22μm stericup filter to remove whole cells 
and cell debris. cHCCF (clarified Harvest Cell Culture Fluid) was then subjected to two rounds 
of chromatographic separation cycles, first based on protein charge (capture IEX) then followed 
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by protein hydrophobicity (intermediate HIC).  The final target protein purity was above 80% as 
determined later on by MS.  
Objective four: Characterization of cell stress and its impact on protease production 
In the last results chapter we presented the data supporting the cell line and HCP characterization 
work. HCP presence in the process stream is a concern due to potentially harmful proteolytic 
product degradation effects and must be monitored and reduced to comply with strict regulatory 
requirements. A series of immunoassays, electrophoretic gels and mass spectrometry techniques 
were used to track specific HCPs throughout the bioprocess. Furthermore we showed how cell 
stress resulting from target product over-expression can have physical effects on cell internal 
structures and can possibly be related to increased HCP release.  
HCP content throughout the bioprocess was assessed via electrophoresis and mass spectrometry. 
The degree of purification of the developed bioprocess can be appreciated by looking at Figure 
6-11. The gel compares cHCCF to post capture step eluate to intermediate step eluate fractions. 
While the GAA band remained visible in all three samples at around 110KDa, impurities were 
greatly reduced.  
LC-MS/MS analysis and emPAI quantification of cHCCF and post capture (IEX) eluate (Figure 
7-8) showed how most identified HCPs were reduced by the capture step, while GAA relative 
amount increased due to product isolation and concentration. The HCP profile of the GAA 
producing cell line was compared to a Null and an antibody producing CHOs via high resolution 
nano LC-MS/MS which revealed that while the majority of HCPs overlap across the three 
species as seen in literature, some are unique to the GAA strain (Figure 7-9).  
High resolution nano LC-MS/MS was also used to show the reduction of HCP in intermediate 
(HIC) step and to identify those species coeluting with the product (Figure 7-10). The number of 
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HCPs identified went from 233 in post IEX to less than 20 in post HIC eluate samples with the 
most abundant coeluting ones being drebrin (3.6%), neuraminidase (2.5%), 78 kDa glucose-
regulated protein (2.1%) and elongation factor 2 (2%). Product purity went from 32% in post 
IEX eluate to 82% in post HIC.   
General protease clarification of the capture IEX step was assessed via zymography and nano 
LC-MS/MS. Zymography revealed that most of the proteases present in cHCCF were cleared 
post capture purification except a significant amount at 80KDa. Mass spectrometry identified 
those as dipeptidyl peptidase 3 and prolyl endopeptidase respectively a serine and a 
metalloproteinase with hydrolytic activity. Effects of their existence in presence of GAA have 
not been evaluated.  
In reference to effects of overexpression over cellular integrity, we presented images taken by a 
Joel 1010 transmission electron microscope of GAA producing cells and compared them with 
similar images of Null CHO. Images showed that while there is no significant difference in most 
cell organelles between the two cell lines, lysosomes of GAA producer are largely dark and 
engorged if compared with their counterparts in Null cell line. While we did not prove that GAA 
is in fact making up the dark matter observed, we know that the lysosome is where most GAA 
not secreted resides. Regardless of the nature of the dark matter observed, this experiment 
showed how product overexpression can subject the cell to physical stress. 
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9 Future work 
Having identified the HCPs released by the generated CHO GAA producer cell line and how 
stress induced by overexpression impacts cellular behaviour has only in part fulfilled the 
original scope of this work. Given more time, additional areas could have been explored more 
in depth. In this section we propose some short and long term projects that could complement 
and enrich this research.  
9.1 Short term 
Recombinant GAA localization in GAA producer cell lines. 
During the project, lysosomal cell stress was assessed by observation of the size and content 
of lysosomes via TEM imaging. We determined that GAA overexpressing cells lysosomes 
were generally darker than their counterparts in Null CHO cells and seemed to be full of 
matter which we putatively hypothesized as being GAA. While this was likely the case, we 
were not able to verify it.  
Although we have a general idea of GAA cellular pathway from (Kornfeld, 1987), specific 
information on enzyme localization in overexpressing lines is still unavailable. In order to 
verify presence of GAA in lysosomes of GAA producer cell lines, a combination of confocal 
microscopy and immunostaining could be applied. By exposing the cells to a GAA primary 
mAb linked to gold particles (immunogold staining) it should be possible to highlight whether 
lysosomes do in fact contain GAA, or instead GAA is just present within cytoplasmic region.  
Because confocal microscope images are not as high resolution as TEM images, lysosomes 
are likely not going to be easily visible. By using a second staining directed to the acidic 
compartment themselves (such as lysosomes in this case) it should be possible to highlight 
presence of lysosomes and eventual coexistence of GAA enzyme within them. LysoTracker® 
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Red DND-99 (Thermo Fisher cat# L7528) provides labeling and tracking of acidic organelles 
in live cells. 
Polish step development  
The bioprocess designed in this work consists in a capture IEX step followed by intermediate 
HIC step. The final purity of the GAA product was measured via LC-MS/MS at 82%. While 
we demonstrated the process to be suitable for the project scope, the final purity of the 
product is still too low to meet to any regulatory requirements for commercial use. We 
propose the use of an additional chromatographic step to increase final product purity.  At this 
stage, as separations by charge, hydrophobicity have already been used, a high resolution gel 
filtration (GF) step would be ideal for polishing. GF is the slowest of all chromatography 
techniques and the size of the column determines the volume of sample that can be applied, it 
is therefore most logical to use GF after techniques which reduce sample volume so that 
smaller columns can be used. We suggest the use of Superdex media, a high resolving gel 
filtration media for short run times and good recovery. Superdex is the first choice at 
laboratory scale and Superdex prep grade for large scale applications. Typical flow velocity is 
up to 75 cm/h. 
9.2 Medium Term 
Protease inhibitors screening to determine which protease in process feed is actually of 
concern. 
From the proteomic approach to process development we have learned how certain classes of 
proteases behave during DSP. We now know that the two potentially harmful cysteine and 
serine proteases (Cathepsin B and Z) that were thought to damage GAA, are present in the 
capture step IEX elution, but eventually are cleared out in intermediate purification by HIC. 
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This information is useful in determining the appropriate conditions for capture step elution 
material storage in order to avoid proteolytic activity and degradation of the product. The 
information generated by this approach however, could potentially be used in another useful 
way. 
Having identified all the HCPs present throughout the process stream of a GAA producer, 
allows for additional screening to take place to determine which ones are actually affecting 
GAA structural integrity. While not all HCPs have proteolytic activity, those that do could be 
individually tested in presence of GAA reference standard and eventual GAA fragmentation 
could be assessed via gel electrophoretic methodology. While incubating GAA with every 
identified protease is unrealistic, we propose an approach based on the use of protease 
inhibitors. GAA reference could be incubated in cell harvest supernatant and different classes 
of protease inhibitors could be individually screened in a high throughput mode. The 
commercially available protease screening kit ProteSEEKER (VWR cat# 786-325) comes 
supplied with 11 concentrated protease inhibitors designed to inhibit all classes of proteases 
known. By comparing GAA degradation occurring with each individual inhibitor, it should be 
possible to determine which class of protease degrades GAA.  
This type of approach would be beneficial not just in GAA process development but could 
potentially be repeated for other therapeutic proteins production where protease degradation 
is of concern.  
9.3 Long term 
Due to enormous financial consequences of late stage failure of a drug candidate, one of 
pharmaceutical companies’ major concern is to make the drug development process as quick, 
reliable and cost effective as possible. For this reason, considerable resources are invested in 
cell and process development. Recent advances in the proteomics analytical capabilities such 
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as the novel high resolution mass spectrometry features shown in this work, are allowing ever 
simpler access to information not only on identification of molecular species present in in-
process samples, but also on biomarker and target discovery, protein mechanisms of action, 
prediction of toxicity.  As these techniques become ever more powerful and fast, the amount 
of generated data can quickly become overwhelming and unfortunately, a substantial number 
of these efforts result only in long lists of proteins but fall short in demonstrating the effects 
of the controlled expression on the desired phenotype. We believe the industry would benefit 
from a new approach at data interpretation, where specialized software would constantly 
monitor process stream and adapt in real time a dynamic DSP based on specific proteases 
found in the feed. As omics technologies advance (genomics, proteomics and metabolomics), 
producing cells could also be specifically engineered to silence genes known of expressing 
harmful proteases, and diminish the amount of HCP present to the bare minimum necessary 
for cell survival and at the same time diminish cellular stress deriving from overexpression.  
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List of Abbreviations 
4MU-αGlc 4-methylumbelliferyl-α-D-glucopyranoside 
ACE   Alglucosidase Alfa Control and Education 
BANA  Benzoylarginine naphthylamide  
CatZ   Cathepsin Z 
CBE  Conduritol B epoxide  
CHCA  α-cyano-4-hydroxycinnamic acid 
CHO   Chinese hamster ovary 
CIP  Clean in Place 
CV  Column Volume 
Da  Dalton 
DAB  Diaminobenzidine  
DHB   2,5-dihydroxybenzoic acid  
dhfr  Dihydrofolate reductase  
DMF  Dimethylformamide  
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid  
DSP  Downstream Processing 
DTT  Dithiothreitol  
ELISA  Enzyme-linked immunosorbent assay 
EURORDIS European Organization for Rare Diseases  
ExPASy  Expert Protein Analysis System 
FDA  Food and Drug Administration 
FF   Fast Flow 
FRT   Flippase recognition target 
FT  Flow through 
GAA   Acid alpha-glucosidase 
GFP  Green Fluorescent protein  
GILT  Glycosylation independent lysosomal targeting 
GRAVY Grand average of hydropathicity 
HCCF  Harvest Cell Culture Fluid 
HCP  Host cell protein  
HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIC  Hydrophobic interaction chromatography  
HRP   Horseradish Peroxidase 
IAA  Iodoacetic acid 
IAM  Iodoacetamide  
IGF2  Insulin-like growth factor 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
LB  Lysogeny broth 
LC   Liquid chromatography 
LDC  Limiting dilution cloning  
LEAP  Laser-enabled analysis and processing  
LSD  lysosomal glycogen storage disease 
M6P   Mannose 6 phosphate 
mAbs  Monolconal antibody 
MALDI  Matrix-assisted laser desorption/ionization 
MBP  Maltose binding protein 
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MCA  Methyl Cumaryl Amide   
MGAM maltase-glucoamylase 
MMP  matrix metalloproteases 
MOPS  3-(N-morpholino)propanesulfonic acid 
MPS   Mucopolysaccharidoses 
MS  mass spectrometry  
MSR   Molar Substitution Rate  
MTX   Methotrexate 
MW  Molecular Weight 
MWCO  Molecular Weight Cut Off 
NaCl  Sodium Chloride 
NEM  n-ethylmaleimide  
NMEs  New Molecular Entities 
NS0  murine myeloma cell  
OD  optical density 
pAb   polyclonal Antibody 
PBS-T  Phosphate Buffered Saline Tween 
PCMB  Chloromercuribenzoic acid  
PEI   Polyethylenimine 
PER.C6 human retina derived 
pH  potential of hydrogen 
PMSF  phenylmethane-sulphonylfluoride 
PVDF   Polyvinylidene fluoride 
R&D   Research and Development 
RE  Restriction Enzyme 
REMS  Risk evaluation and mitigation strategy  
RER   Rough endoplasmic reticulum 
RFU   Relative Fluorescent Units 
RNA   Ribonucleic acid 
RT  Retention Time 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC  Size exclusion chromatography  
TEM  Transmission Electron Microscope 
TIMPs  Tissue Inhibitor MetalloProteases  
TOF  Time of Flight 
TSAP   Thermosensitive Alkaline Phosphatase 
UCL  University College London 
UPLC   Ultra Performance Liquid Chromatography 
w.d.  working dilution 
WHO  World Health Organization 
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 APPENDICES        
 
Description 
Accession 
ID 
Confide
nce 
score 
Anova (p) pI MW GRAVY 
Concentration (mg/L) Percent total (%) 
IEX HIC IEX HIC 
GAA Null mAb GAA GAA Null mAb GAA 
14-3-3 protein theta Q3SZI4 9.3 4.655E-08 4.68 27764.3 -0.512 0.006 0.059 0.000  0.01 0.03 0.00  
28 kDa heat- and acid-stable phosphoprotein Q13442 17.2 4.482E-09 8.84 20630.0 -1.612 0.005 0.111 0.003  0.00 0.05 0.02  
28 kDa heat- and acid-stable phosphoprotein Q3UHX2 17.7 6.999E-09 6.8 20604.9 -1.606 0.000 0.013 0.000  0.00 0.01 0.00  
30S ribosomal protein S6 Q89MW3 9.8 4.197E-06 5.43 18627.6 -0.987 0.141 0.162 0.020  0.15 0.07 0.11  
40S ribosomal protein S6 P47838 11.3 8.44E-08 10.83 28654.5 -0.951 0.240 3.692 0.052  0.25 1.66 0.29  
45 kDa calcium-binding protein Q61112 44.5 1.04E-09 4.8 38308.5 -0.765 0.422 3.854 0.073  0.44 1.73 0.42  
4-hydroxy-tetrahydrodipicolinate synthase A5D2Q5 7.8 1.259E-08 5.53 31588.3 0.084 0.002 0.128 0.001  0.00 0.06 0.00  
78 kDa glucose-regulated protein Q0VCX2 89.0 9.29E-08 5.01 70464.6 -0.477 0.587 2.715 0.045 0.549 0.61 1.22 0.25 2.13 
Acetate kinase Q6LLD4 4.8 0.0470184 5.72 42875.9 0.026 0.191 0.004 0.104  0.20 0.00 0.59  
Acidic phospholipase P81243 14.8 0.0824282 4.58 14304.0 -0.652 0.000 0.001 0.000  0.00 0.00 0.00  
Actin P53689 25.0 1.591E-09 5.38 41622.6 -0.177 7.386 0.099 0.000 0.150 7.66 0.04 0.00 0.58 
Actin, gamma Q9UVW9 47.7 2.649E-07 5.45 41607.5 -0.173 0.236 1.373 0.059  0.24 0.62 0.33  
Actin-10 Q54GX7 44.4 7.769E-05 5.24 41746.7 -0.204 0.273 0.353 0.005  0.28 0.16 0.03  
Actin-17 Q554S6 20.8 2.88E-09 5.28 41571.4 -0.209 0.311 1.475 0.056  0.32 0.66 0.31  
Actin-2 Q9Y707 34.1 1.712E-08 5.31 41663.4 -0.225 0.063 0.469 0.019  0.07 0.21 0.11  
Adapter molecule crk P10365 42.4 5.051E-10 5.39 41635.4 -0.206 0.034 0.674 0.000  0.04 0.30 0.00  
Adapter molecule crk Q04929 15.4 1.305E-08 5.36 33805.6 -0.658 0.005 0.074 0.000  0.01 0.03 0.00  
Angiopoietin-related protein 4 Q9Z1P8 24.0 4.522E-09 8.21 43423.8 -0.733 0.093 0.785 0.000  0.10 0.35 0.00  
Annexin A5 P08758 44.9 1.806E-06 4.93 35805.6 -0.33 0.181 0.314 0.027  0.19 0.14 0.15  
Astrocytic phosphoprotein PEA-15 Q9Z297 6.2 1.073E-08 4.93 15040.1 -0.644 0.003 0.132 0.000  0.00 0.06 0.00  
B box-binding protein Q00436 11.4 0.0044479 9.35 34484.6 -1.514 0.000 0.005 0.000  0.00 0.00 0.00  
Beta-1,4-glucuronyltransferase 1 Q8BWP8 30.6 1.078E-07 6.84 47384.3 -0.266 0.057 0.918 0.021  0.06 0.41 0.12  
Beta-1,4-glucuronyltransferase 1 O43505 30.0 1.223E-07 6.77 47119.1 -0.224 0.011 0.174 0.004 0.078 0.01 0.08 0.02 0.30 
Beta-actin-like protein 2 Q562R1 11.4 3.103E-05 5.39 42003.2 -0.19 0.022 0.004 0.000  0.02 0.00 0.00  
Bifunctional protease/dUTPase P31625 5.0 9.515E-08 8.9 31311.1 -0.094 0.001 0.098 0.000  0.00 0.04 0.00  
Bifunctional purine biosynthesis protein PurH Q87VR9 21.6 1.286E-06 5.81 57463.4 -0.049 0.008 0.359 0.001  0.01 0.16 0.01  
Bleomycin hydrolase P70645 5.5 4.055E-09 6.04 52322.9 -0.389 0.032 0.319 0.001  0.03 0.14 0.01  
Bone morphogenetic protein 1 P13497 50.3 2.308E-07 6.26 98049.8 -0.597 0.192 0.884 0.109  0.20 0.40 0.62  
cAMP-dependent protein kinase catalytic subunit 
gamma 
P22612 5.5 5.278E-08 8.7 40303.3 -0.339 0.475 4.676 0.016  0.49 2.10 0.09  
Cathepsin B P10605 41.4 3.205E-08 5.23 27577.7 -0.306 0.596 1.849 0.035 0.025 0.62 0.83 0.20 0.09 
Cathepsin Z Q9R1T3 18.8 3.976E-07 5.51 27106.2 -0.511 0.099 0.410 0.009 0.015 0.10 0.18 0.05 0.06 
Cell division control protein 42 homolog Q2KJ93 15.2 4.434E-06 6.16 20933.2 -0.222 0.001 0.107 0.000  0.00 0.05 0.00  
Chaperone protein DnaJ Q9RUG2 10.4 0.0007799 5.62 40238.4 -0.517 0.099 0.796 0.046  0.10 0.36 0.26  
Chaperone protein DnaK P71331 9.8 1.309E-08 4.88 68262.9 -0.432 0.062 0.272 0.043  0.06 0.12 0.25  
Chaperone protein DnaK Q7UM31 19.2 1.103E-06 4.62 69422.7 -0.414 0.047 0.843 0.017  0.05 0.38 0.09  
Chaperone protein dnaK2 Q7U3C4 33.0 2.103E-07 4.71 67888.3 -0.314 0.125 2.433 0.048  0.13 1.09 0.27  
Chemotaxis response regulator protein-glutamate 
methylesterase 1 
Q221I1 5.2 0.0003197 6.62 39828.4 0.182 0.033 0.675 0.011  0.03 0.30 0.06  
Chromosomal replication initiator protein DnaA Q1I2G4 23.6 2.809E-09 6.73 57096.2 -0.307 0.008 0.283 0.000  0.01 0.13 0.00  
Clusterin P05371 96.5 2.741E-06 5.45 49076.4 -0.534 3.451 7.611 0.180  3.58 3.42 1.02  
Clusterin Q06890 94.4 7.644E-06 5.45 49344.6 -0.554 0.707 1.736 0.032  0.73 0.78 0.18  
Clusterin (Fragment) P14683 27.8 2.671E-05 5.68 22098.9 -0.639 0.924 2.439 0.026  0.96 1.10 0.15  
Coiled-coil domain-containing protein 6 Q16204 12.8 5.89E-10 6.95 53159.7 -0.981 0.006 0.925 0.002  0.01 0.42 0.01  
Collagen alpha-1(VI) chain Q04857 24.5 2.854E-06 5.15 106386.8 -0.541 0.193 0.874 0.020  0.20 0.39 0.12  
Complement C3 P01026 55.3 9.63E-08 6.12 184110.5 -0.275 1.120 5.623 0.199  1.16 2.53 1.13  
Complement C3 P01025 39.7 3.187E-07 6.06 184601.1 -0.313 0.511 1.395 0.110  0.53 0.63 0.62  
Complement C3 Q2UVX4 44.6 2.495E-11 6.37 185047.4 -0.369 0.014 0.281 0.002  0.01 0.13 0.01  
Complement C3 P12387 38.2 1.812E-07 6.47 184441.5 -0.253 3.404 13.518 0.562  3.53 6.07 3.18  
Complement C3 P01027 62.5 5.104E-07 6.3 184180.1 -0.282 0.646 4.077 0.196  0.67 1.83 1.11  
Cytochrome b5 P00171 13.7 9.103E-09 4.94 15197.9 -0.516 0.015 0.470 0.001  0.02 0.21 0.01  
Cytochrome b6-f complex subunit 8 Q06H04 5.8 1.692E-06 5.59 3197.9 1.628 0.000 0.000 0.000  0.00 0.00 0.00  
Cytochrome c2 P86323 5.6 2.112E-09 9.3 11587.1 -0.642 0.033 0.266 0.012  0.03 0.12 0.07  
D-alanine aminotransferase Q5HF24 16.4 7.153E-05 4.95 31893.9 -0.318 0.002 0.086 0.003  0.00 0.04 0.02  
Dermcidin P81605 11.5 2.806E-05 5.64 9259.3 -0.667 0.021 0.219 0.022 0.012 0.02 0.10 0.13 0.04 
Dihydropyrimidinase-related protein 2 O02675 18.8 5.392E-05 5.95 62277.6 -0.267 0.030 0.093 0.002  0.03 0.04 0.01  
Dipeptidyl peptidase 3 Q99KK7 83.4 4.301E-06 5.26 82766.5 -0.32 0.668 2.568 0.122  0.69 1.15 0.69  
Dolichyl-diphosphooligosaccharide--protein 
glycotransferas 
P12244 15.7 1.604E-08 4.76 55052.9 -0.505 0.019 0.138 0.001  0.02 0.06 0.00  
Doublesex- and mab-3-related transcription 
factor 
Q3LH63 7.9 0.0021919 8.06 36999.2 -0.765 0.017 0.000 0.000  0.02 0.00 0.00  
Drebrin Q07266 9.3 7.445E-10 4.45 77340.8 -0.782 2.896 0.814 0.002 0.929 3.00 0.37 0.01 3.56 
Dystroglycan Q62165 107.6 5.09E-08 9.41 67629.1 -0.376 1.021 6.132 0.181  1.06 2.75 1.03  
Dystroglycan Q29243 66.1 5.891E-08 9.11 65832.4 -0.345 0.035 0.296 0.010  0.04 0.13 0.05  
Dystroglycan Q9TSZ6 65.2 4.8E-05 9.36 67762.3 -0.404 0.005 0.074 0.002  0.00 0.03 0.01  
Dystroglycan O18738 83.9 2.052E-07 9.33 67773.2 -0.427 0.007 0.178 0.003  0.01 0.08 0.02  
Echinoderm microtubule-associated protein-like 
2 
Q7TNG5 28.7 1.462E-08 5.83 70733.7 -0.111 0.033 0.603 0.001  0.03 0.27 0.01  
EGF-containing fibulin-like extracellular matrix 
protein 1 
Q8BPB5 142.6 4.185E-10 4.96 53047.4 -0.355 1.651 6.973 0.128  1.71 3.13 0.72  
EGF-containing fibulin-like extracellular matrix 
protein 1 
Q12805 128.4 1.629E-09 4.85 52765.1 -0.346 0.363 0.038 0.025  0.38 0.02 0.14  
Elongation factor 1-alpha 1 Q90835 22.7 1.251E-05 9.1 50156.9 -0.267 0.041 0.165 0.046  0.04 0.07 0.26  
Elongation factor 2 Q3SYU2 68.9 6.237E-05 6.42 95237.0 -0.212 2.157 4.832 2.468 0.542 2.24 2.17 13.97 2.08 
Endoplasmic reticulum vesicle protein 25 Q5B5L5 4.4 3.908E-07 6.14 21702.7 -0.369 0.003 0.000 0.000 0.028 0.00 0.00 0.00 0.11 
Endoribonuclease YbeY Q161G7 4.7 8.222E-09 4.26 17798.3 0.284 0.021 0.000 0.000  0.02 0.00 0.00  
Enolase (Fragment) P42897 21.6 4.349E-10 5.43 42884.0 -0.192 0.006 0.192 0.000  0.01 0.09 0.00  
Exosome complex component Rrp41 A0RXU1 5.6 8.174E-05 5.04 26319.0 -0.17 0.036 0.413 0.014  0.04 0.19 0.08  
F-actin-capping protein subunit alpha-1 P47753 9.1 8.968E-08 5.34 32808.6 -0.657 0.013 0.088 0.001  0.01 0.04 0.01  
F-box DNA helicase 1 Q8NFZ0 27.9 0.0002112 8.58 117686.3 -0.272 1.694 4.889 0.190  1.76 2.20 1.08  
Ferrochelatase A9BEE9 14.6 7.699E-06 5.05 44606.0 -0.186 0.615 0.038 0.457 0.188 0.64 0.02 2.59 0.72 
Follistatin-related protein 1 Q58D84 74.9 3.903E-09 5.21 32593.5 -0.609 0.807 2.899 0.202  0.84 1.30 1.14  
G kinase-anchoring protein 1 Q5VSY0 5.1 8.707E-12 8.89 42078.1 -1.201 0.000 0.600 0.000  0.00 0.27 0.00  
Gametocyte-specific factor 1-like Q9CWD0 5.3 4.423E-05 8.12 17281.7 -0.767 0.089 0.912 0.023  0.09 0.41 0.13  
Glia maturation factor beta P60984 5.4 1.309E-07 5.19 16582.0 -0.546 0.011 0.080 0.000  0.01 0.04 0.00  
Glyceraldehyde-3-phosphate dehydrogenase P17244 54.7 7.054E-08 8.5 35616.7 -0.084 0.071 0.335 0.001  0.07 0.15 0.01  
Glyceraldehyde-3-phosphate dehydrogenase 1 O16027 12.1 1.467E-08 6.71 34579.6 -0.055 0.046 0.381 0.023  0.05 0.17 0.13  
GTP-binding protein RHO1 Q9HF54 16.0 1.502E-07 7.5 22734.2 -0.271 0.004 0.028 0.001 0.024 0.00 0.01 0.00 0.09 
HD domain-containing protein 2 Q0P565 10.1 2.828E-07 5.08 23192.2 -0.573 0.004 0.110 0.000  0.00 0.05 0.00  
Heat shock 70 kDa Q2TBX4 7.6 8.88E-09 5.23 49729.8 -0.213 0.084 0.669 0.130  0.09 0.30 0.74  
Heat shock 70 kDa protein Q05944 43.7 0.0008125 5.65 71467.8 -0.406 0.134 0.923 0.003  0.14 0.41 0.02  
Heat shock 70 kDa protein P16019 27.9 4.848E-08 5.31 71007.1 -0.464 0.020 1.225 0.003  0.02 0.55 0.02  
Heat shock 70 kDa protein P26791 27.8 9.798E-06 5.14 72051.8 -0.394 0.001 0.041 0.027  0.00 0.02 0.16  
Heat shock 70 kDa protein Q91233 45.8 0.0971841 5.41 70976.1 -0.485 0.000 0.013 0.000  0.00 0.01 0.00  
Heat shock 70 kDa protein 13 Q5R8D9 23.9 3.153E-06 5.52 49651.6 -0.221 0.078 1.311 0.002  0.08 0.59 0.01  
Heat shock 70 kDa protein 1A Q27975 30.3 8.365E-07 5.68 70127.3 -0.402 0.049 0.107 0.000  0.05 0.05 0.00  
Heat shock 70 kDa protein 1A Q61696 54.0 7.128E-07 5.52 69948.0 -0.379 0.024 0.229 0.001  0.02 0.10 0.00  
Heat shock 70 kDa protein 4 P11145 31.5 2.2E-10 5.24 71436.5 -0.331 0.152 2.300 0.025  0.16 1.03 0.14  
Heat shock 70 kDa protein 6 Q9N1U2 21.5 0.2963867 6.06 71156.3 -0.449 0.007 0.084 0.014  0.01 0.04 0.08  
Heat shock 70 kDa protein cognate 1 P29843 53.0 1.535E-07 5.33 70686.4 -0.462 0.006 0.052 0.000  0.01 0.02 0.00  
Heat shock 70 kDa protein IV Q06248 39.5 0.0003235 5.55 69749.8 -0.428 0.040 0.562 0.070  0.04 0.25 0.40  
Heat shock cognate 70 kDa protein Q24789 60.4 2.721E-09 5.66 72554.1 -0.451 0.007 0.076 0.001  0.01 0.03 0.00  
Heat shock cognate 70 kDa protein 1 P36415 43.2 1.576E-09 5.34 70414.6 -0.489 0.032 0.140 0.002  0.03 0.06 0.01  
Heat shock cognate 70 kDa protein 3 Q54BE0 54.5 1.163E-05 5.49 69947.0 -0.461 0.654 1.857 0.018 0.186 0.68 0.83 0.10 0.71 
Heat shock cognate 71 kDa protein P19378 215.5 9.552E-07 5.23 70673.7 -0.448 0.146 3.922 0.021  0.15 1.76 0.12  
Heat shock cognate 71 kDa protein P19120 229.4 1.941E-07 5.37 71109.3 -0.454 0.076 0.782 0.011  0.08 0.35 0.06  
Heat shock cognate 71 kDa protein O73885 165.6 8.95E-09 5.46 70827.0 -0.449 0.015 0.398 0.001  0.02 0.18 0.01  
Heterogeneous nuclear ribonucleoprotein A/B Q99020 23.7 7.245E-07 7.69 30831.3 -0.893 0.001 0.297 0.000  0.00 0.13 0.00  
Heterogeneous nuclear ribonucleoprotein D0 Q14103 5.8 1.427E-09 7.6 38303.0 -0.932 0.007 0.309 0.000  0.01 0.14 0.00  
Heterogeneous nuclear ribonucleoprotein K Q3T0D0 28.0 1.299E-08 5.14 51019.2 -0.702 0.021 0.450 0.000  0.02 0.20 0.00  
Heterogeneous nuclear ribonucleoprotein Q O60506 77.2 4.05E-08 8.68 69471.4 -0.881 1.156 3.176 0.226  1.20 1.43 1.28  
Hsp90 co-chaperone Cdc37 Q5EAC6 28.6 5.911E-07 5.09 44580.2 -0.987 0.006 0.334 0.000  0.01 0.15 0.00  
Hsp90 co-chaperone Cdc37 Q63692 39.5 7.95E-07 5.24 44510.4 -0.969 0.002 0.195 0.001  0.00 0.09 0.00  
Ig gamma-4 chain C region P01861 80.4 0.0001372 6.56 35940.6 -0.423 0.001 0.032 3.104  0.00 0.01 17.58  
Ig kappa chain C region P01834 32.9 1.686E-10 5.42 11608.9 -0.553 0.001 0.000 0.823  0.00 0.00 4.66  
Importin-5 O00410 94.0 1.47E-09 4.83 123498.7 -0.134 0.754 4.259 0.070  0.78 1.91 0.39  
Insulin-like growth factor-binding protein 4 P47879 35.4 8.08E-09 6.62 25760.3 -0.535 0.037 0.919 0.017  0.04 0.41 0.10  
Isopentenyl-diphosphate delta-isomerase A8AUV1 7.7 2.478E-10 5.39 37621.8 -0.328 0.001 0.165 0.000  0.00 0.07 0.00  
Kin of IRRE-like protein 1 Q96J84 15.6 1.146E-10 5.55 81714.6 -0.404 0.011 0.139 0.000  0.01 0.06 0.00  
Lamin-B1 P20700 13.6 2.487E-08 5.11 65961.7 -0.811 0.009 0.180 0.000  0.01 0.08 0.00  
Legumain O89017 31.6 3.451E-05 5.72 34818.2 -0.368 0.433 1.425 0.318  0.45 0.64 1.80  
Lipoprotein lipase Q06000 21.7 0.0027366 8.22 50298.0 -0.422 0.068 0.282 0.002  0.07 0.13 0.01  
Lysine--tRNA ligase P37879 51.6 3.691E-09 5.84 67859.0 -0.418 0.038 0.906 0.001  0.04 0.41 0.01  
Lysosomal alpha-glucosidase P10253 553.1 0.0155703 5.42 105323.7 -0.129 34.791 5.319 0.491 21.317 36.07 2.39 2.78 81.83 
Lysosomal protective protein P16675 50.6 9.753E-07 5.55 51395.2 -0.321 0.800 5.823 0.223  0.83 2.62 1.26  
Lysyl oxidase homolog 1 P97873 21.9 1.963E-08 6.17 56452.1 -0.765 0.003 0.597 0.002  0.00 0.27 0.01  
Matrix metalloproteinase-19 Q9JHI0 11.8 4.96E-08 8.87 46555.8 -0.404 0.108 1.255 0.007  0.11 0.56 0.04  
Metalloproteinase inhibitor P30120 5.3 1.384E-07 8.27 21536.8 -0.109 0.051 0.185 0.011  0.05 0.08 0.06  
Methionine aminopeptidase 2 P50579 10.5 7.263E-10 5.57 52760.4 -0.687 0.001 0.161 0.000  0.00 0.07 0.00  
Multiple inositol polyphosphate phosphatase 1 Q9Z2L6 5.6 2.332E-07 6.5 51546.9 -0.389 0.006 0.365 0.000  0.01 0.16 0.00  
Myosin light chain 6B Q8CI43 5.5 7.276E-09 5.41 22617.7 -0.559 0.006 0.213 0.000  0.01 0.10 0.00  
Myotrophin P62775 20.9 1.934E-07 5.28 12729.6 -0.224 0.012 0.557 0.003  0.01 0.25 0.01  
Na(+)/H(+) exchange regulatory cofactor NHE-
RF1 
P70441 22.7 8.103E-10 5.63 38468.9 -0.75 0.011 0.247 0.000  0.01 0.11 0.00  
N-acetylglucosamine-6-sulfatase Q8BFR4 15.2 1.816E-09 7.63 57632.5 -0.411 0.075 0.208 0.001  0.08 0.09 0.01  
NAD-dependent protein deacylase Q607X6 9.3 3.017E-09 5.98 27494.1 -0.179 0.048 0.422 0.021  0.05 0.19 0.12  
Nascent polypeptide-associated complex subunit P70670 34.8 1.914E-09 9.39 220499.4 -0.329 0.026 0.543 0.001  0.03 0.24 0.01  
alpha, muscle-specific form 
Neudesin Q9CQ45 19.3 1.953E-07 4.79 15612.4 -0.674 0.008 0.222 0.000  0.01 0.10 0.00  
Neudesin Q9UMX5 18.6 4.539E-08 4.81 15684.5 -0.69 0.003 0.077 0.000  0.00 0.03 0.00  
Neudesin Q6IUR5 18.5 8.449E-10 4.79 15684.5 -0.62 0.002 0.071 0.000  0.00 0.03 0.00  
Neuraminidase P67923 9.9 1.473E-07 6.82 51381.6 -0.265 2.844 0.123 1.590 0.648 2.95 0.06 9.00 2.49 
Nidogen-1 P10493 91.2 8.645E-08 5.24 133562.1 -0.365 0.547 5.698 0.045  0.57 2.56 0.25  
Nidogen-1 P14543 40.3 5.759E-09 5.05 133457.5 -0.378 0.463 3.698 0.013  0.48 1.66 0.08  
Nuclear migration protein nudC O35685 33.9 0.0016435 5.17 38358.0 -1.061 0.007 0.073 0.000  0.01 0.03 0.00  
Nuclear migration protein nudC Q63525 35.4 2.075E-05 5.27 38412.1 -1.05 0.151 0.321 0.001  0.16 0.14 0.00  
Nuclear migration protein nudC Q17QG2 24.2 6.283E-08 5.22 38242.9 -1.028 0.024 0.426 0.000  0.02 0.19 0.00  
Nuclear transport factor 2 Q32KP9 5.1 4.986E-07 5.1 14478.5 -0.201 0.002 0.074 0.000  0.00 0.03 0.00  
Nuclease-sensitive element-binding protein 1 P67808 40.7 1.79E-07 9.87 35793.0 -1.495 0.033 0.727 0.029  0.03 0.33 0.16  
Nucleobindin-1 Q63083 110.6 0.0021546 5.01 50919.5 -1.022 0.727 1.260 0.036 0.136 0.75 0.57 0.20 0.52 
Nucleobindin-1 Q02819 85.1 1.475E-09 4.96 50821.4 -1.025 0.099 0.991 0.008  0.10 0.45 0.05  
Nucleobindin-1 Q0P569 94.3 0.00041 5.05 52483.3 -1.007 0.028 0.249 0.000  0.03 0.11 0.00  
Nucleobindin-2 P81117 68.8 0.0001451 5.01 47423.9 -1.085 0.615 1.571 0.036  0.64 0.71 0.21  
Nucleobindin-2 Q9JI85 18.8 2.654E-07 4.96 47253.8 -1.171 0.210 0.901 0.003  0.22 0.40 0.02  
Olfactomedin-like protein 3 Q9NRN5 22.8 8.036E-11 6.18 43800.6 -0.577 0.017 0.385 0.000  0.02 0.17 0.00  
Out at first protein homolog Q8QZR4 5.2 4.213E-08 6.49 28462.4 -0.257 0.073 0.836 0.000  0.08 0.38 0.00  
Peptide methionine sulfoxide reductase MsrA A6WYH5 4.6 0.1352595 5.01 24158.1 -0.416 0.073 0.027 0.027  0.08 0.01 0.15  
Peptidyl-prolyl cis-trans isomerase  B P80311 11.4 2.541E-07 9.13 20200.2 -0.454 0.018 0.265 0.002  0.02 0.12 0.01  
Peroxiredoxin-1 Q9JKY1 22.1 3.391E-10 8.21 22131.4 -0.226 0.009 0.081 0.000  0.01 0.04 0.00  
Phosphoglycerate mutase 1 P18669 90.6 7.735E-08 6.75 28672.7 -0.498 0.094 3.083 0.027  0.10 1.38 0.15  
Phosphoglycerate mutase 1 Q3SZ62 81.4 1.174E-07 6.44 28720.8 -0.518 0.057 1.859 0.016  0.06 0.83 0.09  
Phosphoserine aminotransferase B4SP45 4.4 0.0519085 5.74 38907.2 0.006 0.000 0.005 0.000  0.00 0.00 0.00  
Phosphoserine phosphatase Q99LS3 17.0 6.447E-08 5.8 25095.9 -0.116 0.003 0.155 0.000  0.00 0.07 0.00  
Pigment epithelium-derived factor P97298 48.8 5.516E-08 6.45 44284.7 -0.138 1.435 5.130 0.415  1.49 2.30 2.35  
Pigment epithelium-derived factor P36955 35.6 9.811E-07 5.9 44387.8 -0.164 1.297 0.966 0.184  1.34 0.43 1.04  
Plastin-2 Q6P698 42.8 1.705E-09 5.26 69900.1 -0.294 0.027 0.252 0.000  0.03 0.11 0.00  
Plastin-3 O88818 72.7 7.127E-09 5.47 70795.0 -0.331 0.070 1.525 0.001  0.07 0.68 0.01  
POTE ankyrin domain family member E Q6S8J3 57.7 1.961E-05 5.83 121363.4 -0.683 0.114 0.025 0.006  0.12 0.01 0.04  
Probable aquaporin PIP-type pTOM75 Q6B411 5.0 8.2E-08 8.31 14962.2 -0.647 0.023 0.071 0.009  0.02 0.03 0.05  
Probable dual-specificity RNA methyltransferase 
RlmN 
A1A1I4 19.9 1.96E-08 6.84 42346.1 -0.367 0.890 0.005 0.051 0.157 0.92 0.00 0.29 0.60 
Probable pectinesterase 30 Q3EAY9 14.0 0.0008701 6.71 53060.4 -0.24 0.007 0.269 0.000  0.01 0.12 0.00  
Procollagen C-endopeptidase enhancer 1 Q61398 88.7 1.085E-07 8.63 47630.9 -0.313 1.386 9.429 0.109 0.072 1.44 4.23 0.62 0.28 
Procollagen C-endopeptidase enhancer 1 Q15113 25.2 3.573E-05 7.55 45549.5 -0.286 0.620 0.575 0.129 0.080 0.64 0.26 0.73 0.31 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase Q63321 23.9 0.0005039 6.27 81646.8 -0.4 0.045 0.477 0.020  0.05 0.21 0.11  
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 
1 
O77588 20.1 2.078E-08 6.17 81468.6 -0.391 0.023 0.488 0.000  0.02 0.22 0.00  
Prolyl endopeptidase Q9XTA2 53.4 6.122E-08 5.56 80641.4 -0.353 0.096 0.332 0.002  0.10 0.15 0.01  
Protein crossbronx B4HT57 13.4 0.0517061 5.29 28180.0 -0.466 1.552 0.748 0.024 0.251 1.61 0.34 0.14 0.96 
Protein CYR61 O00622 45.5 0.0017795 8.49 39438.4 -0.381 0.975 1.586 0.715 0.211 1.01 0.71 4.05 0.81 
Protein disulfide-isomerase Q8R4U2 74.8 1.078E-09 4.73 54997.9 -0.453 0.104 0.982 0.008  0.11 0.44 0.05  
Protein disulfide-isomerase A3 P38657 46.7 6.409E-08 5.78 54398.4 -0.637 0.099 0.304 0.001  0.10 0.14 0.01  
Protein disulfide-isomerase A3 P86235 124.9 2.691E-09 4.64 23387.9 -0.55 0.070 0.754 0.010  0.07 0.34 0.06  
Protein disulfide-isomerase A3 Q8JG64 67.9 1.585E-10 5.57 53782.7 -0.557 0.021 0.357 0.013  0.02 0.16 0.07  
Protein S100-A13 P79342 6.0 0.0145453 5.5 11198.9 -0.434 0.002 0.029 0.000  0.00 0.01 0.00  
Proteinase K P06873 12.9 1.012E-08 8.25 28906.8 -0.218 0.014 0.187 0.001  0.01 0.08 0.00  
Purine nucleoside phosphorylase P23492 23.1 1.864E-08 5.78 32277.1 -0.132 0.009 0.645 0.001  0.01 0.29 0.01  
Putative gene 49 protein O48403 5.1 0.0597136 4.79 13332.3 -0.043 0.000 0.017 0.000  0.00 0.01 0.00  
Putative NADH dehydrogenase/NAD(P)H 
nitroreductase Reut_A1586 
Q471I1 9.1 3.522E-05 6.73 21531.5 -0.239 0.056 0.003 0.001  0.06 0.00 0.00  
Putative phospholipase B-like 2 Q4QQW8 15.8 1.061E-07 5.69 61943.4 -0.265 0.244 1.197 0.041  0.25 0.54 0.23  
Pyruvate kinase PKM P11980 32.8 7.584E-06 6.69 57686.6 -0.096 0.048 0.714 0.022  0.05 0.32 0.12  
Pyruvate kinase PKM P14618 38.4 3.493E-09 7.95 57805.7 -0.132 0.046 0.379 0.007  0.05 0.17 0.04  
Ran-specific GTPase-activating protein P34022 10.3 3.301E-10 5.15 23465.2 -1.15 0.018 0.096 0.000 0.139 0.02 0.04 0.00 0.54 
Ras-like GTP-binding protein O-RHO P22122 19.1 1.685E-07 5.82 21140.4 -0.359 0.002 0.274 0.001  0.00 0.12 0.00  
Receptor-type tyrosine-protein phosphatase S B0V2N1 52.0 8.29E-06 6.76 208981.4 -0.39 0.163 1.467 0.002  0.17 0.66 0.01  
Recombination protein RecR B3QYJ4 5.3 7.166E-07 5.61 22842.4 -0.147 0.057 0.861 0.000  0.06 0.39 0.00  
Recombination protein RecR Q2RZH8 4.8 1.929E-07 4.19 25489.1 -0.38 0.003 0.227 0.001  0.00 0.10 0.00  
Retinoid-inducible serine carboxypeptidase Q920A5 43.5 0.012753 5.25 47816.8 -0.079 0.801 1.413 0.247  0.83 0.63 1.40  
Rho GDP-dissociation inhibitor 1 Q5XI73 45.6 6.446E-07 5.1 23276.2 -0.73 0.171 2.293 0.014  0.18 1.03 0.08  
Ribonuclease T2 Q9CQ01 34.1 5.189E-09 5.92 26755.4 -0.589 0.006 0.253 0.009  0.01 0.11 0.05  
Ribonucleoside-diphosphate reductase subunit 
M2 
Q60561 10.4 2.588E-10 5.25 44482.1 -0.179 0.001 0.058 0.000  0.00 0.03 0.00  
Ribose-5-phosphate isomerase P47968 41.3 6.096E-10 7.81 32450.9 -0.233 0.001 0.137 0.001  0.00 0.06 0.00  
R-phycocyanin-1 beta chain P37208 4.9 3.131E-08 4.92 18170.6 0.084 0.014 0.075 0.000  0.01 0.03 0.00  
Septin-2 Q2NKY7 20.1 6.628E-09 6.15 41571.5 -0.529 0.004 0.123 0.000  0.00 0.06 0.00  
Serine protease HTRA1 Q92743 16.4 0.0001173 7.89 49048.1 -0.202 0.020 0.051 0.000  0.02 0.02 0.00  
Serine/threonine-protein kinase PAK 1 Q08E52 9.5 1.112E-10 5.63 60414.6 -0.605 0.003 0.097 0.000  0.00 0.04 0.00  
Serum albumin P02769 131.3 n/a 5.6 66433.0 -0.429 0.276 0.358 0.387 0.308 0.29 0.16 2.19 1.18 
SH3 domain-binding glutamic acid-rich-like 
protein 
O75368 10.7 7.369E-07 5.22 12774.3 -0.691 0.002 0.027 0.001  0.00 0.01 0.00  
Small cysteine-rich outer membrane protein B0B816 5.4 1.452E-08 5.13 7474.4 -0.671 0.006 0.029 0.000  0.01 0.01 0.00  
Small ubiquitin-related modifier 2 Q6LDZ8 7.4 1.241E-06 5.32 10608.9 -0.893 0.126 1.137 0.041  0.13 0.51 0.23  
Soluble calcium-activated nucleotidase 1 Q8VCF1 30.4 1.62E-08 6.28 45652.5 -0.446 0.003 0.085 0.001  0.00 0.04 0.01  
Soluble calcium-activated nucleotidase 1 Q8WVQ1 43.7 3.765E-08 5.72 44839.6 -0.339 0.029 0.944 0.028  0.03 0.42 0.16  
Spermidine/putrescine import ATP-binding 
protein 
A1TXH7 5.3 1.124E-07 4.92 42106.8 -0.398 0.255 1.027 0.018  0.26 0.46 0.10  
Superoxide dismutase [Cu-Zn] 1 O42724 4.6 0.00086 5.82 15757.2 -0.444 0.000 0.008 0.000  0.00 0.00 0.00  
Suprabasin A6QQF6 10.1 1.397E-07 6.74 54505.4 -0.745 0.059 0.365 0.034  0.06 0.16 0.19  
Synaptic vesicle membrane protein VAT-1 Q99536 5.8 2.518E-09 5.88 41789.1 -0.043 0.051 0.231 0.000  0.05 0.10 0.00  
Taurocyamine kinase P16641 17.5 6.933E-08 8.2 83891.0 -0.366 0.017 0.178 0.146  0.02 0.08 0.83  
Tetranectin P05452 28.5 2.312E-09 5.8 20138.9 -0.484 0.034 0.426 0.000  0.04 0.19 0.00  
Thioredoxin P10639 12.7 1.935E-08 4.8 11544.3 -0.034 0.072 1.438 0.015  0.07 0.65 0.08  
Thioredoxin reductase 1, cytoplasmic O62768 17.5 4.709E-06 6.07 54770.5 -0.216 0.028 0.891 0.095  0.03 0.40 0.54  
Thioredoxin reductase 1, cytoplasmic Q9JMH6 44.3 0.0003475 7.42 67083.8 -0.233 0.042 1.087 0.138  0.04 0.49 0.78  
TIP41-like protein O75663 14.6 1.011E-08 5.59 31444.0 -0.401 0.001 0.040 0.000  0.00 0.02 0.00  
Tolloid-like protein 2 Q9Y6L7 34.2 4.124E-11 5.8 97638.1 -0.55 0.075 0.584 0.000  0.08 0.26 0.00  
Transcription initiation factor TFIID subunit 3 Q9P6P0 19.0 1.134E-06 4.7 17681.0 -0.32 0.073 0.394 0.004  0.08 0.18 0.02  
Transmembrane protein 132A Q922P8 15.6 1.144E-07 5.37 106794.2 -0.262 0.112 0.808 0.007  0.12 0.36 0.04  
Tripeptidyl-peptidase 1 O89023 11.9 0.0003276 5.93 39877.6 -0.173 0.082 0.550 0.016  0.09 0.25 0.09  
tRNA 2-thiocytidine biosynthesis protein TtcA A3PNA9 15.3 0.0002483 6.26 33150.2 -0.298 0.035 0.003 0.019  0.04 0.00 0.11  
Trypsin-1 P16049 9.4 6.737E-08 6.36 23835.9 -0.073 0.002 0.067 0.000  0.00 0.03 0.00  
Tryptophan--tRNA ligase, cytoplasmic Q5R4J1 30.9 9E-10 5.99 53241.6 -0.374 0.010 0.312 0.000  0.01 0.14 0.00  
Tryptophan--tRNA ligase, cytoplasmic P32921 31.5 6.973E-09 6.44 54357.9 -0.37 0.000 0.098 0.000  0.00 0.04 0.00  
Tubulin alpha-1 chain O22347 6.0 5.552E-08 4.89 49731.1 -0.191 0.002 0.183 0.001  0.00 0.08 0.00  
Twisted gastrulation protein homolog 1 Q98T89 24.7 4.393E-06 4.97 22179.3 -0.067 0.089 0.707 0.056  0.09 0.32 0.32  
U2 small nuclear ribonucleoprotein A' P09661 20.7 2.356E-07 8.72 28284.4 -0.496 0.310 1.203 0.103  0.32 0.54 0.58  
U2 small nuclear ribonucleoprotein A' P57784 21.7 4.623E-07 8.72 28226.3 -0.482 0.000 0.022 0.000  0.00 0.01 0.00  
Ubiquitin-conjugating enzyme E2 K P61085 17.0 2.253E-09 5.33 22275.5 -0.28 0.003 0.288 0.000  0.00 0.13 0.00  
Uncharacterized protein in bps2 5'region 
(Fragment) 
P55031 27.3 0.2039077 4.92 51088.1 -0.322 2.342 0.872 0.873  2.43 0.39 4.94  
UPF0134 protein MPN_139 P75259 5.4 5.315E-09 9.15 19115.8 -0.855 0.042 0.361 0.000  0.04 0.16 0.00  
UV excision repair protein RAD23 homolog B P54727 18.2 5.843E-07 4.77 43171.2 -0.388 0.010 0.185 0.002  0.01 0.08 0.01  
Vitamin K-dependent protein S P53813 5.5 3.934E-11 4.99 69874.2 -0.285 0.117 0.623 0.000  0.12 0.28 0.00  
V-type proton ATPase subunit S1 Q9R1Q9 22.1 0.0003401 5.25 47737.6 0.149 0.050 0.429 0.043  0.05 0.19 0.24  
TOTAL (ng per 10μl sample) 
      
96.5 222.7 17.7 26.1 100 100 100 100 
 
Supporting data: HCP Full list comparison between GAA, Null and mAb CHO producer. Progenesis QIP software provided resulting data in the form of normalised 
abundance (molar equivalent) in triplicate readings of each species matched in the SwissProt database and the average of each triplicate was converted into 
concentration by dividing it by the specie molecular weight. Respective specie percentages were calculated based on relative amount of each specie out of the sum of 
amounts of all species in each 10 μl sample and were used as bubble graph data set (figure 6). Accession ID, confidence score and Anova (p) were provided by 
Progenesis QIP software. Isoelectric point was calculated using ExPASy pI calculator online tool (ExPASy. Compute pI/Mw tool). Hydropathicity index (GRAVY) was 
also calculated based on amino acidic sequence. 
Sample name Empty lysosomes (E) Half lysosomes (H) Full lysosomes (F) Total lysosomes (T) %F %H+F 
GAA 1 9 9 12 30 40 70 
GAA 2 2 0 12 14 86 86 
GAA 3 1 0 27 28 96 96 
GAA 4 1 1 0 2 0 50 
GAA 5 3 3 4 10 40 70 
GAA 6 2 2 8 12 67 83 
GAA 7 0 1 23 24 96 100 
GAA 8 4 4 8 16 50 75 
GAA 9 2 1 24 27 89 93 
GAA 10 4 2 20 26 77 85 
GAA 11 0 0 6 6 100 100 
GAA 12 2 4 12 18 67 89 
GAA 13 1 0 23 24 96 96 
GAA 14 5 1 4 10 40 50 
GAA 15 2 1 8 11 73 82 
GAA 16 1 0 26 27 96 96 
GAA 17 0 0 3 3 100 100 
GAA 18 0 3 0 3 0 100 
GAA 19 1 3 8 12 67 92 
GAA 20 0 0 11 11 100 100 
GAA 21 5 8 12 25 48 80 
GAA 22 1 1 11 13 85 92 
GAA 23 0 0 16 16 100 100 
GAA 24 0 0 11 11 100 100 
GAA 25 1 0 18 19 95 95 
GAA 26 1 4 2 7 29 86 
GAA 27 2 1 7 10 70 80 
GAA 28 2 3 36 41 88 95 
GAA 29 5 5 9 19 47 74 
GAA 30 1 1 19 21 90 95 
GAA 31 0 0 28 28 100 100 
GAA 32 2 0 9 11 82 82 
Total lysosomes (T) %F %H+F %E 
Average 17 72 87 12 
StDev 9.1 28.5 13.3 13.3 
StError 1.61 5.04 2.36 2.36 
Supporting data. TEM images of  GAA producer CHO Clone 1  
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  Total lysosomes (T) %F %H+F 
Average 14 7 55 
StDev 6.6 10.7 20.1 
St Error 1.15 1.86 3.50 
Supporting data. TEM images of  Null producer CHO Clone 1  
Sample 
name 
Empty lysosomes 
E  
Half lysosomes 
(H) 
Full lysosomes 
(F) 
Total lysosomes 
(T) 
%F %H+F %E  
Null 1 3 6 1 10 10 70.0 30.0 
Null 2 0 5 0 5 0 100.0 0.0 
Null 3 5 5 1 11 9 54.5 45.5 
Null 4 17 6 1 24 4 29.2 70.8 
Null 5 6 3 1 10 10 40.0 60.0 
Null 6 0 8 0 8 0 100.0 0.0 
Null 7 7 9 1 17 6 58.8 41.2 
Null 8 15 6 0 21 0 28.6 71.4 
Null 9 9 11 1 21 5 57.1 42.9 
Null 10 6 6 7 19 37 68.4 31.6 
Null 11 11 21 1 33 3 66.7 33.3 
Null 12 6 3 0 9 0 33.3 66.7 
Null 13 4 5 2 11 18 63.6 36.4 
Null 14 10 5 0 15 0 33.3 66.7 
Null 15 4 3 4 11 36 63.6 36.4 
Null 16 6 10 2 18 11 66.7 33.3 
Null 17 6 4 0 10 0 40.0 60.0 
Null 18 5 6 0 11 0 54.5 45.5 
Null 19 3 3 0 6 0 50.0 50.0 
Null 20 9 6 2 17 12 47.1 52.9 
Null 21 20 4 0 24 0 16.7 83.3 
Null 22 1 3 0 4 0 75.0 25.0 
Null 23 9 7 0 16 0 43.8 56.3 
Null 24 3 2 0 5 0 40.0 60.0 
Null 25 3 4 4 11 36 72.7 27.3 
Null 26 3 8 0 11 0 72.7 27.3 
Null 27 5 5 2 12 17 58.3 41.7 
Null 28 3 18 0 21 0 85.7 14.3 
Null 29 10 5 0 15 0 33.3 66.7 
Null 30 1 2 0 3 0 66.7 33.3 
Null 31 6 3 1 10 10 40.0 60.0 
Null 32 4 14 0 18 0 77.8 22.2 
Null 33 12 4 2 18 11 33.3 66.7 
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BENGGP15 Bioprocess Validation Coursework 
Describe briefly objectives of your research. 
 
Proteases play a critical role in the functioning of the metabolism of all cells but, unfortunately, lead 
to challenges in the purification of proteins for use as pharmaceuticals in the biotechnology industry. 
During the purification of a target protein from a CHO line, both cysteine and serine proteases are 
thought to present particular problems. The understanding of the interaction of these proteases 
with the target protein and their behaviour during chromatography is the topic of this work. 
Here is a list of objectives this research intends to achieve: 
 Create a stable CHO cell line capable of producing the target protein, acid alpha glucosidase 
(GAA) to supply material for purification studies.  
 Develop analytical assays able to characterize the cell line, its growth performance, product 
production, product identification, and protease analysis in the feed stream.  
 Design a two column chromatographic process consisting of AIEX and HIC aimed at purifying 
GAA and eliminating proteases from the process stream. 
2. Describe the significance of your research; especially its (potential) 
contribution to the healthcare sector (1000 characters). 
 
The CHO host expression cell line generated in house is used to provide material used to mimic and 
improve on the industrial bioprocess in place at BioMarin Pharmaceuticals for the production of 
recombinant human Acid Alpha Glucosidase (GAA). This therapeutic enzyme, currently undergoing 
phase 3 clinical trials, is essential in the treatment of Pompe disease, a rare genetic disorder part of 
the lysosomal storage disorder (LDS) group. This disorder has an incidence of one in 40000 live births 
(Martiniuk et al., 1998) and it causes glycogen accumulation in the muscle cells. Adult Pompe 
patients present with progressive skeletal muscle weakness and show difficulties moving and 
breathing and depend on a lifelong supply of replacement GAA enzyme.  
At the moment only one drug is approved for late onset Pompe by the FDA (FDA, 2014), but it lacks 
the ability to bind to key cell receptors, giving Bio Marin’s molecule a clear advantage. Developing a 
purification method capable of ridding specific co-eluting proteases that are thought of affect final 
product quality would constitute a clear contribution to the healthcare sector.  
3. Summarize the key validation issues faced by your sponsoring 
company (i.e. as for equipment supplier, or contract manufacturer, or 
biotech early phase, or big pharma early or late phase or consultant 
etc.) (4000 characters) 
 
More companies in the pharmaceutical industry today are adopting the principles of Quality by 
Design (QbD) for pharmaceutical development and manufacturing. Described in ICH Q8, Q9 and Q10 
guidance documents, QbD enables enhanced process understanding, and a more systematic and 
scientific approach to development, so that better controls may be implemented. The end goal is 
more robust manufacturing processes than those that typically result from traditional approaches to 
drug development (Nethercote, 2010). 
The bioprocess currently in place at BioMarin has been validated for the manufacture of the 
therapeutic enzyme GAA to supply material for phase 3 clinical trials.  
It was recently assessed that the first precolumn filter (capture step) in manufacturing facility, 
needed changing more often than previously thought due to higher than usual amount of cell debris 
in the process stream. An internal investigation has attributed this issue to high amount of shear 
that the cells experience as they are accelerated into the spinning bowl of the centrifuge. It has been 
decided to replace the current aging disk stack centrifuges with the more modern low shear 
hydrohermetic design which supposedly decreases shear stress that cells experience at harvest by 
creating a sealed area filled with liquid for the cells to accelerate to separation velocity. This change 
reduces considerably the amount of debris and as a consequence allows the reduction in filter size 
requirement in the pre chromatography filtration step with substantial economic advantage over the 
overall downstream processing running costs. However, the reduction of filter size has the negative 
impact of reducing flow rate, increasing the possibility of proliferation of viruses and bacteria.  
It is a requirement of GMP that a bioprocess change in a pharmaceutical company is validated 
according to regulatory agency standards.  
The first study that was done was a risk analysis assessment, which aim was to identify the critical 
quality attributes (CQAs) that might be affected by the change of filter size and centrifuge type. 
From this analysis it resulted that only process related attributes were going to be affected and 
specifically viruses and LPS levels due to decreased flow rate (longer residence time), and leachables 
levels (due to new filter potentially leaching in the process stream). From the analysis it also 
emerged that product related attributes were cause for lesser concern as although these changes 
have a great effect on product quality functionality and patient safety, the bioprocess change had 
little to no effect on their occurrence, therefore they were assigned a low class of risk. 
Summarised in the table below are the steps required to validate the process change.  
Step Aim 
Scale down studies  Calculate amount of debris generated by new centrifuge using 
USD device and sigma concept. 
 Determine chromatography resin lifespan and efficiency. 
 Assess Virus and sterile final filtration. 
 Leachable release. 
Identify vendors  Identify multiple vendors to face ‘out of stock’ situations. 
 Let vendor do validation of filter based on specific process 
stream physical characteristics and operation parameters. 
IQ/OQ  Pipes, supports, and all new instruments should be installed by 
qualified personnel. 
 Equipment should be tested by installer and SOP provided to 
customer. 
 Release form should be obtained. 
PQ and Process 
Validation 
 Test instrument for robustness and repeatability. 
 Determine performance limits. 
 Run three consecutive batches successfully at operating 
parameters. 
Cleaning 
Validation 
 Ensure chemicals used for cleaning don’t leave residue. 
 Ensure cleaning is done properly. 
 
Following this validation plan ensures that the change in the bioprocess has no ultimate detrimental 
effect on the final product quality. 
NOTE: The scenario here presented is a hypothetical scenario and does not reflect the sponsoring 
company procedure. 
4. Discuss the regulatory (validation) issues which may affect the take 
up of your research (4000 characters) 
 
As previously explained this research project is designed to mimic the complete bioprocess in place 
at BioMarin to try to improve on certain aspects such as a two-column chromatographic purification. 
Trying to address all the regulatory issues that a therapeutic enzyme produced in house might face 
on its way to market seems unrealistic, particularly due to the fact that the production facility (ACBE) 
does not abide GMP regulations.  
There are two major potential regulatory issues that I feel need to be addressed:  
Product Quality: Isoforms 
At this stage of the research project it has been established that the molecular weight of the human 
recombinant GAA enzyme active form is 110 KDa, and that other isoforms are present due to post 
translational modifications that happen in Golgi and RER before secretion. These species have been 
identified as 100, 95, 91, 76 and 70kDa (Reuser, 1985) and some of them are often visible in Western 
Blot analysis of cell culture supernatant. From a regulatory point of view, allowing any isoform other 
than the 110KDa in the final drug product would not be acceptable as it could cause unknown 
immunogenic response to patients. The current purification method is based on a two column 
chromatographic process, namely an anion exchange column as capture and hydrophobic 
interaction as intermediate. Although these two steps achieve close to 85% purification, they cannot 
guarantee the complete removal of isoforms as some of them have similar hydrophobicity and 
isoelectric point values of the target molecule. In order to clear out isoforms and potential 
aggregates a final polishing gel filtration step should be added to the process to allow separation by 
molecular weight of the final mixtures of isoforms.  
Process: HCP and Proteases 
By measuring the concentration of Host Cell Protein in initial feed and in anion exchange eluate 
using HCP kit AlphaLISA it was determined that the captoQ HiTrap column removes close to 85% of 
HCP present in the harvest.   
The second intermediate HIC step utilises Phenyl  FF Hitrap column to purify the target enzyme. This 
step will be developed to reduce HCP content even further.   
It has been shown however that certain proteases, namely cathepsin D and Z co-purify with the 
target molecule and can affect product activity and purity.   
Before this process development work is to be transferred to a commercial platform, more studies 
have to be done in the protease identification and separation areas, specifically casein zymograms, 
protease screening assay (such as GBiosciences proteSEEKER) and mass spec analysis on feed and 
column eluates. 
A Design of experiment (DOE) study could also come in handy here. Multiple HIC resins and 
conditions could be screened to determine a design space for efficient removal of extra proteases 
while delivering expected purification levels. 
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